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Abstract
The E2F proteins are a family of transcription factors that function in regulating 
the G1 to S phase transition. The activity of E2F is regulated in a cell-cycle dependent 
manner by its physical interaction with members of the retinoblastoma protein (pRb) 
family, which are inactivated via phosphorylation by cyclin-dependent kinases (CDK), 
most notably cyclinD-CDK complexes in Gl. This ensures that the activation of E2F- 
responsive genes is closely coupled with cell cycle position. In this study, the role of 
direct phosphorylation of E2F in the regulation of E2F activity is explored. CyclinE- 
CDK2 can directly phosphorylate E2F-5 in vitro, and phosphorylation is abolished by 
mutation of threonine 251 to alanine in the trans^ctivâtion domain of E2F-5 (T251A), 
whilst mutation of serine 307 to alanine (S307A) did not affect phosphorylation. 
Evidence is presented that phosphorylation of E2F-5 by cyclinE-CDK2 facilitates 
transcription and cell cycle progression. Specifically cyclinE-CDK2 causes a 
significant increase in E2F-5 dependent transcription, which is not observed for T251A. 
In addition, S307A is compromised in its ability to activate transcription. Taken 
together the results suggest that phosphorylation of E2F-5 at distinct sites by cyclinE- 
CDK2 and an as yet unidentified kinase augments E2F-5 dependent transcription.
The p300/CBP family of proteins have been implicated as important co­
activators for a variety of transcription factors, including E2F-1. Here it is shown that 
the binding of E2F-5 to p300 is stabilised upon phosphorylation of E2F-5 by cyclinE- 
CDK2, suggesting enhanced recruitment of p300 is mechanistically important for 
stimulating E2F-5 dependent transcription. Since cyclin E is a well-known E2F 
responsive gene and the results imply that E2F activity may be directly regulated by 
cyclinE-CDK2, an autoregulatory feedback loop may exist between E2F-5 and cyclin E
that drives the expression of E2F target genes, thereby promoting irreversible entry into 
S phase. Overall, these results define a novel level of control in the regulation of cell 
cycle progression by E2F.
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Chapter 1
Introduction
1.1 The Cell Cycle
The mammalian cell cycle has been divided into four distinct phases, G l, S, G2 
and M phase. DNA replication (S-phase) and cell division (M-phase) are separated by 
two gap periods (Gl and G2) during which cells are believed to assess their capacity to 
progress on to the next phase of the cell cycle. A newly divided cell in G l phase has 
several choices. It can commit to DNA replication in preparation for a further round of 
mitosis, or it can become quiescent, differentiate or undergo apoptosis. Growth factors 
trigger signalling cascades which stimulate entry through G l. However at a specific 
point in G l, the commitment point, growth factors are no longer required and 
progression through the cell cycle then depends on the intrinsic workings of the cell 
cycle clock (Sherr, 1993).
1.1.1 Cyclin Dependent Kinases (CDKs)
Progression through the cell cycle is dependent on phosphorylation of key 
regulatory proteins by cyclin-dependent kinases (CDKs) which require binding of 
regulatory subunits known as cyclins as an initial step in their activation (Lees, 1995). 
Whilst the levels of cyclin proteins oscillate throughout the cell cycle, the levels of 
CDK remain relatively stable. The accumulation of cyclin subunits, displacement of 
cell cycle inhibitors and phosphorylation by the CDK-activating kinase (CAK) all
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contribute to the periodicity of CDK activity during the cell cycle. Cyclin accumulation 
is determined by cell cycle-regulated transcription and proteolysis.
In vitro, cyclins are able to bind a large variety of CDKs (Pines, 1995). Most of the 
cyclin-CDKs phosphorylate the same basic consensus sequence in vitro (K/R)-S/T-P- 
X-(K/R) where the basic residues are preferred but not essential (Nigg, 1993; Pines, 
1995). However in vivo only a handful of specific cyclin-CDK substrates have been 
described (Nigg, 1993; Pines, 1995).
1.1.2 Regulation of the Gl-S transition by cyclln-CDKs
The transition from G l into S phase is a key regulatory step in the mammalian 
cell cycle, which is controlled by the Gl cyclins and their associated kinases. Gl 
cyclins comprise D-type cyclins (Dl, D2 and D3) and cyclin E. The levels of D-type 
cyclin mRNA accumulates in Gl and cyclin E mRNA accumulates somewhat later, 
peaking during late G l and declining during early S phase (Sherr, 1993; Ohtsubo et al, 
1995). Destruction of G l cyclins is important for resetting the balance of regulatory 
factors ready for the next cell cycle, such that the timing of subsequent transitions are 
not inappropriately advanced (Koepp et al, 1999).
The mRNA of D-type cyclins accumulates in response to growth factors and 
because both the mRNA and proteins turn over rapidly, cyclin D levels decline 
precipitously when growth factors are withdrawn (Sherr, 1993). The importance of 
cyclin D in regulating progression through Gl has been highlighted by several 
experiments. Inhibition of expression of cyclin D l causes cell cycle arrest before S 
phase and microinjection of cyclin D l antibodies during G l prevents fibroblasts from 
entering S phase (Baldin et al, 1993). However antibody injection is ineffective in
16
preventing S phase entry when cells are injected in late G l, suggesting the function of 
cyclin D l is to stimulate progression through Gl rather than promote the Gl-S 
transition.
The D-type cyclins are known as growth factor sensors. When cyclin D l is 
over-expressed cells enter S phase early and have a reduced dependence on growth 
factors (Quelle et ah, 1993). Mitogen stimulated activation of Ras triggers a signalling 
cascade which promotes transcription of the cyclin D l gene via the activation of the 
extracellular signal-regulated protein kinases (ERKs), although the actual physiological 
target(s) that mediates this process has not been defined (reviewed in Sherr, 1993).
Members of the cyclin D family assemble with their catalytic partners, CDK4 
and CDK6 and the resulting group of kinases are most recognised for their role in 
phosphorylating pRb, which plays an important role in the regulation of the G 1/S 
transition (see Section 1.1.5).
The rise in cyclinE-CDK2 kinase activity which occurs at the end of Gl is 
necessary for entry into S phase in most cells (Koff et al., 1992; Ohtsubo et al., 1995). 
The transcription factors, Myc and E2F have been implicated in transcriptional 
regulation of the cyclin E promoter (Perez et al., 1999; see section 1.2). Furthermore 
when Myc and Ras are overexpressed they cooperate to generate cyclinE-CDK2 
activity and allow S-phase induction without the induction of cyclinDl-kinase activity 
(Leone et al, 1997). Cyclin E regulates its own levels through autophosphorylation by 
cyclinE-CDK2 on threonine 380, which acts as a signal for its destruction by the 
proteosome (Won and Reed, 1996).
In vitro cyclinDl-CDK4 can phosphorylate pRb, whereas cyclinE-CDK2 has a 
much broader specificity being able to phosphorylate histone H I, pRb and the cyclin 
dependent kinase inhibitor, p27 (Sheaff et al, 1997; Mittnacht, 1998). Recently the
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consensus motif for phosphorylation by cyclinDl-CDK4 was shown to differ from that 
for phosphorylation by cyclinE/A-CDK2 (Kitagawa et al, 1996). Thus differences in 
target sequence specificity may account for their ability to phosphorylate different 
substrates.
1.1.3 CDK-activating kinase (CAK)
The CDKs themselves are regulated by phosphorylation. The binding of a 
cyclin to a CDK causes a conformational change which makes threonine 160 in the 
CDK more accessible for phosphorylation by the CDK-Activating Kinase, CAK 
(Jeffrey et al, 1995; Fisher and Morgan, 1994). Phosphorylation of this conserved 
threonine residue is critical for the activity of CDK complexes (Fisher and Morgan,
1994).
CAK is a multimeric enzyme complex composed of a distantly related 
cyclin-CDK pair, cyclin H-CDK7 and the assembly factor MATl (Serizawa et al,
1995). CAK is also associated with the basal transcription factor TFIIH, suggesting it 
may have an additional direct role in the regulation of the basal transcription complex.
It can phosphorylate the carboxy-terminal domain (CTD) of RNA Pol II (Serizawa et 
al, 1995). Free CAK has a different substrate specificity to TFIIH associated CAK, 
suggesting that the association with TFIIH may convert if from an activator of CDKs to 
a kinase primarily responsible for regulating transcription (reviewed in Dynlacht et al, 
1997).
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1.1.4 Cyclin dependent kinase inhibitors (CDI)
The CDK inhibitors (CDI) sequester CDKs to halt cell cycle progression in 
response to a variety of signals (Figure 1.1). In mammals there are two families of 
CDIs. The INK4 (inhibitors of CDK4) family of cyclin-dependent kinase inhibitors 
specifically inhibit the catalytic subunits of CDK4 and CDK6 by interfering with the 
formation of cyclinD dependent kinase complexes (Hall et ah, 1995). The family 
consists of four related polypeptides: p l6  {INK4a), pl5 {INK4b), p i 8 {INK4c) and pl9 
(INK4d) (Shen* and Roberts, 1999; Figure 1.1). The gene encoding p l6  is known as the 
INK4a/ARF locus as it also encodes pl9 ARF, from a separate promoter and using an 
alternative reading frame (Quelle et al, 1995). ARF stabilises the tumour suppressor 
protein p53 and is required for p53 dependent growth arrest. Although signals leading 
to the synthesis of INK4 proteins are poorly understood the p i6 inhibitor accumulates 
progressively as cells age and may be involved in the maintenance of cellular 
senescence.
The other group of cyclin dependent kinase inhibitors is the CIP/KIPAVAF 
family, which comprises three distinct gene products: p21, p27 and p57 (Sherr and 
Roberts, 1999; Figure 1.1). These polypeptides share an amino-terminal conserved 
region shown to be important for interaction with, and inhibition of cyclin-CDK 
complexes (Nakanishi et al, 1995). They have a broader action than the INK4 proteins 
and are capable of interacting with and inhibiting all G l cyclin-CDK complexes in 
vitro (Sherr and Roberts, 1999). They do not detectably associate with kinase subunits 
unless a cyclin is present (Hall et al, 1995). Evidence for the importance of p27 in the 
inhibition of proliferation has been gained by inactivating p27 in mice (Nakayama et
19
Negative 
growth signals
1 
I
Mitogenic
signals
1
Negative 
growth signals
p21, p27, p57
CDK4/6
CDK2
I 
I
p16, p15, p18, p19
GO 
G1
Figure 1.1 Control of the G1-S transition
D-type cyclins accumulate in G 1 in response to mitogenic signals and complex with 
CDK4/6 forming a kinase reponsible for the initial phosphorylation o f  pRb. In late G 1 
cyclinE-CDK2 activity accumulates and is believed to complete the process o f  pRb 
phosphorylation and promote entry into S phase by an Rb-independent mechanism 
(see Section 1.4.1). Counteracting the cyclin-CDKs are two classes o f  CDKIs, which 
are thought to be induced by negative growth signals. (Adapted from Zhang, 1999)
al, 1996). p27‘^ ‘ null mice are larger than control mice as a result of increased numbers 
of cells in all tissues and organs.
Recent studies have shown that the interaction of CIP/KIP proteins with 
cyclinD-dependent kinases in vivo, can cause activation of cyclinD 1-CDK4 by 
promoting both its assembly and its nuclear localisation (La Baer et al, 1997; Cheng et 
al, 1999). Furthermore primary mouse embryonic fibroblasts (MEF) deficient in p21 
and p27 have compromised cyclinD-dependent kinase activity, which can be restored 
to physiological levels by réintroduction of p21 or p27 into the cells (Cheng et al, 
1999). Sequestration of cyclinD-CDK complexes by p27 in proliferating cells is 
believed to contribute to the emergence of cyclinE-CDK2 activity during cell cycle 
progression (Sherr and Roberts, 1999). Moreover p27 has also been demonstrated to be 
a substrate for cyclinE-CDK2 and phosphorylation of p27 targets it for destruction by 
the proteosome (Sheaff et al, 1997; Montagnoli et al, 1999). Thus cyclinE-CDK2 can 
augment its own activity, enabling cells to transit from Gl into S phase.
Cell cycle arrest resulting from the activation of a CDI occurs in response to a 
variety of signals, including mitogen starvation, DNA damage and transforming- 
growth-factor-p (TGF-P). For example the p53 tumour suppressor protein induces the 
expression of p21 in response to DNA damage (Ko and Prives, 1996). Thus, p21 is the 
mediator of a ‘checkpoint’ which results in cell cycle arrest allowing for DNA repair. 
Furthermore mouse embryonic fibroblasts that lack p21 are significantly deficient in 
their ability to arrest in G l in response to DNA damage (Deng et al, 1995).
Cell cycle arrest induced by INK4 proteins may indirectly depend on an 
interaction of CIP/KIP family members with cyclinE-CDK2. For example, cell cycle 
arrest activated by TGF-p in MvlLu cells leads to an increase in p l5  levels which
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sequesters CDK4, thereby preventing the interaction of CDK4 with p27 and favouring 
the interaction of p27 with cyclinE-CDK2 (Reynisdottir et al, 1995). The cytoplasmic 
location of p i5 ensures that the interaction of CDK4 occurs prior to contact with 
nuclear p27 (Reynisdottir and Massagué, 1997). G l arrest mediated by p l6  also 
requires the indirect inhibition of cyclinE-CDK2 by p27 (Jiang et al, 1998).
1.1.5 Regulation of pRb by Gl cyclin dependent kinases
The tumour suppressor gene, RB, is frequently found to be mutated in human 
tumour cells (Weinberg, 1995). These mutations frequently occur in a region of pRb 
referred to as the ‘pocket’ which is necessary for its negative growth regulating 
activity. The pocket binds to a number of proteins involved in the regulation of the cell 
cycle, including the E2F transcription factor, and several viral oncoproteins, such as 
adenovirus El A (La Thangue, 1994).
One of the best studied mechanisms of negative growth control by pRb is 
through its ability to form a physical complex with E2F, an interaction which coincides 
with the inactivity of E2F target genes and cell cycle arrest (Dyson et al, 1998; Lam 
and La Thangue, 1994). pRb activity is controlled principally through the regulated 
phosphorylation of pRb, which occurs as cells progress through the early cell cycle 
(Weinberg, 1995; Figure 1.1). During G l of the cell cycle pRb is hypophosphorylated 
and in this state it binds to E2F. As cells progress from mid to late G l, pRb becomes 
increasingly phosphorylated and undergoes a conformational change, which leads to its 
dissociation from E2F. The rise in free E2F relative to the levels of E2F/pRb complexes 
leads to the activation of E2F target genes, the mechanisms of which aie discussed in 
section 1.4.
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The D-type cyclin-dependent kinase, composed of cyclin D l, D2 or D3 bound 
to CDK4 or CDK6, appears to be the CDK that is primarily responsible for initiating 
the phosphorylation of pRb (Hinds et ai, 1992; Hatakeyama et al, 1994), whilst 
cyclinE-CDK2 is believed to be involved in completing the process of pRb 
phosphorylation at additional sites (Lundberg et al, 1998; reviewed in Mittnacht, 1998; 
Figure 1.1). Different cyclin-CDK complexes preferentially phosphorylate pRb at 
distinct sites in vitro, suggesting they may exert distinct effects on pRb function in vivo 
(Kitagawa et al, 1996; Zarkowska and Mittnacht, 1997).
Several lines of evidence indicate phosphorylation of pRb by cyclin-CDKs 
inactivates its growth-inhibitory activity. In the Rb-deficient cell line, SA0S2, ectopic 
expression of pRb causes cell cycle arrest and this is rescued by co-expression of 
cyclinE-CDK2, correlating with pRb phosphorylation (Hinds et al, 1992). Furthermore 
Gl arrest induced by p l6  requires a functional pRb (Lukas et al, 1995). Another study 
revealed that expression of a dominant-negative Ras protein (Ras-N17) blocks the 
activation of cyclin D-CDKs. Ras-N17 blocked the induction of S phase in but 
not Rb' '^ cells (Leone et al, 1997). Thus the primary target of D-type cyclin-CDKs is 
pRb and a necessary step in the induction of cell cycle progression by cyclin D-CDKs 
is the phosphorylation of pRb.
There are 16 consensus phosphorylation sites in pRb and the contribution that 
individual sites play in the inactivation of pRb is controversial (Mittnacht, 1998). A 
recent study examined the effect of a panel of pRb phosphorylation site mutants on cell 
cycle progression and demonstrated that sites in the carboxy-terminus of pRb were 
critical for pRb inactivation (Chew et al, 1998). Furthermore, overexpression of a 
phosphorylation-defective pRb in cells caused an S phase arrest suggesting pRb
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phosphorylation is important for S phase completion in addition to its role in 
controlling entry into S phase.
1.2 The E2F pathway
The transcription factor E2F mediates the coordinated induction of a host of 
genes required for entry into S phase of the mammalian cell cycle. Binding sites for 
E2F have been identified in the promoters of genes that encode proteins required for 
DNA synthesis and replication of the genome, for example DHFR, DNA polymerase a, 
cyclinE and cdc6 (Slansky and Famham, 1996). The transcriptional activity of E2F is 
regulated during the cell cycle, which provides a means of coupling the induction of 
E2F-regulated-genes with cell cycle position.
1.2.1 E2F and DP Families
E2F is a heterodimer composed of an E2F protein and a DP protein (Lam and 
La Thangue, 1994; Wu et al, 1996). To date there are six known E2F proteins, E2F-1 
to E2F-6 and three DP proteins, DP-1 to DP-3 (Helin et al, 1992; Kaelin et al, 1992; 
Shan et al, 1992; Girling et al, 1993; Ivey-Hoyle et al, 1993; Lees et al, 1993; 
Beijersbergen et al, 1994; Ginsberg et al, 1994; Hijmans et al, 1995; Ormondroyd et 
al, 1995; Sardet et al, 1995; Wu et al, 1995; Zhang and Chellapan, 1995; Rogers et 
al, 1996; Morkel et al, 1997; Cartwright et al, 1998; Trimarchi et al, 1998). The E2F 
proteins share several discrete functional domains. All have a central DNA binding
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domain and a heterodimerisation domain (Figure 1.2). With the exception of E2F-6, the 
carboxy terminus of each E2F protein contains the rran.sactivation domain (TAD) and 
embedded within the TAD is a region involved in binding to pRb family proteins 
(Dyson, 1998; Figure 1.2). When E2F is bound to pRb it is converted from an activator 
to a repressor of transcription (Helin et al, 1993a). However E2F-6 is thought to act 
solely as a repressor of transcription (Cartwright et al, 1998; Trimarchi et al, 1998). In 
this thesis the term E2F describes the heterodimer and the individual components are 
referred to by their appropriate number preceded by E2F or DP.
E2F-1, E2F-2 and E2F-3 have a number of structural and functional distinctions 
which place them in a separate subfamily to E2F-4 and E2F-5. The most striking 
difference is the presence of an additional 100 amino acids at the N-terminus of the 
E2F-1 subfamily (Figure 1.2). This region contains a cyclinA-CDK2 binding domain, 
the function of which is described in section 1.3 (Krek et al, 1994). E2F-2 and E2F-3 
have a high degree of similarity to E2F-1, particularly in their DNA binding domain 
(Ivey-Hoyle et al, 1993; Lees et al 1993). E2F-4 and E2F-5 are more similar to each 
other (80% similarity) than to other members of the E2F family (between 52% and 
60% similarity) (Beijersbergen et al, 1994; Ginsberg et al, 1994; Hijmans et al, 1995; 
Sardet et al, 1995).
Recently, E2F-3 has been shown to be transcribed from two different start sites 
within the E2F-3 gene locus (Adams et al, 2000). This produces two different 
transcripts. E2F-3a, the larger of the two products contains similar domains to E2F-1, 
whereas E2F-3b is truncated at the N-terminus resulting in a product lacking the
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Figure 1.2 The organisation of the E2F and DP family members.
(a )  Conserved domains within the E2F family.
(b) Conserved domains within the DP family, indicating the region with greatest 
sequence similarity to E2F family members.
cyclinA-CDK2 binding domain. Thus E2F-3b has a unique combination of 
characteristics shared with both the E2F-1 subfamily and the E2F-4 subfamily.
The first member of the DP family, DP-1 was isolated by purification from F9 
embryonal careinoma cells and was shown to be an E2F site specific DNA binding 
protein and a frequent component of E2F DNA binding activity (Girling et al, 1993; 
Bandara et al, 1994). A second DP, designated DP-2 was cloned in Xenopus (Girling 
et al, 1994). Human DP-1 and DP-2 were cloned using a probe from mouse DP-1 (Wu 
et al, 1995; Zhang and Chellapan, 1995; Rogers et al, 1996). A third DP, murine DP-3 
(also referred to as human DP-2) was shown to exist in multiple alternatively spliced 
forms termed a, (3, y and Ô (Ormondroyd et al, 1995). One consequence of this 
processing is the presence of a region, namely the E-region, in the a  and 6 forms which 
is necessary for localisation of DP-3 in the nucleus (see Section 1.3). The expression of 
human and Xenopus DP-1 and DP-2 is restricted to specific tissues (Wu et al, 1995; 
Zhang and Chellappan, 1995; Girling et al, 1994) and expression of the subtypes of 
DP-3 RNA also vary in different tissues (Ormondroyd et al, 1995), suggesting the DP 
composition of E2F may reflect the proliferative requirements of a particular tissue. 
Drosophila homologues of E2F and DP have also been identified, designated dE2F and 
dDP (Hao et al, 1995).
Bacterially expressed E2F-1 can bind DNA as a homodimer (Ivey-Hoyle et al, 
1993). However E2F and DP polypeptides synergistically bind DNA and activate 
transcription as a heterodimer (Bandara et al, 1993; Krek et al,  1993; Helin et al, 
1993b; Beijersbergen et al, 1994; Buck et al, 1995). DP I has a small region of 
sequence similarity to E2F-1 in the second helix of the E2F-1 DNA binding domain 
which enables heterodimerisation (Girling et al, 1993). The crystal structure of E2F-
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4/DP-2 has recently been determined and indicates that the residues of E2F that contact 
DNA are conserved among the E2F family members (Zheng et a t, 1999).
The existence of multiple forms of E2F opens up the possibility of particular E2F 
activities consisting of different E2F and DP combinations targeting specific promoters.
1.2.2 The pocket protein family
The activity of E2F is tightly regulated during the cell cycle by association with 
pRb and the related proteins, pl07 and pl30 (Dyson, 1998). The region of pRb that 
binds to E2F is called the ‘pocket’ and pRb, pl07 and pl30 are collectively referred to 
as the pocket proteins. The ‘pocket’ region also interacts with viral oncoproteins such 
as E l A, SV40 Large T antigen and E7 of human papilloma virus (La Thangue, 1994). 
Interaction of viral oncoproteins with pocket proteins disrupts their interaction with 
E2F, thereby preventing growth suppression. In pl07 and pl30 there is a discrete 
element in the pocket region, the spacer, which binds to cyclinA-CDK2 and cyclinE- 
CDK2 (Ewen et al, 1992).
Like pRb, both pl07 and pl30 form a physical complex with E2F, but associate 
with E2F during different stages of the cell cycle. The pRb/E2F complex is detected 
predominantly in G1 cells and declines after the Gl-S transition, correlating with the 
rise in activity of the cyclinD and cyclinE-CDK2 kinases (Shirodkar et a l, 1992). 
pl07/E2F complexes are found in G1 phase and remain abundant throughout S phase 
(Lees et a l, 1992; Shirodkar et a l, 1992). In contrast, pl30/E2F complexes are most 
prevalent in quiescent or differentiated cells and are rarely detected in cycling cells 
(Cobrinik et a l, 1993; Vairo et a l, 1995; Smith et a l, 1996). In late G1 both pl30/E2F 
and pl07/E2F complexes also contain cyclinE-CDK2 and during S phase pl07/E2F
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and cyclinA-CDK2 complexes have been detected (Lees et a l, 1992; Shirodkar et al, 
1992; Cobrinik et al, 1993). The function of the cyclin-CDK associated with pl07 and 
pl30 and E2F is unknown. However it has been demonstrated that the cyclin-CDK2 
binding domain in p i07 and p 130 can inhibit both cyclinA-CDK2 and cyclinE-CDK2 
kinase activity and is related to and has comparable activity to the p21 GDI (Zhu et al,
1995). Thus, p i07 and p i30 may have an additional role to pRb in growth suppression.
The pocket proteins may restrict repression mediated by a particular E2F to a 
certain stage of the cell cycle as they specifically associate with different subsets of 
E2F. E2F-1, E2F-2 and E2F-3 bind exclusively to pRb (Lees et a l, 1993), whereas 
E2F-4 and E2F-5 are regulated primarily by pl07 and pl30 (Beijersbergen et al, 1994; 
Ginsberg et a l, 1994; Hijmans et al 1995; Vairo et a l, 1995). However there are 
exceptions to this generalisation, for example E2F-4/pRb and E2F-4/pl30 complexes 
have also been detected in cycling cells (Moberg et al, 1996; Vairo et al, 1995). In 
addition E2F-5 has been shown to bind preferentially to p i30 in human GAMA breast 
carcinoma cells (Hijmans et a l, 1995). The presence of distinct E2F pocket protein 
combinations opens up the possibility of targeting repressive complexes to specific E2F 
regulated promoters at different times during the cell cycle.
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1.2.3 E2F regulated genes
The consensus E2F binding site ‘TTTCGCGC’ is found in the adenovirus E2a 
promoter and similar sequences are found in the promoters of cellular E2F target genes. 
E2F target genes include genes that regulate the cell cycle (e.g. cyclins A, D1 and E, 
cdc2), genes that induce DNA synthesis (e.g. DNA Polymerase a, dihydrofolate 
reductase (DHFR)) and genes that encode S phase regulatory proteins (e.g. cdc6). 
Mutational analysis of E2F sites within the promoters of E2F target genes has been 
used to investigate the role of E2F in transcription and has revealed that E2F sites can 
have a stimulatory or inhibitory effect on transcription (Slansky and Famham, 1998). 
Mutation of E2F-binding sites in the DHFR promoter resulted in loss of activation 
during cell cycle progression, suggesting that these binding sites mediate transcriptional 
activation during S phase entry (Slansky et al, 1993; Fry et a l, 1997). In contrast, 
mutation of the E2F site in the B-myb promoter was sufficient to relieve transcriptional 
repression in Go and resulted in a promoter with constitutively high activity (Lam and 
Watson, 1993).The cyclin A promoter is also repressed during the G1 phase of the cell 
cycle (Henglein et al., 1994). In vivo footprinting of the cyclin A promoter 
demonstrated that E2F sites were protected in cells arrested in GO/Gl by serum 
starvation and this protection was lost when cells entered S phase (Rech et ah, 1995).
The cyclin E promoter contains a combination of E2F sites that are involved in 
either activation or repression of transcription (Ohtani et al., 1995; Botz et a l, 1996; 
Geng et al, 1996; Cam et a l, 1999). A variant E2F site in the cyclin E promoter can 
cooperate with an upstream AT-rich sequence to delay cyclin E expression until late G1 
(Cam et a l, 1999). In extracts from Swiss 3T3 fibroblasts, a cyclin E repressor
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complex (CERC) consisting of E2F-4, DP-1, pl07 and additional unidentified proteins 
was shown to bind to this site but not to canonical E2F sites (Cam et a l, 1999).
E2F sites in the E2F-1, B-myb and HsORCl genes have been demonstrated to 
be important in repression in response to growth arrest by TGF-p (Li et a l, 1997). 
Figure 1.3 summarises the role of E2F sites in a variety of promoters.
Gene Function of gene 
product
Effect of E2F sites
DNA Polymerase a DNA synthesis Not reported
DHFR Activating
Thymidine kinase Activating
ORCl Repressing
CDC6 S phase regulation Repressing
CDC2 Proliferation control Repressing
Cyclin D Activating
Cyclin E Repressing and 
Activating
Cyclin A Repressing
Rb Not reported
pl07 Activating
c-myc Not reported
B-Myb Repressing
E2F-1 Repressing
CDC25A Repressing
CDC25C Repressing
pl9ARF Apoptosis Not reported
Figure 1.3 Role of E2F sites  in a variety of E2F regulated  prom oters and 
function of their gene products. Adapted from: Helin, 1998 and data also from 
Cam e/a /., 2000; Zwicker ef (zf 1995; Zhu e t a l ,  1995; Rech et al 1995; Botz et a l ,  1995; 
Neuman et al., 1994; Johnson et a l ,  1994; Li et a l ,  1994; Slansky et a l ,  1993; Lam and 
Watson, 1993.
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1.3 Regulation of E2F activity
The activity of E2F is tightly regulated during the cell cycle. There are several 
mechanisms that influence E2F activity including: interaction of E2F with pocket 
proteins, regulation of E2F synthesis and degradation, phosphorylation of E2F and 
regulation of E2F subcellular localisation (reviewed in Muller and Helin, 2000). The 
regulation of E2F activity by phosphorylation of pRb and DP-1 as cells progress from 
G1 to S phase is summarised in figure 1.4.
1.3.1 Phosphorylation of pocket proteins
During G1 phase of the cell cycle pRb is phosphorylated by CDKs, a process 
which coincides with release of E2F from pRb and cell cycle progression (Figure 1.4; 
see section 1.1.5). Similarly the phosphorylation of the pRb related proteins, pl07 and 
pl30 are cell cycle regulated. Ectopically expressed cyclinD 1-CDK4 but not cyclinE- 
CDK2 can phosphorylate pl07, leading to its dissociation from E2F-4 (Beijersbergen et 
ah, 1995). Moreover the timing of endogenous pl07 phosphorylation in cells correlates 
with cyclin D1 induction and occurs well before cyclin E induction, suggesting cyclin 
D1 is the most likely cyclin candidate to control pl07 phosphorylation (Beijersbergen 
et ah, 1995; Xiao et aL, 1996).
The phosphorylation of p i30 in mid-Gl correlates with the increase in cyclin 
D1 protein levels (Mayol et a l, 1995), resulting in its dissociation from E2F 
(Beijersbergen et al, 1995), and also targeting it for destruction by the proteosome 
(Smith et a l, 1998). Although pocket proteins are phosphorylated by CDKs in G l, 
complexes of E2F with pocket proteins persist in S phase. The function of these is
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Figure 1.4 Sequential activation and inactivation of E2F by cyciin-CDKs
In GO and Gl E2F regulated genes are (1) actively repressed by pRb, (2) pRb physically 
blocks the E2F activation domain. In late GI pRb is phosphorylated by D-type cyclin-CDKs 
and cyclinE-CDK2, releasingit from E2F and allowing E2F to (3) activate transcription. In S 
phase the E2F heterodimer is released from DNA after phosphorylation of the DP subunit by 
cyclinA-CDK2. Green circles represent phosphate groups.
unknown. However some of these complexes have been detected in the cytoplasm so 
may not be associated with transcription (see Section 1.3.2).
1.3.2 Regulation of E2F subcellular localisation
The mechanism of nuclear uptake of E2F is an important consideration in the 
regulation of E2F activity as E2F must be present in the nucleus to regulate 
transcription, E2F-1, -2 and -3 contain a nuclear localisation signal (NLS) and 
ectopically expressed E2F-1, -2 and -3 are predominantly localised in the nucleus in 
transfected cells (Magae et al., 1996; Allen et a l, 1997; Lindeman et ah, 1997). In 
contrast, ectopically expressed E2F-4 and E2F-5 are predominantly cytoplasmic, being 
devoid of an NLS. Two distinct mechanisms govern their nuclear localisation. Either 
pocket proteins or a nuclear DP heterodimeric partner can supply an NLS in trans to 
E2F-4 or E2F-5. DP-1 does not contain a NLS and ectopic DP-1 did not accumulate in 
the nucleus unless it was coexpressed with E2F-1, E2F-2, or E2F-3 (Magae et al,
1996). However two alternatively spliced DP-3 isoforms, namely DP-3 a  and DP- 
30 contain a region that functions as a NLS (de la Luna et a l, 1996), and both DP-3a 
and DP-3Ô can transport E2F-4 and E2F-5 into the nucleus (Allen et al, 1997).
Ectopically expressed E2F-4/5 and DP-1 are predominantly cytoplasmic and the 
heterodimer can be transported into the nucleus by co-expression of a pocket protein 
(Magae et a l, 1996; Allen et al, 1997; Lindeman et al, 1997). Moreover, the level of 
endogenous E2F-4 and E2F-5 in the cytoplasm increases progressively between early 
G l and S phase (Allen et al, 1997; Lindeman et a l, 1997), consistent with the idea that 
nuclear localisation of E2F-4 and E2F-5 in early Gl is mediated by pocket proteins. 
Thus, regulation of E2F nuclear localisation through different subunit composition
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provides a means of controlling the presence of activating or repressive E2F complexes 
in the nucleus.
1.3.3 Phosphorylation of E2F
Several studies have shown that phosphorylation of E2F influences E2F 
activity. In serum stimulated 3T3 cells phosphorylation of DP-1 occurs at the Gl-S 
transition correlating with the increase in E2F DNA binding activity observed at this 
stage of the cell cycle (Bandara et ah, 1994). E2F-1 and DP-1 are effectively 
phosphorylated in vitro by cyclinA-CDK2, but they are poor substrates for cyclinE- 
CDK2 (Dynlacht et aL, 1994; Kitagawa et a l, 1995). Furthermore in phosphopeptide 
mapping studies, tryptic phosphopeptides derived from E2F-1 phosphorylated in vitro 
by cyclinA-CDK2 overlap with phosphopeptides derived from E2F-1 phosphorylated 
in vivo, indicating that cyclinA-CDK2 may be responsible for the majority of E2F-1 
phosphorylation in vivo (Xu et a l, 1994; Kitagawa et al, 1995).
Phosphorylation of DP-1 in vivo is dependent on the presence of the cyclin A- 
CDK2 binding domain in E2F-1, as transfection of an E2F-1 mutant lacking the 
cyclinA-CDK2 binding domain abolishes DP-1 phosphorylation (Krek et al, 1994; 
Dynlacht et al, 1997). CyclinA-CDK2 phosphorylation of DP-1 coincided with a 
reduction in E2F DNA binding activity in S phase and may therefore contribute to the 
downregulation of E2F activity in late S phase (Krek et a l, 1994; Figure 1.4). In 
support of this idea in vitro phosphorylation of the E2F-1/DP-1 heterodimer by 
cyclinA-CDK2 reduced its ability to bind DNA (Dynlacht et a l, 1994; Xu et al, 1994; 
Kitagawa et al, 1995). Overexpression of E2F-1 and a phosphorylation deficient DP-1 
in cells caused a delay in S phase followed by apoptosis, suggesting that E2F activity 
must be downregulated for normal progression through S phase (Krek et al, 1995).
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One of the sites in E2F-1 phosphorylated by cyclinA-CDK2 has been mapped 
to serine 375 and phosphorylation of this site in vitro has been correlated with 
increased binding to pRb (Peeper et a l, 1994). Conversely, phosphorylation of E2F-1 
on serine 332 and serine 337 can inhibit the interaction of E2F-1 with pRb in vivo, 
although the kinase responsible is unknown (Fagan et a l, 1994). It has recently been 
demonstrated that phosphorylation of E2F-1 on serine 403 and threonine 433 can be 
mediated by a kinase associated with TFIIH (Vandel and Kouzarides, 1999).
E2F-4, E2F-5 and DP-2 have also been shown to be phosphoproteins but the 
functional significance of their phosphorylation is unknown (Ginsberg et al, 1994; 
Hijmans et al, 1995; Rogers et al, 1996). E2F-1, E2F-2 and E2F-3 all bind to CDK3, a 
cyclin dependent kinase with an unknown cyclin partner, and this appears to be 
involved in activation of E2F in late G l (Hofmann and Livingston, 1996).
1.3.4 Regulation of E2F abundance
The pool of E2F in a cell is determined by the level of transcription of the E2F 
genes, and the stability of the individual E2F proteins. The E2F-1, E2F-2 and E2F-3 
genes have E2F sites in their promoters, which are repressed in GO and early G l, likely 
mediated through an E2F-pocket protein complex (Neuman et a l, 1994; Johnson et al, 
1994; Adams et a l, 2000). As a result E2F-1, E2F-2 and E2F-3a mRNA and protein 
are undetectable in quiescent cells but induced in mid-late G l (Kaelin et a l, 1992; 
Slansky et al, 1993; Moberg et a l, 1996; Leone et a l, 1998).
E2F-4, E2F-5 and DP-1 mRNA levels are relatively constant throughout the cell 
cycle, although there is a marginal increase in E2F-5 and DP-1 mRNA levels in mid Gl 
(Ginsberg et al, 1994; Sardet et a l, 1995; Moberg et a l, 1996). Thus E2F-4 and E2F-
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5 may regulate E2F-dependent genes in GO and early G l, prior to the synthesis of other 
E2Fs. The shorter E2F-3, namely E2F-3b, differs from E2F-3a in that its promoter is 
not regulated by E2F and consequently its expression during the cell cycle resembles 
that of E2F-4 and E2F-5 (Adams et al., 2000). However E2F-3b is structurally similar 
to E2F-3 as both contain a NLS and associate with pRb. E2F-3b is the predominant 
E2F associated with pRb in quiescent cells and therefore may have a unique function at 
this stage of the cell cycle.
Many proteins involved in cell cycle regulation are degraded at defined points 
in the cell cycle, e.g. cyclins and GDIs. E2F-1 and E2F-4 are unstable proteins and their 
degradation is mediated by the ubiquitin-proteosome pathway (Hateboer et al., 1996; 
Hofmann et a l, 1996; Campenero and Flemington, 1997). Ubiquitination of E2F-1 is 
dependent on a component of the SCF ubiquitin-protein ligase, p45^^^^ and may be 
involved in the downregulation of E2F-1 activity in the S/G2 phase of the cell cycle 
(Marti et a l, 1999).
An epitope in the C-terminus of E2F-1 and E2F-4 is responsible for their 
instability and pocket protein binding stabilises both E2F-1 and E2F-4 (Hateboer et al, 
1996; Hofmann et al, 1996; Campenero and Flemington, 1997). Adenovirus ElA  and 
E lb  also inhibit breakdown of free E2F, despite their interference with E2F/pocket 
protein interactions and may thus provide a mechanism to facilitate S phase entry in 
adenovirus infected cells (Hateboer et a l, 1996). Conversely the stabilisation of E2F by 
pocket proteins may have a role in differentiation or in the maintenance of quiescence. 
Consistent with this idea, during myogenic differentiation there is no change in E2F-1 
protein levels, despite the fall in E2F-1 mRNA and the presence of a hypo- 
phosphorylated pRb (Martelli and Livingston, 1999).
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1.4 Functional significance of the E2F pathway
The complexity in the regulation of E2F activity suggests that individual 
family members may have distinct roles at particular stages of the cell cycle. E2F can 
positively and negatively regulate the transcription of genes whose expression is 
required for entry into S phase of the cell cycle. There is strong evidence emphasising 
the importance of either E2F rm^j^activation or E2F-mediated repression of genes in 
cell cycle progression but the overall contribution of each of these processes is 
unknown. Many studies are based on overexpression of E2F and pocket proteins, which 
may compensate for normal regulatory interactions. Furthermore cell type specific 
variations exist and the processes that regulate transformed cells can differ from those 
that regulate primary cells.
1.4.1 importance of E2F in cellular proliferation
Overexpression of E2F-1 or dE2F in quiescent cells is sufficient to drive cells 
into S phase, an effect which is dependent on the rmna^activation domain of E2F-1, 
suggesting it is mediated by E2F dependent transcriptional activation (Johnson et al, 
1993; Qin et a l, 1994; Asano et al, 1996). In support of this E2F and DP proteins are 
oncogenic. E2F-1, E2F-4, E2F-5 and DP-1 can cooperate with activated Ras to 
transform cells, and these cells produce tumours when implanted into nude mice 
(Johnson et a l, 1994b; Singh et a l, 1994; Jooss et al, 1995; Polanowska et a l, 2000). 
In another study E2F-1, E2F-2 and E2F-3 alone were sufficient to transform NIH3T3 
cells (Xu e ta l, 1995).
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The effect of different E2F proteins on transcription and cell cycle progression 
varies. Overexpression of the individual E2F proteins in cells induced the expression of 
a panel of E2F-target genes to different degrees (DeGregori et al., 1997). E2F-1, E2F-2 
and E2F-3 have been shown to induce S phase in serum starved Rati and REF52 cells, 
whilst E2F-4 and E2F-5 could only drive quiescent Rati cells into S phase when they 
were overexpressed together with DP-1 (Lukas et al., 1996; DeGregori et al., 1997). 
However E2F-1 and E2F-4 were demonstrated to have similar abilities to induce 
proliferation in transgenic mice (Wang et al, 2000).
One approach to investigate E2F function has been to inactivate individual E2F 
proteins in cells. E2F-1 knock-out mice develop normally, but exhibit defects in T-cell 
apoptosis and develop a broad spectrum of tumours (Field et a l, 1996; Yamasaki et al,
1996), suggesting E2F-1 functions as a tumour suppressor. Consistent with these 
observations overexpression of E2F-1 in serum starved fibroblasts can trigger apoptosis 
(Shan and Lee, 1994). The ability to induce apoptosis may be a unique property of 
E2F-1 as expression of the other E2F proteins did not induce apoptosis in serum 
starved fibroblasts (DeGregori et a l, 1997). E2F-5'^' mice are viable but die after 
several weeks from hydrocephalus caused by an excessive secretion of cerebral spinal 
fluid in the choroid plexus, suggesting a specific role for E2F-5 in differentiation of the 
choroid plexus (Lindeman et al, 1998). The absence of a more dramatic phenotype in 
E2F-5 knockout mice may be explained by some degree of redundancy among the E2F 
proteins.
E2F-3'^' mice arise at one-quarter of the expected frequency demonstrating that 
E2F-3 is important for normal development (Humbert et al, 2000). Furthermore, 
mouse embryonic fibroblasts (MEFs) derived from these animals have reduced 
expression of numerous E2F-responsive genes, including B-myb, cyclin A and DHFR
39
(Humbert et al., 2000). E2F ~F^ ' MEFs exit Go between three and four hours later than 
wild-type cells indicating E2F-1 is essential for timely S phase entry from Go (Wang et 
al., 1998). Microinjection of E2F-3 antibodies into fibroblasts synchronised in G2 
caused a reduction in the number of cells entering S phase, whilst an E2F-1 antibody 
had no effect (Leone et al., 1998). Moreover in synchronised cells E2F-3 DNA-binding 
activity accumulates at the Gl/S transition of each cell cycle, whereas E2F-1 only 
accumulates during the initial G l following a growth stimulus (Leone et a l, 1998). 
Taken together these results suggest that E2F-1 and E2F-3 have distinct roles in cell 
cycle progression. Whilst E2F-3 regulates expression of S phase genes in proliferating 
cells, E2F-1 is required for Go exit.
Many studies have investigated whether E2F activity is absolutely required for 
entry into S phase. Several observations have indicated that E2F activity is rate-limiting 
for entry into S phase. The proportion of cells in G 1 is increased by the overexpression 
of a dominant-negative DP-1 (Wu et al, 1996). In Drosophila, null mutations in dE2F 
and dDP cause lethality in late development (Duronio et al., 1995; Royzmann et al., 
1997). Drosophila mutations of dDP or dE2F that reduce the activity of E2F 
diminished the rate of DNA replication suggesting a quantitative relationship between 
the levels of E2F/DP and the efficiency of DNA replication (Duronio et a l, 1998). 
Delays in S phase entry were only detected with severe reductions in E2F function. In 
contrast, partial loss of function of cyclin E resulted in a delay in S phase entry without 
detectable fall in the rate of DNA replication (Duronio et a l, 1998).
Cyclin E acts downstream of E2F as it is an E2F target gene (Botz et a l, 1996). 
However, cyclinE-CDK2 phosphorylates pRb resulting in E2F activation (Lundberg 
and Weinberg, 1998). Thus cyclin E and E2F cooperate in an autoregulatory feedback 
loop. The activity of cyclinE-CDK2 is necessary for entry into S phase in mammalian
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cells (Ohtsubo et al., 1995) and in Drosophila (Duronio et al., 1996). Ectopic 
expression of cyclin E can override Gl arrest imposed by either p 16 or a 
phosphorylation deficient mutant pRb and can also overcome a G l block induced by 
expression of a dominant negative mutant DP-1 (Alevizopoulos et al., 1997; Lukas et 
al., 1997). Furthermore Myc and Ras can collaborate in the induction of cyclinE-CDK2 
activity and stimulate cells to enter S phase in the presence of a hypophosphorylated 
pRb (Leone et a l, 1997), Taken together these results suggest the cyclin E can promote 
S phase independently of pRb phosphorylation and can compensate for E2F mediated 
rran.yactivation. Therefore cyclin E is likely to be a key E2F-target gene and it is 
possible once a threshold of cyclin E is achieved cells can proceed into S phase and 
E2F activity is no longer required for DNA replication. Moreover cyclinE-CDK2 may 
target at least one other critical effector of cell cycle progression besides pRb, This idea 
is supported by the observation that, in growth-arrested G l cells, expression of the E2F 
DNA-binding domain stimulates entry into S phase without significant phosphorylation 
of pRb, whereas complete cell-cycle progression requires the cyclinE-CDK2 complex 
(Zhang et a l, 1999).
Further understanding of E2F function in vivo has been acquired by analysing 
primary mouse cells deficient in specific pocket protein family members. Rb' '^ embryos 
die in utero between day 13.5 and 15.5 of embryogenesis (Clarke et a l, 1992). In 
addition, ectopic cell cycle entry and increased levels of apoptosis are apparent in some 
tissues (Clarke et a l, 1992; Jacks et al, 1992). mouse embryonic fibroblasts 
(MEFs) have a slightly shorter G l phase and enter S phase earlier than wild type cells 
(Herrera et al, 1996). Mice deficient in either pl07 or pl30 were viable, whereas 
double knockout (plOT^\ p i30' '^) animals suffer lethal abnormalities, indicating p i07 
and p i30 are functionally redundant (Cobrinik et al, 1996). Deficiency of p i07 also
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enhances the developmental abnormalities of Rh^' embryos indicating there is also 
some degree of functional overlap between pl07 and pRb (Lee et al., 1996). It was 
demonstrated that Rb^', p i07"^ ' pups have an increased mortality rate during the first 
three weeks after birth and those that survived developed multiple retinal dysplasia.
pl0T^',pl30'^' MEFs showed strongly derepressed expression of a broad range 
of genes, including B-myb, cdc2 and E2F-1 whereas there was no difference in 
expression of these genes in MEFS deficient in either of these proteins alone (Hurford 
et a l, 1997). Therefore, pl07 and pl30 share overlapping functions. Subtle 
derepression of the cyclin E and pl07 genes have been detected in Rb  ^ MEFs, whilst 
expression of the cyclin E gene was unchanged in plOT^', p i30' '^ MEFS (Hurford et al,
1997). Furthermore cyclin E is prematurely activated in Rb ''' MEFS (Lukas et al,
1997). These observations indicate the cyclin E gene is repressed in GO/Gl by E2F/pRb 
complexes.
In cells arrested by y-irradiation E2F becomes a potent transcriptional repressor 
and sequestration of E2F in these cells allows the cells to bypass the cell cycle block 
and progress into S phase (He et a l, 2000). Moreover, overexpression of the E2F DNA 
binding domain in cells prevents Gl arrest by TGF-p, despite the accumulation of 
hypophosphorylated pRb (Zhang et a l, 1999). Taken together these observations 
suggest that G l arrest requires active repression mediated by E2F and 
hypophosphorylated pRb. Mutational analysis of E2F sites has demonstrated that a 
broad range of E2F target genes primarily mediate repression (see Section 1.2.3). Thus 
direct repression of transcription mediated by E2F/pocket proteins complexes plays an 
important role in the timely expression of genes required for entry into S phase.
42
1.4.2 Mutation of E2F pathway in cancer
Cancer is a disease of cellular proliferation caused by genetic changes that lead 
to the activation of oncogenes or inhibition of tumour suppressor proteins. Given the 
importance of E2F in the regulation of proliferation any mutation that augments E2F 
transcriptional activity could provide a cell with a proliferative advantage and 
contribute to its tumourigenic potential. A strong correlation has been made between 
tumourigenesis and unregulated E2F activity.
The most widespread aberration in cancer is mutation of the tumour suppressor 
gene, p53 (Levine, 1997). p53 can promote cell cycle arrest or apoptosis via several 
mechanisms. Activation of the p21(WAFl) promoter by p53 causes cell cycle arrest 
due to inhibition of cyclin-CDK complexes and consequently pRb is hypo­
phosphorylated. Apoptosis mediated by p53 can be either E2F-dependent or E2F- 
independent. E2F-dependent apoptosis may result from activation of pl9^^^, the 
promoter of which is directly regulated by E2F (Bates et al., 1998). p l9 ^ ^  stabilises 
p53 in response to DNA damage. Inactivation of p l9  has been observed in a wide 
spectrum of human cancers (Ruas and Peters, 1998). Thus inactivation of p53 or 
PI9ARFtuniour  cells bypasses a G l checkpoint, allowing cells to proliferate with 
damaged DNA.
There have been few reports of E2F genes being mutated in transformed cells. 
Chromosomal amplifications and overexpressions of the E2F-5 gene have been 
detected in breast tumours (Polanowska et al., 2000). Another study demonstrated 
amplification of the E2F-1 locus in an erythroleukaemia cell line (Saito et al., 1995).
Genetic aberrations that disrupt the pRb pathway, which involves pRb, cyclin 
D, CDK4 and p l6 has been frequently detected in human cancer (Sherr, 1996).
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Inheritance of a defective allele of RB provides a strong predisposition for developing 
the rare childhood cancer, retinoblastoma. Loss of the remaining functional allele of RB 
appears to be a rate-limiting event for tumour initiation (Whyte, 1995). The pRB gene 
RBI is mutated in approximately 30% of human cancers. All naturally occurring 
mutations occur within the pocket domain, which is necessary for binding to E2F. DNA 
tumour viruses such as simian virus 40 (SV40) and adenovirus can also transform cells, 
in part by interfering with the interaction of E2F and pocket proteins (Bandara and La 
Thangue, 1991; Li et al., 1993; Zamanian and La Thangue 1992). The viral 
oncoproteins sequester pocket proteins, through regions in the viral proteins necessary 
for transformation, thereby releasing active E2F.
Unlike the frequent inactivation of Rb in human tumours, no mutations in the 
p i07 gene and only a few mutations of the pl30 gene have been demonstarted to occur 
in tumours (Helin et al., 1997). This may be due to redundancy between pl07 and 
pl30, which has been highlighted in studies with mice carrying mutant alleles of pl07 
and pl30 (see Section 1.4.1).
Many tumours that retain a wild-type Rb allele, have genetic alterations in other 
components of the pRb pathway. The pl6(INK4a) gene is rearranged, deleted, or 
mutated in a majority of gliomas, leukaemias and melanomas (Kamb et al., 1994). The 
cyclin D1 locus is disrupted in a wide range of tumours, including lymphomas, 
squamous cell tumours and breast carcinomas (Pines, 1995). Hyperactivity of cyclin D 
can transform cells. The most recognised role of cyclin D is to initiate the 
phosphorylation of pRb, thereby releasing E2F and enabling activation of E2F target 
genes (see section 1.1.5). However it has been suggested that the transforming ability 
of cyclin D1 could also result from its ability to sequester CIP/KIP proteins leading to
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the activation of cyclinE-CDK2 (see section 1.1.4; reviewed in Sherr and Roberts, 
1999).
In conclusion, mutation of RBI gene, overexpression of cyclin D l, and 
inactivation of p l6 have all been detected in transformed cells. The consequence of 
each of these aberrations is to free E2F from pRb control thus overriding this critical 
Gl checkpoint and contributing to tumourgenesis.
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1.5 Mechanism of transcriptional activation and repression by E2F
In eukaryotic cells genes are condensed and packaged into chromatin. To fully 
understand how transcription factors activate and repress genes in a physiological 
context the accessibility of genes in chromatin needs to be explored. The primary 
component of chromatin structure is the nucleosome. Nucleosomes organise 
chromosomal DNA into structures that resemble beads on a string. They are comprised 
of histones H2A, H2B, H3 and H4, which together form an octomeric core wrapped 
around approximately two turns of DNA. Nucleosome assembly is regulated by hi stone 
acétylation. Acétylation is generally associated with transcriptional activity of genes as 
it disrupts nucleosome structure, thereby unfolding DNA and allowing transcription 
factors to bind to DNA (Grunstein, 1997; Shikama et al., 1997).
1.5.1 Mechanism of E2F activation
E2F proteins have a C-terminal ^ran^activation domain which can activate 
transcription when attached to the DNA-binding domain of an heterologous protein 
(Kaelin et al., 1992). The E2F-1 rran^activation domain can interact with components 
of the basal transcription machinery, TBP and TFIIH, in vitro (Hagemeier et al., 1993; 
Pearson and Greenblatt, 1997). Furthermore fmnjractivation by E2F-1 has been 
correlated with the ability to bind TBP and TFIIH, suggesting that transcriptional 
activation is mediated by direct contact with components of the basal transcription 
machinery. Alternatively E2F-1 and TBP can interact with the p300/CBP family of co­
activators resulting in the formation of a physical bridge between the E2F activation 
domain and components of the basal transcription machinery (see Section 1.6).
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It has also been demonstrated that the E2F heterodimer can bend DNA, an 
effect which was abolished by the interaction of pRb with E2F (Cress and Nevins,
1996). The DNA bending contributed to transcriptional activation and thus may 
facilitate the ability of upstream activators to make appropriate contacts with the basal 
transcription machinery.
1.5.2 Mechanism of E2F repression
Pocket proteins can inhibit E2F transcriptional activation by masking the 
activation domain of E2F, which interferes with its interaction with the basal 
transcription machinery (Pearson and Greenblatt, 1997). There is also strong evidence 
that pocket proteins can act as active repressors of transcription. pRb can repress 
transcription when tethered to a promoter by a heterologous DNA binding domain 
(Bemner et a l, 1995; Sellers et a l, 1995). Furthermore there are numerous genes 
containing E2F sites which mediate repression, likely through an E2F/pocket protein 
complex (see section 1.2.3).
Two mechanisms of pocket protein repression have been described. One 
mechanism depends on the ability of pRb to interact with the rran^activation domain of 
surrounding transcription factors on the promoter (Weintraub et a l, 1995). Sequence 
similarity between pRb, TBP and TFTIB suggests that pRb can mimic components of 
the basal transcription machinery, and consequently block the interaction between 
transcription factors and the basal transcription machinery (Hagemeier et a l, 1993; 
Weintraub et a l, 1995). This mechanism appears to be E2F dependent as E2F is 
required to tether pRb to the promoter (Weintraub et a l, 1995).
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In the second mechanism, pRb is tethered to the promoter through E2F and 
recruits hi stone deacetylases (HD AC), which induces nucleosome assembly thereby 
blocking access of transcription factors to the promoter (Brehm et ah, 1998; Luo et al, 
1998; Magnaghi-Jaulin et al, 1998). Several lines of evidence support a role for 
hi stone deacetylase in active repression of transcription mediated by pocket proteins. 
Trichostatin A, a specific and irreversible inhibitor of HD AC, can block Gal4-pRb 
mediated repression of a reporter construct consisting of the adenovirus major late 
promoter modified with upstream Gal4 sites (Luo et al, 1998). Phosphorylation of pRb 
or interaction with viral oncoproteins disrupts the interaction of pRb with HDACl 
(Brehm et al, 1998; Ferreira et a l, 1998). It has also been demonstrated that both pI07 
and pl30 can interact with HDACl (Ferreira et al, 1998). Furthermore pl07 is able to 
interact with HDACl and E2F-4 simultaneously, suggesting it can recruit HDACl to 
E2F-4 containing heterodimers. pRb-mediated repression of certain transcription 
factors e.g. PU. 1 is independent of histone deacetylase activity, supporting the idea that 
there is more than one mechanism of pRb-mediated repression (Luo et al, 1998).
Sequential phosphorylation of pRb has been proposed to be important for its 
ability to inactivate E2F-1 and actively repress transcription in association with HD AC 
(Harbour et a l, 1999). First, phosphorylation of a set of CDK sites in pRb block its 
ability to bind to HD AC resulting in a loss of active repression mediated by pRb. 
Subsequently phosphorylation of another set of CDK sites disrupts the pRb pocket 
structure resulting in release of pRb from E2F, and a loss in inhibited complexes. 
Recently an additional level of control for the regulation of Rb-mediated repression has 
been described (Zhang et al, 2000). The hSWFSNF nucleosome remodelling complex 
can interact with pRb and repress transcription of the cyclin E and cyclin A genes. It 
was proposed that a trimeric complex between Rb, HD AC and hSWFSNF is required
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to repress the cyclin E  gene and that after subsequent loss of HD AC from the complex 
during cell cycle progression, Rb-hSWI/SNF is sufficient to maintain repression of the 
cyclin A gene. Therfore different multiprotein complexes may be important in 
controlling the temporal gene expression as cell progress from GO/Gl into S phase.
1,6 The p300/CBP family of co-activators
1.6.1 Regulation of transcription by p300/CBP
The p300 protein and the related CREB binding protein (CBP) are highly 
homologous nuclear proteins that were originally identified by their ability to interact 
with adenovirus E l A and with the transcription factor CREB respectively (Chrivia et 
al, 1993; Eckner et al, 1994). Both possess co-activating properties as they do not 
contain a DNA binding domain but can stimulate transcription when tethered to a 
promoter by fusion with a foreign DNA-binding domain (reviewed in Shikama et al,
1997). activation domains (TADs) have been identified in both the N-terminus 
and C-terminus of CBP and deletion of the N-terminal TAD greatly reduced the ability 
of CBP to activate CREB-mediated transcription (Swope et al, 1996). Several discrete 
functional domains have been identified in p300/CBP, including a central 
bromodomain and three cysteine/histidine rich domains (CHI, CH2 and CH3) 
(Shikama et al, 1997; Figure 1.5). The modular organisation of p300/CBP allows the 
formation of multimeric transcription mediating complexes.
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Figure 1.5
Schematic representation of p300/CBP. The cysteine/histidine-rich domains (CHI, 
CH2 and CH3) and the bromodomain are indicated. Note that the numbers indicate the 
amino acid residues in human p300. CBP has a similar organisation and contains 2440 
(2441 in mouse) amino acid residues. The binding domains o f various target proteins 
are indicated and blue text denotes a protein with more than one binding region. 
(Adapted from Shikama et al ,  1997).
A constantly increasing array of transcription factors are able to form stable 
physical complexes with and respond to the co-activating properties of p300/CBP 
(Shikama et al, 1997; Figure 1.5). These include E2F-1, c-Jun, c-Fos, c-Myb, CREB, 
MyoD, Stat 2, YYl, p53 and nuclear hormone receptors. Some of these are the 
products of proto-oncogenes, for example c-Myb, whilst others are tumour supressors, 
for example p53, or are involved in differentiation, such as MyoD. p300/CBP can also 
physically interact with components of the basal transcription machinery and act as a 
bridge between sequence specific binding factors and the basal transcription machinery, 
thereby facilitating transcriptional activation (Shikama et al, 1997).
Transcriptional activation mediated by p300/CBP and several transcriptional 
activators can be abolished directly and specifically by E l A binding to p300/CBP 
(Arany et a l, 1995; Yang et al, 1996). The disruption of the MyoD-p300 interaction 
by E l A inhibits MyoD-dependent transcription (Yuan et al, 1996). Thus, ElA  may 
keep cells in the proliferative state by suppressing the p300/CBP-mediated activation of 
genes whose products are required differentiation. However, it is somewhat surprising 
that E lA  counteracts the interaction between p300 and transcription factors implicated 
in enhancing proliferation, such as AP-1, a heterodimer composed of c-Fos and c-Jun 
(Arany et a l, 1995; Lundblad et al, 1995). An understanding of the regulation of 
p300/CBP activity may shed light on how these different processes are controlled by 
p300/CBP.
In addition to their role as adapter proteins, p300/CBP also possesses intrinsic 
histone acetyltransferase (HAT) activity. Both p300 and CBP can acetylate all four core 
hi stones and thus may contribute directly to transcriptional regulation by remodelling 
chromatin (Bannister and Kouzarides, 1996; Ogryzko et a l, 1996). Moreover, 
p300/CBP may influence chromatin remodelling by recruiting other acetyltransferases
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to the promoter (reviewed in Shikama et a l, 1997). One such protein is p/CAF 
(p300/CBP-associated factor). A possible scenario is that transcription factors need to 
recruit multiple HATs in order to overcome the repressive effects of deacetylation on 
promoter activity.
Recent studies have demonstrated that p300 and p/CAF can also directly 
acetylate several non-histone substrates, including p53, TFIIF, p53, MyoD and E2F-1 
(Gu and Roeder, 1997; Imhof et al, 1997; Sartorelli et a l, 1999; Martinez-Balbas et 
al, 2000), opening up the possibility that acétylation of sequence specific DNA- 
binding proteins may play a role in the regulation of transcription.
Both p300 and CBP have been demonstrated to interact with E2F-1 and 
enhance E2F-1 dependent transcription (Trouche et al, 1996; Trouche and Kouzarides, 
1996; Lee et al, 1998). Moreover, E2F-1 recruitment of CBP is critical for activation 
of the DHFR promoter (Fry et a l, 1999). A recent study has revealed that p/CAF and to 
a lesser extent, p300 can acetylate E2F-1 in vitro (Martinez-B alb as et al, 2000). 
Acétylation of E2F-1 in vivo by p/CAF was shown to increase the half-life and DNA 
binding activity of E2F-1, thereby augmenting E2F transcriptional activity. Taken 
together these studies suggest that p300/CBP plays a critical role in mediating E2F-1 
dependent transcription.
1.6.2 Regulation of differentiation, proiiferation and apoptosis by 
p300/CBP
The importance of p300/CBP in differentiation and proliferation has been 
highlighted by studies of p300/CBP knockout mice and in the disruption of p300/CBP 
in human disease. An autosomal dominant inheritable disease called Rubinstein-Taybi
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syndrome (RTS) is characterised by loss of one CBP allele (reviewed in Goodman and 
Smolik, 2000). Symptoms of RTS include mental retardation, physical abnormalities, 
such as bone malformation and an increased incidence of neoplasia. CBP heterozygous 
mutant mice have abnormal skeletal patterning (Tanaka et ah, 1997). Another study has 
shown that CBP^  ^ mice develop a high incidence of hematological malignancies as 
they age (Kung et aL, 2000). The phenotype of RTS patients is similar to that of mice 
deficient in one CBP allele. The inactivation of one p300 allele causes embryonic 
lethality in mice (Yao et al, 1998). Moreover double heterozygosity for p300 and CBP 
was invariably associated with embryonic death. Thus, mouse development is sensitive 
to the overall gene dosage of p300 and CBP.
The studies from CBP and p300 heterozygotes have suggested that the levels of 
CBP and p300 are limited in the cell (Tanaka et al, 1997; Yao et a l, 1998). 
Competition for a limiting amount of p300/CBP by different transcription factors may 
allow cross-talk between different signalling pathways. Consistent with this idea, 
nuclear hormone receptors can antagonise the AP-1 transcription factor, and expression 
of either CBP or p300 can abrogate this inhibition (Kamei et a l, 1996). Furthermore, in 
conditions where E2F-1 and p53 co-operate in apoptosis E2F-1 can effectively compete 
for p300, causing a reduction in p53-dependent transcription (Lee et a l, 1998). Thus, 
competition between the activation domains of p53 and E2F-1 for p300 may be 
instrumental in determining whether p53-dependent G1 arrest or E2F-1-dependent 
apoptosis ensues.
The effects of partial inactivation of CBP or p300 suggest p300/CBP is a 
tumour suppressor. In agreement with this role, various forms of leukaemia are 
associated with CBP-disrupting chromosomal translocations, for example the fusion of 
the gene encoding MOZ (monocytic leukaemia zinc finger protein) onto the amino
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terminus of CBP (reviewed in Goodman and Smolik, 2000). The ability of p300/CBP 
to act as a tumour suppressor is epitomized by its interaction with p53. p300/CBP 
mediates transcriptional activation of the p53 responsive p21WAFl, MDM-2 and Bax 
promoters, the gene products of which are important for G1 arrest and apoptosis 
(Avantaggiati et a l, 1997). The importance of p300 in mediating p53 apoptotic 
function has been highlighted by the recent identification of a novel p300-interacting 
protein called JMY, which augments p53-dependent apoptosis (Shikama et al., 1999). 
Therefore, the interaction of p300 with additional proteins may be important in 
dictating a particular functional outcome.
The ability of adenovirus E l A to promote cell cycle progression by binding to 
pocket proteins was discussed in section 1.4.2. p300/CBP constitutes another major 
target of E l A and their interaction is sufficient to promote the entry of cells into S 
phase, suggesting that deregulation of p300/CBP activity has a role in cellular 
transformation (Moran, 1993). E lA  mutants that lack the p300-binding site have lost 
the properties of E l A-driven cell cycle progression and its transforming potential. 
Moreover, p/CAF can compete with E l A for binding to CBP, thereby counteracting 
ElA-induced mitogenicity (Yang et al, 1996). Thus, E lA  may inhibit p300 by altering 
histone acétylation through competition with p/CAF. Alternatively, as E lA  and TFIIB 
interact with a common domain in p300, (Felzien et a l, 1999), E lA  may inhibit p300- 
dependent transcription by preventing p300 from interacting with the basal 
transcription machinery.
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1.6.3 Regulation of p300/CBP activity
The ability of p300/CBP to regulate diverse cellular processes is a major 
paradox. Thus regulation of p300/CBP levels and activity is likely to be important in 
dictating when p300/CBP mediates the transcriptional activity of a particular target 
protein. The function of p300/CBP is modulated by a number of signalling pathways, 
including the cAMP activated protein kinase A (PKA) and nerve growth factor 
activation of the mitogen activated protein (MAP) kinases, p42/p44 (Chivria et ah, 
1993; Liu et a l, 1998). Moreover, it is known that p300/CBP is phosphorylated in a 
cell cycle dependent manner (Yaciuk and Moran, 1991). Both cyclin/CDC2 and 
cyclin/CDK2 can phosphorylate p300 and binding of p300 to E lA  can block these 
phosphorylation events (Banerjee et al, 1994). It has been demonstrated that a region 
in the carboxy terminus of p300 binds to cyclinE-CDK2 (Perkins et al, 1997). 
Furthermore, inhibition of p300 bound cyclinE-CDK2 by p21 correlated with enhanced 
rraw.sactivation by NF-kB.
Another study has demonstrated that the HAT activity of CBP is modulated in a 
cell cycle dependent manner, peaking around the Gl-S transition (Ait-Si-Ali et al,
1998). Moreover phosphorylation of CBP by cyclinE-CDK2 in vitro, was shown to 
enhance the HAT activity of CBP. The regulation of p300/CBP by cyclinE-CDK2 and 
p21 provide potential mechanisms for the coordination of p300/CBP-mediated 
transcription with cell cycle progression.
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1.7 Regulation of transcription by phosphorylation
Phosphorylation is one of the major post-translational mechanisms by which the 
activity of transcription factors is regulated. To activate and repress transcription, 
transcription factors must localise in the nucleus, bind DNA and interact with the basal 
transcription machinery. Accordingly, phosphorylation may regulate transcription 
factor activity by affecting one or more of these processes (reviewed in Hunter and 
Karin, 1992). Several examples of transcription factors that are modulated by these 
mechanisms are described below and summarised in figure 1.6.
The Rel family of transcription factors, which includes NF-kB p50 and NF-KB 
p65, bind to their DNA recognition site as homodimers and heterodimers. In 
unstimulated cells, NF-kB is held in the cytoplasm in an inactive complex with the 
inhibitory protein, IkB (Inhibitor of NF-kB) (Karin, 1999). Upon treatment of cells 
with inducers such as tumour necrosis factor a, interleukin-1 and phorbal esters, IkB 
becomes phosphorylated, which acts as a signal for its destruction by the proteosome. 
Consequently NF-kB is released and translocates to the nucleus, where it activates 
transcription. This regulation ensures the rapid activation of NF-kB in response to a 
variety of signals.
More recently it has been demonstrated that the p65 subunit of NF-kB is 
phosphorylated by cAMP-dependent activation of protein kinase A (PKA) and this 
modification is required for efficient transcriptional activation (Zhong et a l, 1997). The 
mechanism of NF-kB activation by PKA was proposed to result from the unmasking of 
a domain within NF-kB which binds to the p300/CBP co-activator, thereby enabling 
p300/CBP to mediate NF-kB dependent transcription (Zhong et al, 1998).
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Figure 1.6 Properties of transcription factors that are targets for kinases. Data from Kawasaki et 
al., 2000; Karin ,1999; Prives et al ,  1998; Zhong et al ,  1997; Shieh et a l ,  1997; Musti et al ,  1997; Hill 
and Triesman, 1995; Bannister et al ,  1995; Chivria et a/., 1993; Lin et al ,  1992; Pulverer et al ,  1991; 
BoylQetal ,  1991;
57
There are several examples of phosphorylation of transcription factors 
stimulating transcription through enhancement of their interaction with p300/CBP. A 
variety of genes induced by cAMP contain a cAMP-response element (CRE) in their 
promoters which binds to the CRE-binding protein, CREB. Phosphorylation of CREB 
by PKA at serine 133 stimulates the transcriptional activity of CRE-dependent genes in 
part by enabling the kinase-inducible domain (KID) in CREB to interact with CBP 
(Chrivia a/., 1993).
Signal transduction cascades induced by extracellular mitogenic stimuli can 
ultimately lead to the activation of a group of kinases, the extracellular response 
kinases (ERK), a subfamily of the mitogen-activated protein (MAP) kinases. The ERKs 
are proline-directed serine/threonine kinases that recognize a proline at the +1 position 
of a potential substrate (Songyang et al., 1996). Two other MAP kinase families have 
been found in vertebrates, Jun N-terminal kinase (JNK) and the p38 MAP kinases. 
MAP kinases have been shown to phosphorylate a variety of transcription factors that 
have been implicated in controlling the expression of genes required for cell 
proliferation (Hill and Treisman, 1995; Hunter, 1995).
Several kinases have been implicated in the phosphorylation of c-Jun, a subunit 
of the mitogen activated transcription factor AP-1 (Boyle et al., 1991; Pulverer et al., 
1991). AP-1 consists of homo and heterodimers of Jun, Eos, ATP (activating 
transcription factor) and bZIP (basic region leucine zipper proteins) proteins (reviewed 
in Karin et al, 1997). Phosphorylation of residues in the amino-terminal activation 
domain of c-Jun by JNK reduces the ubiquitination of c-Jun, thereby preventing its 
degradation (Musti et al, 1997). The phosphorylation of c-Jun by JNK has also been 
demonstrated to enhance its interaction with CBP (Bannister et a l, 1995). Thus,
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phosphorylation of specific sites in a transcription factor may regulate its activity by 
multiple mechanisms.
There is also evidence that phosphorylation of a set of sites in c-Jun inhibits 
its activity (Lin et a l, 1992). Phosphorylation of threonine 231 and serine 249 by 
casein kinase II (CKII) inhibits c-Jun DNA binding and their dephosphorylation in 
response to phorbol esters is associated with increased AP-1 activity (Boyle et al, 
1991). The transcription factor ATF-2 binds to the cyclic AMP response element as a 
homodimer or hereodimer with c-Jun (reviewed in Karin et a l, 1997). Recently it has 
been shown that ATF-2 has intrinsic HAT activity, which is essential for CRE- 
dependent transcription (Kawasaki et al, 2000). Moreover, the HAT activity of ATF-2 
was modulated by phosphorylation by JNK or signal-activated-protein kinases 
(SAPKs). This provides a link between signal activated protein kinase cascades and the 
regulation of transcription through the ability of a sequence specific DNA binding 
protein to regulate transcription by directly acetylating histones.
The phosphorylation of p53 is induced by DNA damage and correlates with 
enhanced transcription of p53 target genes (Prives, 1998). Serine 15 and serine 37 have 
been identified as sites of phosphorylation following DNA damage, in studies using 
phosphospecific antibodies (Shieh et a l, 1997; Siliciano e ta l, 1997). Phosphorylation 
by several kinases, including DNA-PK, CKII, cdc2 and protein kinase C, in vitro 
enhanced the in vitro sequence-specific DNA-binding capability of p53 (Prives, 1998). 
However there is little information available about the kinases responsible for the 
phosphorylation of p53 in vivo.
The stability of p53 is regulated by MDM-2, which targets it for destruction by 
the proteosome. Phosphorylation of serine 15 inhibits binding of MDM-2 to p53 and 
blocks MDM-2 inhibition of p53-mediated ^ran^activation (Shieh et a l, 1997).
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However it has also been shown that mutation of various phosphorylation sites in p53, 
including serine 15, has no effect on the stabilisation of p53 following DNA damage 
(Ashcroft et al, 1999). Thus the importance of individual phosphorylation sites in the 
regulation of p53 function requires further investigation.
1.8 Objectives
The regulation of E2F activity through phosphorylation of pRb by cyclin-CDKs 
provides a mechanism for co-ordinating cell cycle progression with the regulation of 
E2F-dependent transcription. However relatively little information is available on other 
levels of control that influence E2F activity. Phosphorylation of the DP-1 subunit of 
E2F by cyclinA-CDK2 is believed to be important for the downregulation of E2F 
activity in S phase. Furthermore, although E2F-1 can be phosphorylated in vitro, the 
physiological importance of E2F phosphorylation is unknown.
In this study the role of E2F-5 phosphorylation in cell cycle progression was 
investigated. Phosphorylation of E2F-5 at two sites in the fran^activation domain was 
shown to be important in stimulating E2F-5-dependent transcription. E2F-5 contains a 
consensus CDK site positioned at threonine 251, which is absent in other E2F family 
members. A clue to the identity of the kinase responsible for the phosphorylaton of 
threonine 251 came from the analysis of E2F-5 during the Rati cell cycle. At the Gl-S 
transition in Rati cells a slower migrating E2F-5 polypeptide was detected by SDS- 
PAGE analysis. This polypeptide was of an identical mobility to that detected by 
overexpressing E2F-5 and cyclinE-CDK2 in cells. In vitro and in vivo phosphorylation 
of E2F-5 with cyclinE-CDK2 confirmed that it was indeed the kinase responsible for 
phosphorylation of threonine 251.
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The next part of this project aimed to understand the mechanisms by which 
phosphorylation of E2F-5 enhanced E2F-5 dependent transcription. To this end, mutant 
E2F-5 derivatives that could not be phosphorylated on threonine 251 or serine 307 were 
constructed. An analysis of these mutants revealed that phosphorylation at these sites 
did not effect the ability of E2F-5 to bind to DNA or interact with pocket proteins. 
However phosphorylation at threonine 251 by cyclinE-CDK2 enhanced the interaction 
of E2F-5 with p300, an important co-activator of E2F-5 dependent transcription. Thus a 
link between the cell cycle machinery and the activation of transcription was made.
An understanding of the role of phosphorylation in the regulation of E2F 
activity should ultimately shed light on the mechanisms whereby E2F causes the timely 
induction of target genes that promote cell cycle progression.
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Chapter 2
Materials and Methods
2.1 Plasmids
The following plasmids have been described previously: pG4-DP-l (Bandara et 
al., 1993), pCMV-Pgal (Zamanian and La Thangue, 1992), pCMV-HA-E2F-5, pCMV- 
HA-E2F-5‘''*'“  ^(Allen et a l, 1997), pGDP-35 (de la Luna et a l, 1996), pCMV-pl07 
(Beijersbergen et al., 1994), pCMV-HApl30 (Vairo et al., 1995), pCE-luciferase (Botz 
et al., 1996), pG5E 1 b-luciferase (Lee et a l, 1998), pVP16-TAD (Lee et al, 1998), 
pSG5 (Green et a l, 1988), pX-cdk2, pX-cdk4, pX-cycE and pX-cycDl (Zerfass- 
Thome et a l, 1997), p300'^^^ '^“  and his-E2F-5"’^'‘*''^  (Yang et a l, 1996). Flag- 
tagged p300"^^'^‘"'* was a gift from Ho Man Chan (Shikama et al, 2000), Baculovirus 
vectors for his-cycE, his-cycA and his-cdk2 were gratefully received from David 
Morgan (Desai et a l, 1995).
To construct Gal4-E2FS'^^'^^^ pCMV-HAE2F-5'^^ "^ was digested with Xhol 
and the resulting insert cloned into pG4polyII (Bandara et a l, 1993). His-E2F5 and 
His-T251A were constructed by inserting into pET28c (Novagen) an EcoRl fragment 
from pCMV-HA-E2F-5/HA-T251A/HA-S307A (Morris et a l, 2000). GST-E2F-5, 
GST-T251A and GST-S307A were generated from EcoRl fragments of pCMV- 
HAE2F-5 (or the relevant mutant construct) cloned into pGEX2T (Pharmacia).
For the mammalian two-hybrid assay, pVP16-E2F-5, pVP16-T251A, pVP16- 
S307A, were constructed by digesting pCMV-HAE2F-5/T251A/S307A with EcoRl 
and EcoRV and cloning the insert into pVP 16-TAD (Lee et a l, 1998). The resulting 
constructs contained an N-terminal VP16 TAD and residues 90-335 of E2F-5.
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2.2 Site-directed mutagenesis
pCMV-HAE2F-5 or was used as a template to make T251A,
T251D, S307A and S307D using the Sculptor in vitro mutagenesis system 
(Amersham). Single stranded DNA was prepared from pCMV-HAE2F-5 or pCMV- 
HAE2F-5^^ '^^^^, using the M13K07 derivative of bacteriophage M13 (Sambrook et al, 
1989). The following oligonucleotides were annealed to the single stranded template 
DNA to introduce single site mutations into E2F-5 (bases which differ from wild-type 
E2F-5 are indicated in bold):
T251A: 5 ' T CTG TGG AGC CAC TGA AGT TG 3 '
T251D: 5 ' T CTG TGG ATC GAG TGA AGT TG 3 '
S307A: 5 ' G GGT AGG AGC AAG GGG TAA AAG 3 '
S307D: 5 ' G GGT AGG ATC AAG CGG TAA AAG 3 '
A summary of the reactions and enzymes used is shown in figure 2.1.
Oligonucleotide containing 
A to G transversion to give 
Thr to Ala mutation at 251.
-ecT^
Anneal mutant 
oligonucleotide
Extend & Ligate 
incorporating dCTP-S  
 ►
DNA Polymerase I 
T4 DNA Ligase
Single Stranded DNA  
carrying E2F5 gene Nick wild-type 
Strand
Net I
Re-poiymerise 
gapped strand 
I------------------------
DNA Polymerase I 
T4 DNA Ligase
Partially digest 
nicked strand
Exonuclease III
Double Stranded DNA  
carrying mutated E2F5 gene
Figure 2.1 Summary of site-directed mutagenesis procedure.
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The DNA from the mutagenesis reactions was transformed into TG-1 bacteria and 
DNA minipreps were prepared. DNA sequencing was carried out either manually for 
both strands (Sequenase, Amersham) or with an ABI dye terminator cycle sequencing- 
ready reaction kit (Perkin Elmer) and an automated DNA sequence analyser.
2.3 Cell Culture and Transfection
Mammalian cells were grown in Dulbecco’s modified eagles medium (DMEM) 
supplemented with 10% foetal calf serum (GIBCO) and antibiotics, 10|ig/ml 
streptomycin and lOOU/ml penicillin (GIBCO), at 37°C in a 5% CO2/ HzO-saturated 
atmosphere. Rati cells were serum starved by transfering cells at 50% confluency into 
DMEM supplemented with 0.2% foetal calf serum for 72 hours, s p  cells were grown 
in TCI00 (GIBCO) supplemented with 5% ECS.
Cells for transient transfection were plated out 24 hours before transfection at 
approximately 1.5 x 10  ^cells per 100mm dish (for immunoprécipitation and flow 
cytometric analyses), 5 x 10  ^cells per 60mm dish (for luciferase and P-galactosidase 
assays, extracts for immunoblotting and gel retardation) or 2 x 10  ^cells per 35mm dish 
(on coverslips for immunofluorescence). Two hours before the transfection, the 
medium from the cells was removed and replaced with fresh growth medium.
Transient transfection of U20S and SA0S2 cells was performed by the calcium 
phosphate precipitation method. The relevant plasmid DNA was mixed with a final 
concentration of 250mM CaClz and the resulting solution (100p,l per 35mm dish, 250p.l 
per 60mm dish and 500p.l per 100mm dish) was added drop wise to an equal volume of 
2xHBS solution (50mM HEPES pH7.1, 280mM NaCl, and 1.5mM Na2HPÜ4) and
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added to the media on cells. COS7 cells were transfected using Lipofectin Reagent 
(GIBCO). For every l|ig  of DNA transfected, 2\i\ of Lipofectin was used.
To maintain a constant amount of plasmid DNA in each sample, either pcDNA3 
(Invitrogen) or pSG5 was transfected as appropriate. Cells were washed three times 
with PBS at 14-16 hours (U20S and COS7) or 8-10 hours (SAOS2) post transfection. 
U20S and SAOS2 cells were harvested 40-46 hours post transfection and C0S7 cells 
were harvested 64-70 hours post transfection.
U20S cell-lines stably transfected with doxycyclin inducible HA-tagged E2F-5 
(refered to as W Tl) and S307A (refered to as S5) were prepared by Liz Allen (Allen 
and La Thangue, personal communication).
2.4 Cell extract preparation and phosphatase treatment
Cells were lysed in ice-cold buffer (20mM HEPES pH 7.6, 400mM KCl, ImM 
EDTA, 25% glycerol, ImM DTT, 0.1% NP40, 5mM NaF, ImM Na3V04, ImM PMSF) 
for 30 minutes and centrifuged for 10 minutes to remove insoluble material. The 
protein content of extracts from Rati and F9EC cells was estimated by the method of 
Bradford (1976).
Extracts to be used for phosphatase treatment were lysed in the absence of NaF 
and Na3V04. Phosphatase treatment of F9EC and Rati cell extract (50|Ltg) was carried 
out in a 50p,l reaction containing 200U of X-protein phosphatase (NE Biolabs), 50mM 
Tris pH 7.8, 5mM DTT, 2mM MnCL, 100 jig/ml BSA. The reactions were incubated at 
30°C for 1 hour and terminated by addition of SDS loading buffer.
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2.5 Immunoblotting
Typically, 50|xg of extract was blotted but where transfected extracts were 
analysed one third of the cells harvested from a 60mm dish was used. Samples were 
separated by 10% SDS-PAGE, except for p300 detection where 6% SDS-PAGE was 
used. The gels containing the resolved proteins were transferred to a nitrocellulose 
membrane (Inverclyde Biochemicals Ltd), blocked in PBS-10% non-fat milk for 30 
minutes, then incubated with primary antibody for at least one hour. After washing in 
PBS-0.1 %Tween-20 the blot was incubated with secondary antibody, either anti-rabbit 
or anti-mouse alkaline phosphatase conjugated antibody (Promega; 1:7,500). 
Alternatively, horseradish peroxidase-conjugated goat anti-rabbit or -mouse IgG 
(1:4,000) was used for ECL detection (Amersham).
2.6 Immunoprécipitation and binding assays
For all immunoprécipitations the antibodies were prebound to Protein A beads 
(Roche) in 50mM Tris (pH8), 5mM EDTA, 120mM NaCl (TNE). For 
immunoprecipation of kinases to be used for in vitro phosphorylation reactions Rati 
cell extract (200|Lig) was diluted with 2 volumes of 50mM Tris (pH8), 5mM EDTA and 
immunoprecipitated with anti-cdk2, anti-cycE M20 or anti-Gal4 (all from Santa Cruz). 
The beads were washed twice with TNE and twice with kinase buffer (see section 2.18) 
before being used in a kinase assay.
For immunoprécipitation of proteins from Rati, RAGI or F9EC extract, 
between 0.5 and Img of extract (as indicated in the results section) was diluted with 2 
volumes of 50mM Tris (pH8), 5mM EDTA to give a final salt concentration of
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130mM. The diluted extracts were precleared by incubating with Protein A beads for 1 
hour at 4^C and thereafter combined with the relevant antibody bound to Protein A 
beads and agitated on a Vibrax machine for three hours at 4°C. The bead pellet was 
washed (3x 10 minutes) in TNE containing 0.1% NP-40 and after the final wash 
solution was removed the pellet was resuspended in 20-40pl of SDS-loading buffer 
(250mM Tris-HCl, pH6.8, 20% glycerol (v/v), 4% SDS (w/v), 0.1% bromophenol blue 
(w/v), 200mM DTT and 5% P-mercaptoethanol). The samples were then analysed by 
SDS-PAGE and immunoblotting.
Purified flag-p300 was incubated with in vitro phosphorylated His-E2F-5 or 
His-T251A for 2 hours at 4°C and washed 4 times in 50mM Tris (pH8), 12.5mM 
MgCL, 120mM NaCl, ImM PMSF, ImM Na3V04. The bound proteins were subjected 
to 10% SDS-PAGE and detected by immunoblotting with anti-E2F5 (see section 2.20). 
Pulidowns were quantified with a BIORAD imaging densitometer GS-670 using 
Molecular Analyst software.
2.7 Immunofluoresence
Cells were transfected in 35mm dishes containing three coverslips (see section 
2.3). The cells were fixed to the coverslips in 4% paraformaldehyde at room 
temperature for 15 minutes, washed in PBS, then permeabilised in PBS containing 
0.2% Triton X-100 for 10 minutes. Fixed cells were then washed three times with 
PBS-1% FCS and incubated in primary antibody diluted in PBS-5% FCS for 30 
minutes. Subsequently the coverslips were washed in PBS-1% FCS, cells were 
incubated in secondary antibody; goat anti-mouse or anti-rabbit IgG conjugated to
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fluorescein isothiocyanate (FITC) or tetramethyl rhodamine isothiocyanate (TRITC) 
(Southern Biotechnology Associates Inc.) diluted in PBS-10% FCS for 30 minutes at 
room temperature. After three final washes in PBS, the coverslips were mounted onto 
slides using citifluor (Citifluor Ltd), and viewed using a fluorescence microscope 
(Olympus).
2.8 Gel retardation analysis
The E2F recognition site from the adenovirus E2a promoter (or a mutant site) 
was used in all gel retardation analysis (Girling et al, 1993):
Wild-type 5’-GATCTAGTTTTCGCGCTTAAATTTGA-3’ and 
3 ATC A A A AGCGCG A ATTT AAACTCT AG-5 '
Mutant 5 -GATCTAGTTTTCGATATTAAATTTGA-3' and 
3'-ATCAAAAGCTATAATTTAAACTCTAG-5'
Typically, 10p.g of cell extract was used per gel retardation sample. When 
transfected cell extract was analysed, 3-5% of cells harvested from a subconfluent 
60mm tissue culture dish for used for one sample. The cell extract was combined with 
binding buffer (lOmM HEPES pH7.6, 0.1 M KCl, ImM EDTA, 4% Ficoll, 0.5mM 
DTT), 2|ig of sheared salmon sperm DNA and 200ng of mutant promoter oligo to 
reduce the non-specific DNA binding activity. Antibodies for supershifts were added 
and complexes were allowed to form at room temperature. After 15 minutes, Ing of a 
^^P-labelled E2F site was added for a further 20 minutes. Complexes were resolved on 
a 4% polyacrylamide gel in 0.5x Tris-borate EDTA (TBE) at 4°C for 2 hours (200V).
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2.9 Heparin-Sepharose column chromatography
A 3ml heparin-Sepharose column was poured using a slurry of heparin- 
Sepharose CL-6B (Pharmacia) suspended in NEP buffer (20mM, HEPES pH7.9, 
lOOmM KCl, 12.5mM MgCh, lOmM EDTA, 0.5mM PMSF, 0.5mM DTT). The 
plunger was inserted to exclude all air bubbles in the column. The column was washed 
at a rate of two column volumes per hour for two hours. F9EC extract (6mls) was 
thawed rapidly and loaded onto the column at a rate of 1 column volume per hour. The 
column was washed for a further hour and proteins were eluted in a linear KCl gradient 
(between O.IM and l.OM). The gradient was set up using an Econo system controller 
(Bio-Rad), and NEP buffer containing either 0.1 or l.OM KCl. Fractions (200pl) were 
collected using a Bio-Rad Model 2110 Fraction Collector and dialysed against NEP 
buffer overnight. 10% glycerol was added before storage at -80“C.
2.10 Affinity matrix preparation
The E2F recognition site from the adenovirus E2a promoter (see Section 2.8) 
was covalently coupled to Sepharose to prepare an affinity matrix, based on the method 
by Kadonaga and Tijan (1986). Briefly, annealed, 5’-phosphorylated and ligated oligos 
(100|4g of the wild-type and mutant E2F site) were prepared. Approximately 0.6g of 
cyanogen bromide-activated Sepharose CL4B (Pharmacia) was combined with ImM 
HCl and washed for 15 minutes in ImM HCl using a sintered glass funnel. To activate 
the coupling groups the matrix was then washed with lOOmls of lOmM KPO4 buffer.
The activated resin was divided between two 50ml falcon tubes, each 
containing 4mls of lOmM potassium phosphate buffer pH 8.35 and either the wild-type
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or mutant pre-ligated DNA, and rotated for 16 hours at 4°C. Each slurry was then 
washed with dHaO (50ml), followed by IM ethanolamine pH 8.5 and thereafter rotated 
for 4 hours in ethanolamine at room temperature. Finally, the beads were washed 
sequentially, using the following buffers: 50ml lOmM KPO4 buffer pH 8.35, 50ml IM 
KPO4 buffer pH 8.35, 50ml IM KCl, 50ml dH^O, 50ml (lOmM Tris pH 7.6, 0.3M 
NaCl, ImM EDTA, 0.02% NaNs). The matrix was stored in the final wash buffer at 
4°C.
2.11 Metabolic labelling
At 36 hours post-transfection U20S cells (100mm dishes) were washed twice 
with phosphate-free medium and labelled with [^^P]orthophosphate (0.2mCi/ml) in 
phosphate-free medium for 12 hours. The cells were lysed in 50mM Tris pH8.0, 
150mM NaCl, ImM EDTA, 1% NP40, pre-cleared for 30 minutes with protein G beads 
and immunoprecipitated for 2 hours with anti-HAll monoclonal antibody (Babco). 
Immunoprecipitates were washed three times in RIPA buffer (150mM NaCl, 1.0% NP- 
40/Igepal (v/v), 0.5% DOC (w/v), 0.1% SDS (w/v), 50mM Tris-HCl (pH8.0), once in 
50mM Tris pH8.0, 400mM NaCl, ImM EDTA, 1% NP40 followed by a final wash in 
50mM Tris pH8.0, 150mM NaCl before resuspending in SDS sample buffer and 
resolving on a 10% gel. The immunoprecipitated proteins were transferred to 
nitrocellulose and visualised by autoradiography.
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2.12 CnBr phosphopeptide mapping
Cyanogen Bromide (CnBr) cleavage was performed according to the 
method by Luo et a l, (1990). The phosphorylated E2F-5 polypeptides were excised 
from nitrocellulose and cleaved with CnBr (lOOmg/ml CnBr in 50% formic acid) for 2 
hours at room temperature. Phosphopeptides were resolved on a 24% acrylamide gel 
and visualised after a two week exposure on a phosphoimager. CnBr cleaves at 
methionine residues and the predicted sizes of the E2F-5 peptides are 153, 62, 43, 39 
and 38 residues; the 62-residue peptide contains threonine 251 and was clearly resolved 
from the other cleavage products.
2.13 Flow Cytometry
Cells were harvested in PBS and fixed in 50%(v/v) ethanol/PBS. Cells were 
treated with RNase (125U/ml) for 30min, harvested by centrifugation and suspended in 
propidium iodide (20|Xg/ml) in PBS at 4°C for Ihour. Cells were analysed in a Becton 
Dickinson FACScan.
Cells that had been labelled by BrdU were fixed in 70% ethanol containing 
2mM glycine (pH 2.0) for 20 minutes at -20°C and labelled with anti-BrdU (see section 
2.14), prior to propidium iodide treatment.
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2.14 BrdU incorporation
Following transfection and overnight incubation, U20S cells were 
incubated with bromodeoxyuridine BrdU (Boehringer Mannheim) for 10 minutes. The 
cells were fixed in 70% ethanol containing 2mM glycine (pH2.0) for 20 minutes at - 
20°C. BrdU incorporation was detected by incubating for 30 minutes with a primary 
mouse anti-BrdU, followed by three washes with PBS and a further incubation with an 
anti-mouse IgG conjugated to fluorescein isothiocyanate (FITC) (all supplied in a kit 
from Boehringer Mannheim).
Transfected cells were identified by immunostaining with an anti-DP-1 
antiserum and anti-rabbit tetramethyl rhodamine isothiocyanate (TRITC) (Southern 
Biotechnology Associates Inc.) and the level of BrdU incorporation expressed relative 
to the total number of transfected cells. The same procedure was followed with the 
stable cell lines (WTl and S5), although thereafter these were analysed by flow 
cytometry (see section 2.13).
2.15 Protein purification from Baculovirus infected Sf9 cells
S p  insect cells were co-infected with the appropriate recombinant baculoviruses 
and whole cell extracts were prepared 48 hours post-infection. Briefly cells were lysed 
in buffer A (25mM HEPES pH7.6, 400mM KCl, 12.5mM MgCh, O.lmM EDTA, 30% 
glycerol, 0.1% NP40), centrifuged to removed unsoluble material and the resulting 
lysate was diluted dropwise with 2 volumes of buffer B (25mM HEPES pH7.6, lOOmM 
KCl, 12.5mM MgCL, O.lmM EDTA, 10%glycerol, 0.1% NP40), then incubated with 
either anti-FlagM2-beads (Sigma) or Ni^'^-beads (Qiagen), as appropriate for 1 hour at
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4°C. The beads were washed three times with buffer B containing 200mM KCl (and 
20mM imidazole for His-tagged proteins). His-tagged proteins were eluted with 
250mM imidazole in buffer B and dialysed against the same buffer without the 
imidazole. Flag-tagged p300 was eluted with 1 mg/ml of Flag peptide (Sigma) in 
buffer B.
2.16 GST and His-tagged recombinant protein-purification
Transformed BL21 (DE3) bacteria (Invitrogen) were grown to mid-logarithmic 
stage in 500ml of LB-broth containing the appropriate antibiotic at 37°C. Thereafter, 
protein expression was induced by the addition of 0.5 mM (final concentration) 
isopropyl-P-D-thiogalactopyranoside (IPTG) for 4 hours at 30°C.
For GST purification, bacterial pellets were resuspended in 10ml PBS/1 % 
Triton X-100 and 0.5mM PMSF on ice, and then sonicated briefly (3 x lOsec) on ice. 
Bacterial debris was pelletted by centrifugation and re-centrifugation at 10,000rpm for 
15min (at 4°C) each. A 400|il suspension of glutathione-Sepharose beads (50% v/v; 
Pharmacia), which had been prewashed in PBS, were added to the supernatant and 
mixed with constant rotation at 4°C for 30 minutes. The suspension was washed three 
times with 50ml PBS by spinning in a bench-top centrifuge at 5,000rpm for 5 minutes 
(at 4°C). The GST proteins were eluted from the beads by incubating the bead pellet 
with an equal volume of 50mM Tris pH8, containing lOmM of glutathione.
For his-tagged purification the bacterial pellets were resuspended in 10ml of 
denaturing buffer (4M Urea, lOOmM KCl, 20mM Tris pH8, 10% Glycerol, 0.1% NP- 
40) and gently stirred for 12 hours at room temperature. MgCl^ was added to a final 
concentration of 5mM, and cellular debris was cleared by repeated centrifugation at
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4°C. A 500fxl suspension of nickel-agarose (50% v/v, Qiagen) and 10ml of wash buffer 
(lOOmM KCl, 20mM Tris-HCl pH7.9, 10% Glycerol, 0.1% NP-40, lOmM imidazole 
pH 8) were added to the supernatant, which was then rotated for 1 hour at room 
temperature. The urea in the supernatant was diluted by the addition of a further 20ml 
of wash buffer and the tube was rotated at 4 °C for two hours, to allow the proteins 
bound to the nickel-agarose to refold. The supernatant was removed and the beads 
were washed twice and rotated for a further 2-4 hours at 4 °C. Protein was eluted by 
incubating the resin with an equal volume of imidazole buffer (200mM Imidazole, 
lOOmM NaCl and 20mM Tris-HCl pH7.9). Imidazole was removed from the eluted 
protein by dialysis with lOOmM NaCl and 20mM Tris-HCl (pH7.9) buffer, for 6 to 8 
hours.
Protein expression was measured by Coomassie after SDS-PAGE.
2,17In vitro protein expression
In vitro transcription and translation was carried out using a TNT T7 coupled 
reticulocyte lysate system (Promega) as recommended by the manufacturer, in the 
presence of methionine. To check expression Ipl was subjected to SDS-PAGE and 
autoradiographed.
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2.18 //I vitro kinase assays
Phosphorylation reactions (40p,l) were performed in 20mM HEPES (pH7.6), 
lOmM MgCla, ImM EGTA, 2mM MnClz, 10% glycerol, ImM DTT, 50p,M ATP and 
5pGi [y-^^PJATP and incubated with IjLtg of His-E2F-5, His-T251A or histone HI. 
Reactions to be used in subsequent p300 binding assays were performed cold with 
ImM ATP without [y-^^P]ATP. The kinase activity was supplied to the reaction by 
either purified baculovirus cyclinE-CDK2 or immunoprecipitated cyclinE or CDK2 
from Rati cells. After 30 minutes at 30°C the reactions were terminated with SDS 
loading buffer and analysed by 10% SDS-PAGE.
2.19 in wfro acétylation assays
In vitro acétylation reactions (30jLtl) were performed in 50mM Tris pH 8, 5% 
Glycerol, 0.1% EDTA, 50mM KCl, ImM DTT, 1 mM PMSF, lOmM sodium butyrate 
and C^"^-Acetyl CoA (Amersham) and incubated with l-2pg of his-E2F-5 or GST-E2F- 
5, together with lOOng of flag-p300. A histone octomer preparation (prepared by L 
Smith) was used as a positive control. After 30 minutes at 30°C the reactions were 
terminated with SDS loading buffer and analysed by 10% SDS-PAGE and 
autoradiography.
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2.20 Antibodies
The following antibodies were used:
E2F-5 Polyclonal anti-E2F-5 antiserum (directed against a C-terminal peptide:
residues 320-335 (C )N E G V C D LFD V Q ILN Y ) and pre-immune serum 
(Bucket al, 1995)
HA monoclonal antibody H A ll (BabCO).
p300 Anti-p300 N15 rabbit polyclonal anti serum (Santa Cruz).
DP-1 Affinity purified polyclonal anti-DP-1 (anti-D) directed against peptide
D (Sprensen et al, 1996):
Peptide D (residues 385-400) (C )R VETPVSYVG ED DD D D  
Affinity purified polyclonal anti-DP-1 (anti-A) directed against peptide
A (Sprensen et al, 1996):
Peptide A (residues 3-15) (C )K D A S LIEA N G ELK  
Monoclonal anti-DP-1 (32.3), directed against peptide D
(Sprensen et al, 1996). 
pl07 mouse monoclonal SD9 (SantaCruz)
pGal mouse monoclonal (Roche)
cdk2 anti-CDK2 M2 rabbit polyclonal (Santa Cruz)
cyclinE rabbit polyclonal anti-cyclinE M20 (Santa Cruz)
Gal4 anti-Gal4 DBD (Santa Cruz).
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Chapter 3
Characterisation of E2F-5 in cells
3.1 Introduction
E2F is a heterodimeric transcription factor consisting of an E2F family member 
(E2F-1 to -6) and a DP family member (DP-1 to -3). It is becoming apparent that 
different E2F heterodimers have distinct roles in cell cycle control (DeGregori et a l , 
1997). This chapter describes the study of the endogenous E2F-5 protein and its 
interaction with other proteins, in an attempt to gain insight into the specific function of 
this E2F family member.
E2F-5 was isolated on the basis of its interaction with DP-1 in a yeast two- 
hybrid screen (Buck et a l, 1995). The protein sequence, molecular organisation and 
certain functional properties of E2F-5 are more closely related to E2F-4 than other 
members of the E2F family (Buck et al, 1995; Hijmans et a l, 1995; Sardet et al,
1995). Based on these similarities E2F-4 and E2F-5 make up a subfamily of E2F. Both 
E2F-4 and E2F-5 are physiological components of E2F DNA binding activity in a 
variety of cell lines. The level of their mRNA remains relatively constant throughout 
the cell cycle (Ginsberg et a l, 1994; Sardet et al, 1995). E2F-5 mRNA levels are 
particularly high in leukaemic cell lines, for example RAGI and DAUDI and in F9 
embryonal carcinoma (EC) cells (Buck et a l, 1995). In contrast E2F-1 transcription is 
cell cycle regulated and the levels of E2F-1 mRNA rise dramatically towards the end of 
G1 phase. Moreover E2F-1 expression is relatively low in a range of cell lines that 
highly express E2F-4 or E2F-5 (Buck et al, 1995). An observation perhaps related to 
the ability of E2F-1, but not E2F-4 or E2F-5 to cause apoptosis.
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Much of endogenous E2F-5 is found as a heterodimer with DP-1, some of 
which is associated with the pocket protein p i30 (Hijmans et ah, 1995). DP-1 is a 
frequent component of E2F DNA binding activity throughout the cell cycle in several 
cell lines (Bandara et al, 1994), whilst its E2F partner varies and has been shown to be 
cell type and cell phase specific (reviewed in Dyson, 1998).
3,2 E2F-5 is an abundant component of E2F DNA binding activity
E2F-5 is an abundant component of E2F DNA binding activity in a variety of 
cell types, including F9EC cells and DAUDI cells (Buck et a l, 1995; Fig 3.1a and 
3.1b). E2F DNA binding activity was examined by gel retardation analysis with an 
E2F-site probe containing the E2F binding sequence from the adenovirus (Ad5) E2a 
promoter. This site was chosen as it is a high affinity E2F binding site and has 
previously been used to define E2F in F9EC cells (La Thangue et a l, 1990). Several 
complexes were resolved in gel retardation analysis using extracts from F9EC and 
DAUDI cells. All three of the complexes detected in F9EC cell extract were specific 
for E2F site recognition since binding to the labelled probe was competed by addition 
of excess unlabelled probe (Fig 3.1b, compare lanes 1 and 2). However in DAUDI cell 
extract there were two specific complexes and one non-specific complex (Fig 3.1a, 
compare lanes 1 and 4). The identities of the complexes were assessed using a panel of 
antibodies. A polyclonal anti~E2F5 antiserum directed against a peptide in the C 
terminus of E2F-5 (anti-E2F-5) supershifted the fastest migrating complex in F9EC 
cells and DAUDI cells (Fig 3.1a, lanes 2 and 3; Fig 3.1b, compare lanes 3 and 4). The 
pre-immune anti serum did not shift any complex indicating the supershift generated by
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Figure 3.1
E2F-5 is an abundant component of DNA binding activity in DAUDI and F9EC 
ceils.
Gel retardation analysis of E2F complexes in DAUDI and F9EC extracts using 
the sequence of the E2F site taken from the adenovirus E2A promoter.
(a) The DNA binding activity of DAUDI extract is shown in lane 4. Lane 1 included 
the addition of a 100-fold unlabelled E2F site as a competitor to the labelled E2F 
probe. Extracts in lane 2,3,5 and 6 were supershifted with the indicated antisera. 
PI: rabbit pre-immune serum.
(b) The DNA binding activity of F9EC extract is shown in lane 1. Lane 2 included 
the addition of a 100-fold unlabelled E2F site as a competitor to the labelled E2F 
probe. Extracts in lane 3 and 4 were supershifted with either anti-E2F-5 or the 
pre-immune (PI) serum as indicated.
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anti-E2F-5 was specific. An anti-DP-1 (oD) antiserum supershifted all of the 
complexes in DAUDI extract (Fig 3.1a, compare lanes 5 and 6). Thus the fastest 
migrating complex in DAUDI cells consisted of an E2F-5/DP-1 heterodimer.
The E2F-5 protein was detected as a heterogenous set of polypeptides by 
western blot analysis with anti-E2F-5 (Fig 3.2a). In C0S7 cells, transiently transfected 
with an E2F-5 expression vector, exogenous E2F-5 was resolved as three closely 
migrating polypeptides, two of which had an identical mobility to the endogenous E2F- 
5 polypeptides detected in F9EC cells (Fig 3.2a, compare lane 2 and 3). By including 
the homologous peptide in the primary antiserum incubation the recognition of these 
three bands was abolished, demonstrating that the polypeptides were specifically 
recognised by the anti-E2F-5 antiserum (Fig 3.2a, lanes 1 and 4).
The E2F-5 polypeptides were defined as, Lower (E2F-5L), Middle (E2F-5M) 
and Upper (E2F-5U), in order of decreasing mobility on SDS-PAGE (Fig 3.2a). The 
distribution of these polypeptides varied in F9EC cells and Rati cells (Fig 3.2b). In 
F9EC cells the L and M forms were most abundant, whereas in Rati fibroblasts forms 
M and U were most readily detected (Fig 3.2b).
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3.3 E2F-5 may be modified by phosphorylation
One study has suggested that E2F-5 is phosphorylated in vivo (Hijmans et al 
1995). The authors characterised E2F-5 from cells metabolic all y labelled with [^^P]- 
orthophosphate, from which they immunoprecipitated a range of polypeptides with two 
different E2F-5 antibodies that likely represented differentially phosphorylated forms 
ofE2F-5.
To investigate whether phosphorylation was responsible for the presence of the 
multiple forms of E2F-5 in F9EC and Rati cells, extracts from these cells were treated 
with X-phosphatase. Western blot analysis of the treated extracts revealed a shift in 
mobility of the E2F-5U and E2F-5M bands to the position of E2F-L, suggesting that 
the bands reflected different phosphorylated forms of E2F-5 (Fig 3.2c),
In vitro translation of E2F-5 using a rabbit reticulocyte lysate produced several 
E2F-5 polypeptides, possibly the result of differential phosphorylation of E2F-5 by 
kinases in the lysate (Fig 3.2d, lane 1). A similar pattern of polypeptides was observed 
when a C-terminal fragment of E2F-5 (198-335) was in vitro translated (Fig 3.2d, lane 
2), implying phosphoacceptor sites may be concentrated between amino acids 198 and 
335 of the E2F-5 sequence.
3.4 Analysis of the DNA binding properties of the E2F-5/DP-1 heterodimer
It is well known that phosphorylation regulates the DNA binding activity of 
numerous diverse transcription factors (Hunter and Karin, 1992). Phosphorylation of 
the tumour suppressor protein, p53 dramatically stimulates its ability to bind to target 
sites in the p21WAFI promoter (Wang and Prives, 1995). The DNA binding activity of
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Figure 3.2
Cell extracts contain multiple E2F-5 polypeptides with different electrophoretic
mobilities and the slowest mobility polypeptide becomes more abundant after
phosphatase treatment.
(a) Immunoblot of E2F-5 in F9EC cell extract and in an extract from COS7 cells 
transfected with an E2F-5 expression vector. Gel lanes were cut in half and 
probed with either anti-E2F-5 (lane 2 and 3) or anti-E2F-5 in the presence of the 
homologous peptide from which the antibody was generated (lane 1 and 4).
(b) Immunoblot of E2F-5 in F9EC and Rati cell extract. The presence of the 
different forms (U, M and L) is shown.
(c) Immunoblot of E2F-5 after treatment of an F9EC and Rati cell extract with X- 
phosphatase (lane 2 and 4) and control treatments performed in the absence of X- 
phosphatase (lane 1 and 3).
(d) Expression vectors for full length E2F-5 and E2F-5^^ '^^^  ^were in vitro 
transcribed and translated in the presence of -Methionine (see Materials and 
Methods) and subjected to SDS-PAGE and autoradiography.
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E2F itself is regulated during the cell cycle by cyclinA-CDK2 dependent 
phosphorylation (see Introduction: section 1.3.3). One study has shown that two 
immunochemically distinct forms of DP-1, which the authors interpreted as 
differentially phosphorylated DP-1, differed in their ability to bind to the E2F 
consensus site (Bandara et al, 1994). To further explore the regulation of E2F DNA 
binding activity it was decided to investigate whether E2F-5L, E2F-5M or E2F-5U 
differed in their ability to bind DNA.
Heparin-Sepharose chromatography was used to purify E2F DNA binding 
activity from F9EC cells. Proteins were eluted in a linear KCl gradient (0 to IM) and 
the fractions assessed for DNA binding activity by gel retardation. DNA binding 
activity peaked in fractions 32 to 38, corresponding to a KCl concentration ranging 
from 300 to 400mM (Fig 3.3a, lanes 6-12). Immunoblotting of these fractions with 
anti-E2F-5 revealed they were enriched with E2F-5 and two forms of E2F-5 (L and M) 
were detected in these ‘peak’ fractions in a similar ratio as detected in crude extract 
(Fig 3.3b, compare lane 5 and lane 9). Similarly E2F-5L and E2F-5M were detected in 
column flow through-fractions, which were non-DNA binding (Fig 3.3b, lanes 2-4).
Two DP-1 antibodies, anti-D and anti-A, were used to investigate the presence 
of immunochemically distinct forms of DP-1 in these fractions. Anti-D is a polyclonal 
antibody directed against a peptide in the extreme C-terminus of DP-1 that recognises a 
single DP-1 polypeptide at 55kDa, designated p55L (Bandara et a l, 1994: see 
Materials and Methods). This polypeptide is also recognised, albeit much more weakly, 
by anti-A (directed against an N-terminal peptide) and anti-A also recognises an 
additional DP-1 polypeptide designated p55U (Bandara et a l, 1994). DNA binding 
fractions were enriched with p55L (Fig 3.3c, compare lane 5 and lane 1), whilst the
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Figure 3.3
Separation of E2F DNA binding activity by binding to heparin-Sepharose.
(a) Gel retardation analysis of F9EC extract fractionated over a heparin-Sepharose 
column, using the E2F site taken from the adenovirus E2A promoter. Lane 1 
shows the DNA binding activity of crude F9EC extract. Lanes 2-12 show the 
DNA binding activity of the indicated fractions. Fractions were eluted from the 
column at the indicated KCl concentrations.
(b) Immunoblot of E2F-5 in the indicated heparin-Sepharose fractions described in
(a). Lane 1 and lane 5 show the reactivity of the E2F-5 antibody with crude F9EC 
extract.
(c) Immunoblot of DNA binding fractions from (a) with two different DP-1 
antibodies. The gel lanes were cut in half and probed with either anti-A or anti-D 
as indicated (see Materials and Methods). Lane 1 shows the crude F9EC extract. 
The fraction number is indicated above each lane (lanes 2-8).
(d) Immunoblot of DP-1 to compare DP-1 in crude extract (lane 1) with DP-1 in 
heparin-Sepharose fraction 5 and 6 (non-DNA binding). The gel lanes were cut in 
half and probed with either anti-A or anti-D as indicated. The asterisk indicates 
the position of the p55U foim of DP-1 in fractions 5 and 6. MW is a lane 
showing the sizes of the molecular weight size markers.
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‘flow-through’ from the column contained only p55U (Fig 3.3d, lanes 3 and 4). Thus 
two immunochemically distinct foiTns of DP-1 were separated in the ‘peak’ and ‘flow- 
through’ fractions. These results are in agreement with a previous study that showed an 
immunochemically distinct form of DP-1, namely p55U, could exist in a non-DNA 
binding state (S0rensen et al, 1996). In conclusion, heparin-Sepharose chromatography 
had fractionated two forms of DP-1 with distinct electrophoretic mobilities, into a 
DNA-binding an non DNA-binding fraction. By contrast, E2F-5L and E2F-5M were 
present in both of these fractions.
A more direct way of determining the ability of different forms of E2F-5 to 
interact with the E2F site is to apply cell extracts to an affinity matrix containing the 
E2F DNA-binding site. The DNA binding site was taken from the adenovirus E2a 
promoter, identical to the sequence used in the previous gel retardation experiments. 
E2F-5 from F9EC cell extracts bound to the wild-type E2F binding site but not to a 
mutant site (Fig 3.4a, compare lanes 1 and 5). Co-incubation of the wild-type site 
affinity matrix with a 100-fold excess of free wild-type DNA binding site disrupted this 
interaction, indicating the binding was specific for the E2F site (Fig 3.4a, compare 
lanes 1 and 3). All forms of E2F-5 in the F9EC extract bound to the E2F site (Fig 3.4a, 
lanel), whereas there was no detectable binding to the mutant E2F site (Fig 3.4a, lane 
5). In Rati extracts considerably more E2F-5 was detected bound to the wild-type site 
than was bound to the mutant site (Fig 3.4b, compare lanes 1 and 3). Moreover both 
E2F-5M and E2F-5U bound to the E2F site. When the mutant E2F-site affinity matrix 
was co-incubated with Rati extract the majority of E2F-5 remained in the non-binding 
fraction (Fig 3.4b, lane 4). In conclusion all three forms of E2F-5 aie capable of 
binding to DNA and there appeared to be no detectable difference in their affinity for 
the E2F site.
Figure 3,4
E2F-5L, E2F-5M and E2F-5U can all Interact with the consensus E2F binding 
site from the adenovirus E2A promoter.
Cell extracts were incubated with an affinity matrix consisting of the E2F site from 
the adenovirus E2A promoter or a mutant E2F site (see Materials and Methods). 
Lanes labelled with ‘B’ indicate fractions of extract that remained bound to the 
matrix after three washes, whilst ‘S’ (Supernatant) indicates the fraction of extract 
that did not bind to the affinity matrix.
(a) F9EC extract (400pg) was incubated with the wild-type E2F site affinity matrix 
(lanes 1-4) or mutant E2F-site affinity matrix (lane 5 and 6). 100-fold excess of 
‘free’ wild-type E2F site was added as a competitor to the wild-type E2F site 
matrix in lane 3 and 4. Thereafter, the bound proteins were released and 
immunoblotted with anti-E2F-5, alongside 20% of the unbound proteins 
remaining in the supernatant. Track 7 shows the reactivity of 10% of the amount 
of crude F9EC extract used in the affinity matrix incubations.
(b) Rati extract (400pg) was incubated with either the wild-type E2F site affinity 
matrix or mutant E2F-site affinity matrix, as indicated. Thereafter, the bound 
proteins were released and immunoblotted with anti-E2F-5 (lane 1 and 3), 
alongside 25% of the unbound proteins remaining in the supernatant (lane 2 
and 4).
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3.5 E2F-5 associates with DP-1 and p107 in vivo
Previously gel retardation analysis demonstrated that E2F-5 exists as a 
heterodimer with DP-1 on the consensus E2F binding site (see Fig 3.1). However gel 
retardation cannot distinguish whether a particular form of E2F-5, either U, M or L, 
preferentially binds to DP-1. Therefore co-immunoprecipitation experiments were 
performed to investigate the ability of these different forms of E2F-5 to associate with 
DP-1. Extracts from F9EC cells were subjected to immunoprécipitation with a 
monoclonal anti-DP 1 directed against a peptide in the C-terminus of DP-1 (see 
Materials and Methods) in the presence of either a homologous or control peptide. 
Subsequent immunoblotting with anti-E2F-5 revealed that two forms of endogenous 
E2F-5 were detected in F9EC extract and both of these bound specifically to DP-1 (Fig 
3.5a, compare lane 2 and 3). Similarly extracts from COS7 cells, transfected with either 
E2F-5 alone or E2F-5 and DP-1 together, were subjected to immunoprécipitation with 
the anti-DPI monoclonal antibody. Three forms of exogenous E2F-5 were detected in 
DP-1 immunoprecipitates from cells co-transfected with E2F-5 and DP-1, whilst E2F-5 
was absent in DP-1 immunoprecipitates from cells transfected with DP-1 alone (Fig 
3.5b, compare lane 1 and 2). These results indicate that all three forms of E2F-5 (L, M 
and U) are capable of interacting with DP-1 in vivo.
One way of gaining further insight into processes that regulate E2F-5 is to 
identify proteins that interact with E2F-5 in vivo. It has been reported that E2F-5 
preferentially binds to pl30, which is most abundant in quiescent cells (Hijmans et al, 
1994; Cobrinik et al, 1993). However, in asynchronous cultures of F9EC cells and 
many other cells during S phase the major pocket protein complexing with E2F is pl07 
(Lees et al, 1992; Shirodkar et al, 1992). Several studies have shown that these
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Figure 3.5
E2F-5 associates with DP-1 and pl07 in vivo.
(a) Extract prepared from F9EC cells (400pg) was subjected to immunoprécipitation 
(IP) with an anti-DP-1 monoclonal antibody (see Materials and Methods), in 
either the presence (lane 3) or absence (lane 2) of the homologous peptide from 
which the antibody is directed. The immunoprecipitates were resolved by SDS- 
PAGE and then immunoblotted with anti-E2F-5. The reactivity of 40|Lig of F9EC 
extract with anti-E2F-5 is shown in lane 1.
(b) Expression vectors for E2F-5 (5fig) and DP-1 (5p,g) were introduced into a 10cm 
plate of COS7 cells as indicated and extracts were prepared and subjected to 
immunoprécipitation (IP) with an anti-DP-1 monoclonal antibody (see Materials 
and Methods). The immunoprecipitates were resolved by SDS-PAGE and then 
immunoblotted with anti-E2F-5, alongside 10% of the quantity of crude extract 
used in the immunoprécipitation (lane 3).
(c) RAGI extract (Img) was immunoprecipitated with an anti-pl07 monoclonal 
antibody (SD9, Santa Cruz) or a control antibody (IG4), as indicated. The 
immunoprecipitates were resolved by SDS-PAGE and then immunoblotted with 
anti-E2F-5. The reactivity of 100p,g of RAGI extract with anti-E2F-5 is shown in 
lane 3.
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complexes specifically contain E2F-4 (Shirodkar et al, 1992; Moberg et al, 1996). To 
investigate whether E2F-5 and pl07 were also associated in vivo an 
immunoprécipitation assay was employed. E2F-5 was found associated with pl07 in 
immunoprecipitates from RAGI cell extract using an anti-pl07 monoclonal antibody 
(SD9), but not when an irrelevant antibody (IG4) was used (Fig 3.5b). Therefore E2F-5 
interacts with p i07 in this cell line.
3.6 E2F-5 co-operates with DP-1 and DP-3 In transcriptional activation
The E2F family of proteins is known to activate transcription synergistically 
with DP proteins through the formation of heterodimers (Bandara et al, 1993). The 
ability of E2F-5 to activate transcription in association with a DP partner was studied 
by transient transfection using a luciferase reporter gene driven by the murine cyclin E 
promoter, a well-studied E2F regulated promoter (Botz et al, 1996). Neither DP-1 nor 
DP-36 significantly activated the cyclin E promoter when expressed without E2F (Fig 
3.6a). Moreover a titration of the E2F-5 expression vector resulted in at best 2-fold 
activation of the cyclin E promoter. A synergistic effect in ?ran.çactivation was seen 
when the levels of E2F-5 were titrated together with a constant amount of DP-1 or DP- 
36 (Fig 3.6a). DP-36 was more effective than DP-1 in cooperative activation of cyclin E 
promoter.
E2F-1 and DP-1 cooperate in transcriptional activation of the DHFR promoter 
(Lee et al, 1998). However E2F-5 did not cooperate with DP-1 in transcriptional 
activation of the DHFR promoter (Fig 3.6b). Therefore the response of promoters to 
overexpression of different heterodimers may be variable. Based on the results shown
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Figure 3.6
Synergistic activation of the cyclin E  promoter by E2F-5 and either DP-1 or 
DP-36.
(a) U20S cells were transfected with the cyclin E-luciferase reporter (Ipg), together 
with expression vectors for HA-E2F-5 (0.5, 0.75, l.Opg), DP-1 (0.75pg) or DP- 
36 (0.75pg) as indicated. The ‘+’ in lane 4 indicates that l.Ojiig of HA-E2F-5 was 
transfected.
(b) U20S cells were transfected with the DHFR-luciferase reporter (Ipg), together 
with expression vectors for HA-E2F-5 (0.5, 0.75, l.Opg) and DP-1 (0.75pg) as 
indicated. The ‘+’ in lane 3 indicates that l.Opg of HA-E2F-5 was transfected.
In both (a) and (b) pCMV-pGal (Ipg) was transfected throughout as an internal 
control. Values shown are the means of two separate readings and represent the ratio 
of luciferase to p-galactosidase activity.
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earlier, the murine cyclin E promoter was chosen as a model system to study E2F-5 
rran^activation in subsequent experiments.
3.7 Regulation of E2F-5 during the cell cycle
Cell cycle control of E2F-1 occurs at the transcriptional level, E2F-1 mRNA 
levels peaking at the Gl-S transition at the time when E2F activity is at its highest 
(Kaelin et al, 1992; Slansky et ah, 1993; Johnson et al, 1994). However the mRNA 
which encodes either E2F-4 or E2F-5 is relatively constant throughout the cell cycle 
and both genes are expressed in quiescent cells (Beijersbergen et al, 1994; Ginsberg et 
al, 1994; Sardet et al, 1995). Post-translational mechanisms of control, such as 
regulation of nuclear localisation, may provide one way of regulating these E2F 
proteins.
To determine whether E2F-5 was subject to cell cycle regulation an analysis of 
the E2F-5 protein during the Rati cell cycle was performed. Rati cells are particularly 
amenable to cell cycle analysis, being easily arrested in GO/Gl by serum deprivation. 
Rati cells were arrested by serum starvation for 70 hours and stimulated to enter the 
cell cycle by the addition of 20% serum. At the indicated time intervals, flow cytometry 
was performed to monitor the proportion of cells in different phases of the cell cycle 
(Fig 3.7a). For example, in serum starved cultures 67% of the cells were in G l, 13% 
were in S, and 20% were in G2/M (Fig 3.7a, panel ii). In western blot analysis of 
extracts from the arrested cells E2F-5 was resolved as a single polypeptide species 
(form M). At 16 hours post serum stimulation, coincident with cells entering S phase, a 
slower migrating polypeptide (form U) was detected (Fig 3.7a, panel v; Fig 7.3b). The
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Figure 3.7
E2F-5U is a cell cycle regulated form of E2F-5.
(a) Cell cycle distribution of Rati cells after serum starvation (panel ii), and at the 
indicated time points (in hours) after addition of serum (panels iii to x). Panel i 
shows the cell cycle distribution of the asynchronous population. The histograms 
show the cell number along the y-axis and the DNA content (as measured by PI 
intensity) along the x-axis. The number of cells in the different cell cycle phases 
in the serum starved population was Gl: 67%, S: 13%, 02: 20% (panel ii) and at 
16 hours post serum stimulation was Gl: 25%, S: 23%, G2: 52% (panel v). The 
markers used for the estimation of G1:S:G2/M are shown in panel vi.
(b) Extracts from Rati cells treated identically to those in (a) were prepared; AS 
indicates asynchronous cultures, SS indicates the serum starved cultures. The 
time in hours after serum addition is indicated at the top of each lane. 50pg of 
extract from each cell cycle stage were immunoblotted using an anti-E2F~5 
specific antiserum. The presence of the E2F-5M and E2F-5U are indicated.
(c) Gel retardation analysis of E2F complexes in Rati extracts at the indicated time- 
points on a consensus E2F site taken from the adenovirus E2A promoter.
Extracts from serum starved cells and cells 16h post serum stimulation were 
supershifted with the indicated antisera, and an F9 embryonal carcinoma (EC) 
cell extract is shown for comparison (lane 11); PI indicates the rabbit pre- 
immune serum. The predominant species of ‘free’ E2F is an E2F-5/DP-1 
heterodimer during S phase and at least some of the E2F/pl07 complex contains 
E2F-5.
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previous phosphatase experiment suggested that E2F-5U is a hyper-phosphorylated 
E2F-5 (see Fig 3.2c). Therefore the timing of the appearance of E2F-5U during cell 
cycle progression suggests it is the result of phosphorylation by a kinase whose 
activity is cell cycle regulated.
To assess the significance of the observed regulation of E2F-5 an investigation 
of the DNA binding properties of E2F during the Rati cell cycle was performed by gel 
retardation analysis. Rati cell extracts contain a number of discrete DNA binding 
complexes, which migrated in equivalent positions to those previously characterised in 
F9EC extract (Fig 3.7c, lanes 10 and 11). Relevant antisera revealed the presence of a 
p i07 containing complex and ‘most’ of the free E2F consisted of an E2F-5/DP-1 
heterodimer (Fig 3.7c, lanes 16-19). When the synchronised extracts were assessed for 
their ability to bind to the E2F site, there was an overall increase in DNA binding 
activity as cells entered the cell cycle. This was most striking at 12 hours post serum 
stimulation when an increase in ‘free’ E2F and the pl07 complex were detected (Fig 
3.7c, compare lane 1 and 2). At 14 to 16 hours after serum addition some of the ‘free’ 
E2F started to decline. This ‘free’ E2F DNA binding activity was not supershifted by 
the anti-E2F-5 antibody so it is likely to consist of another E2F family member (Fig 
3.7c, compare lane 16 and 17). In contrast there was no change in the level of E2F- 
5/DP-l heterodimer as cells progressed through the cell cycle (Fig 3.7c, compare lanes 
2 to 10). Therefore the regulation of E2F-5U did not correlate with any changes in the 
level of E2F-5 DNA binding activity, suggesting that the presence of E2F-5U may 
reflect another aspect of E2F-5 activity.
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3.8 Conclusion
Data presented in this chapter demonstrated that E2F-5 is an abundant
component of E2F DNA binding activity in a range of different cell types, such as
fibroblasts and cancer cell lines. Thus it may make a significant contribution to the
control of the G l to S phase transition in these cells. At the protein level E2F-5 was
detected as a heterogeneous set of polypeptides that likely result from differential
phosphorylation of E2F-5. These were designated E2F-5U, E2F-5M and E2F-5L, in
order of increasing mobility on SDS-PAGE. Interestingly one of these polypeptides,
namely E2F-5U, was absent in Rati cells arrested in GO/Gl, but appeared as the cells 
entered the cell cycle. This observation opens up the possibility that E2F-5 may be
phosphorylated in a cell cycle dependent manner. The appearance of E2F-5U during
the Rati cell cycle did not conelate with any change in the level of E2F-5 DNA-
binding activity. Furthermore in DNA affinity purification of Rati cell extract both
E2F-5U and E2F-5M bound to DNA with equal efficiency. Therefore the regulation
of E2F-5 which results in the appearance of E2F-5U during the Rati cell cycle may
be controlling some other aspect of E2F activity.
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Chapter 4
Analysis of E2F-5 phosphorylation 
by site-directed mutagenesis
4.1 Introduction
The activity of E2F is regulated through the phosphorylation of pocket proteins. 
Direct phosphorylation of E2F also occurs, but the functional significance of this is not 
fully understood. The best studied mechanism of E2F phosphorylation is the 
phosphorylation of E2F-1 and DP-1 by cyclinA-CDK2 kinase. CyclinA-CDK2 binds to 
a domain in the N-terminal region of E2F-1, which is conserved in E2F-2 and E2F-3 
but not in E2F-4 and E2F-5. The cyclinA-CDK2 binding domain is required for in vitro 
phosphorylation of E2F-1 by cyclinA-CDK2 (Krek et al, 1994). CyclinA-CDK2 can 
phosphorylate DP-1 (Krek et al, 1995) and this phosphorylation has been correlated 
with down-regulation of E2F DNA binding (Krek et al, 1994), thereby reducing the 
activity of the E2F heterodimer as cells progress through S phase.
Phosphorylation sites have been identified in E2F-1 by site-directed 
mutagenesis (Fagan et al, 1994, Peeper et al, 1995). Phosphorylation of serine 332 
and serine 337 in the C-terminal of E2F-1 prevented E2F-1 from binding pRb (Fagan et 
al, 1994). In contrast, phosphorylation of E2F-1 on serine 375 greatly enhanced its 
affinity for pRb in vitro (Peeper et al, 1994). However the in vivo significance of 
phosphorylation at these sites has yet to be determined.
It has also been suggested that E2F-4 and E2F-5 are phosphoproteins 
(Beijersbergen et al, 1994, Hijmans et al, 1995). The objectives of this chapter were to 
define phosphorylation sites in E2F-5 and investigate their role in the regulation of 
E2F-5 activity.
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4.2 Site directed mutagenesis of E2F-5
Data presented in the previous chapter suggested that E2F-5 was 
phosphorylated in cells in a cell cycle-dependent manner, and therefore may be a target 
for cyclin-dependent kinases (CDKs). To investigate whether E2F-5 is regulated by 
phosphorylation a mutational analysis of E2F-5 was perfoiTned at potential CDK 
phosphorylation sites. The consensus amino acid sequence for phosphorylation by 
CDKs is S/T-P-X-K/R. There are several CDK consensus phosphorylation sites in E2F- 
5. One site, positioned at threonine 251, fits the consensus for CDK phosphorylation 
perfectly. In addition there are several threonines and serines preceding proline residues 
that are potential targets for phosphorylation by either CDKs or other proline directed 
kinases, for example MAP kinases.
In the previous chapter in vitro translation of a C-terminal fragment of E2F-5 
generated several polypeptides, which were suggested to result from differential 
phosphorylation (see Fig 3.2d). In agreement with this idea, the majority of putative 
CDK phosphorylation sites are in the C-terminus of E2F-5. A sequence and structure- 
based prediction of phosphorylation sites has been made using an artificial neural 
network method (Blom et al, 1999; Net Phos@cbs.dtu.dk). The polypeptide sequence 
of the protein of interest is input and the prediction results are output as a score 
between 0 and 1. True phosphorylation sites should obtain a score close to 1, whereas 
non-phosphorylation sites should obtain a score close to 0. In E2F-5, serine 307 is one 
of the highest scoring residues at 0.995 and threonine 251 scored at 0.220. Therefore, 
two individual point mutations were made in the C-terminal region of E2F-5 at 
threonine 251 and serine 307 (Fig 4.1a). The mutants were designated T251A and 
S307A, to indicate that the selected residues were substituted with alanine (single
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Figure 4.1
M utant derivatives of E2F-5.
(a) Diagram of E2F-5 indicating the domains conserved with other family members 
and the threonine residue (T251) and serine residue (S307) which were mutated 
to alanine (A), the mutant derivatives being referred to as T251A and S307A 
respectively. The sequences around T251 and S307 are shown, and PP indicates 
the pocket protein-binding domain.
(b) COS7 cells were co-transfected with expression vectors for DPI (Ipg) and either 
HA-tagged E2F-5, HA-tagged T251A or HA-tagged S307A (IfXg) as indicated. 
Extracts were prepared from transfected cells and subjected to immunoblotting 
using an anti-HA monoclonal antibody. The arrow indicates an E2F-5 
polypeptide species which is absent from T251A expressing cells.
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amino acid code). Alanine substitution results in the replacement of the OH group in 
serine/threonine with a CH3 side chain, thereby preventing phosphorylation. 
Furthermore being a small, uncharged residue it is less likely than other amino acids to 
cause conformational changes to a protein. The serine at 307 is conserved in E2F-1, 
E2F-2, E2F-4 and E2F-5, whereas threonine 251 is unique to E2F-5.
Synthetic peptides have been used as substrates to show specificity between 
CDK sites preferentially phosphorylated by cyclin D1-CDK4 and cyclin A/E-CDK2 
(Kitagawa et al, 1996), The authors showed that S/T-P-X-K/R, such as the sequence 
mutated at T251, is preferentially phosphorylated by cyclinA/E-CDK2. The sequence 
surrounding serine 307 (306-LSPTP-310) more closely resembles the site of 
phosphorylation of other proline directed kinases, such as MAP kinases or cyclin D l- 
CDK4, rather than a cyclin A/E-CDK2 site.
4.3 Analysis of mutants derivatives of E2F-5
When wild-type E2F-5 is over-expressed in COS-7 cells, four E2F-5 
polypeptides were detected by western analysis (Fig 4.1a, lane 2). Three of these 
polypeptides were equivalent in mobility to E2F-5U, E2F-5M and E2F-5L, defined in 
the previous chapter (see Fig 3,2a), and the fourth form was resolved between E2F- 
5M and E2F-5U. In cells transfected with the T251A mutant derivative, the slowest 
mobility E2F-5 polypeptide, E2F-5U, was absent implying that phosphorylation on 
threonine 251 was unique to this form of E2F-5 (Figure 4.1b, compare lanes 2 and 3).
In cells transfected with S307A only two E2F-5 polypeptides were detected in western 
blot analysis (Figure 4.1b). One of these polypeptides, E2F-5L, was more abundant 
than it was in cells transfected with wild-type E2F-5 (Figure 4.1b, compare lanes 2 and
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4). However, in cells transfected with S307A mutant derivative, E2F-5U was 
undetectable and the level of E2F-5M was significantly lower than that detected in cells 
transfected with wild-type E2F-5 (Figure 4.1b, compare lanes 2 and 4). There are two 
possible explanations for this pattern. Firstly, E2F-5M may consist of E2F-5 
polypeptides that are phosphorylated at serine 307. Secondly, phosphorylation of serine 
307 in E2F-5 may be required prior to phosphorylation of E2F-5 at other sites, which 
results in the appearance of the heterogenous set of wild-type E2F-5 polypeptides.
4.4 The DNA binding activity of S307A or T251A is not compromised
To determine the functional consequences of E2F-5 phosphorylation at serine 
307 or threonine 251 the mutants derivatives were assessed for their ability to bind to 
DNA in association with a DP partner. U20S cells were transfected with E2F-5, T251A 
or S307A, alone and in combination with DP-1. Gel retardation analysis with an E2F 
site probe (see Section 3.1) revealed that extracts from cells transfected with DP-1, 
E2F-5, T251A or S307A had a similar level of DNA binding activity to extracts from 
untransfected cells (Fig 4.2b). However when E2F-5 or either of the mutants were co­
transfected with DP-1 a distinct complex of E2F-5/DP-1 heterodimer was detected, that 
was of a similar intensity for wild-type E2F-5 and both of the mutants (Fig 4.2b, lanes 
6-8). Western blotting of the same extracts showed that the level of E2F-5 was equal 
and thus directly proportional to the DNA binding activity (Fig 4.2b). Figure 4.2 is a 
representative example of three experiments. The results therefore suggest that 
phosphorylation of threonine 251 and serine 307 is unlikely to influence the ability of 
E2F-5 to heterodimerise with DP-1 and bind DNA.
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Figure 4.2
The DNA binding activity of T251A and S307A is not compromised.
(a) Gel retardation analysis of extracts from U20S cells transfected with expression 
vectors for HA-tagged E2F-5, HA-tagged T251A or HA-tagged S307A (4pg), 
DP-1 (4pg), as indicated. The position of the E2F-5/DP-1 heterodimer and a non­
specific (NS) band are indicated.
(b) Immunoblot using the HA monoclonal antibody of extracts from lanes 6,7,8 in
(a), containing HA-tagged E2F-5, HA-tagged T251A or HA-tagged S307A, 
together with DP-1.
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It is noteworthy that exogenous E2F-5 was resolved as a single polypeptide in a 
western blot of the U20S extracts used in the above gel retardation analysis (Fig 4.2b). 
This is clearly different from the cluster of E2F-5 polypeptides detected in COS7 cells 
(Fig 4. lb). In other U20S transfections exogenous E2F-5 was resolved as multiple 
polypeptides and therefore the expression of individual E2F-5 polypeptides may vary 
with transfection efficiency. In conclusion wild-type E2F5, T251A and S307A do not 
differ in their DNA binding activity when over-expressed with DP-1 in U20S cells. 
This is consistent with the data in chapter 3, which showed that both E2F5L and E2F- 
5M bound to DNA (see Fig 3.4a).
4.5 T251A and S307A retain the ability to bind to pocket proteins
In order to test whether phosphorylation of threonine 251 or serine 307 in E2F-5 
influenced binding to pocket proteins, expression vectors for E2F-5 and the mutant 
derivatives were transfected into U20S cells together with DP-1 and either p i30 or 
p i07. Gel retardation analysis of extracts containing exogenous wild-type E2F-5, DP-1 
and pl30 resolved a distinct pl30 complex (Fig 4.3a, lane 7). This complex was 
dependent on the transfection of all three plasmids as it was not detected in control 
extracts containing the individual plasmids were transfected alone (Fig 4.3a, lanes 2,3 
and 6). An identical complex was detected when extracts containing T251A or S307A, 
DP-1 and p i30 were subject to gel retardation analysis. In addition to the p i30 complex 
some of the E2F-5 in these extracts resolved as a ‘free’ E2F-5/DP-1 heterodimer, 
suggesting the level of pl30 was limiting. Furthermore the ratio of ‘free’ E2F-5/DP-1 
to complexed E2F-5/DP-l/pl30 was identical in all three transfections, suggesting the 
mutant derivatives did not differ from E2F-5 in their affinity for pl30. Western blotting
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Figure 4.3
T251A and S307A retain the ability to bind to pl30.
(a) Gel retardation analysis of extracts from U20S cells transfected with expression 
vectors for HA-tagged E2F-5, HA-tagged T251A or HA-tagged S307A (4fxg), 
DP-1 (4pg) and HA-tagged pl30 (4|Lig), as indicated. The position of the Tree’ 
E2F-5/DP-1 heterodimer and E2F-5/DP-l/pl30 complex are indicated. NS is a 
non-specific band.
(b) Immunoblot using the HA monoclonal antibody of extracts (a). The lane numbers 
in (a) and (b) coirespond to the same extract. The position of the HA-tagged pl30 
and HA-tagged E2F-5 and the mutant derivatives are indicated.
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confirmed that pl30 expression was equal in each of these treatments (Fig 4.3b). An 
increase in E2F-5 protein occurred when E2F-5 or the mutant derivatives were co­
expressed with DP-1 and p i30 (Fig 4.3b, compare lanes 4-5 with lanes 7-9). This was 
not due to increased transfection efficiency, as the P-galactosidase activity in the 
extracts, resulting from the P-galactosidase plasmid transfected as an internal control, 
remained constant. A potential explanation for this observation is suggested by recent 
evidence that E2F-1 and E2F-4 are stabilised by binding to pocket proteins (Hateboer et 
al, 1996; Hofmann et al, 1996). An analogous situation may occur when E2F-5 and 
p i30 interact.
Figure 4.3b also shows a clear difference in the polypeptide profile of the wild- 
type and mutant derivatives of E2F-5, with E2F-5U appearing only when wild-type 
E2F-5 but not when T251A is transfected (Fig 4.3b, compare lane 7 and 8). In addition 
the S307A mutant is seen to clearly consist of a combination of two polypeptides, E2F- 
5L being the most abundant and E2F-5M is also present at reduced levels (Fig 4.3b, 
lane 9). The presence of E2F-5M is possibly a result of phosphorylation of S307A on 
threonine 251 which remains intact in this protein, although there may be several other 
sites phosphorylated. Phosphopeptide mapping is required to confirm this.
The above gel retardation analysis was repeated using extracts transfected with 
pl07 instead of pl30 but a pl07 complex was not detected (data not shown). This 
observation may reflect a reduced affinity of E2F-5 for pl07 compared to pl30, as 
E2F-5 has been shown to preferentially interact with pl30 (Hijmans et al, 1995). The 
interaction of p i07 with each of the mutants is investigated further in section 4.6 and 
chapters 5 and 6.
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4.6 Cellular Localisation of E2F-5
During these studies work was published to show that the majority of E2F-5 and 
DP-1 is cytoplasmic when over-expressed in U20S cells, as both proteins lack an 
inherent nuclear localisation signal (NLS) (Allen et al, 1997). Moreover pl07 can 
supply a NLS to the E2F heterodimer, transporting it into the nucleus. It was possible 
therefore that the phosphorylation status of E2F-5 affected the ability of the E2F-5/DP- 
1 heterodimer to bind and co-localise in the nucleus with pl07. To explore this idea the 
cellular localisation of the E2F-5 mutant derivatives and p i07 was determined.
HA-tagged E2F-5, T251A, S307A and DP-1 were expressed in U20S cells by 
transient transfection and their cellular distribution determined by indirect 
immunofluorescence. Two different secondary fluorescent-tagged antibodies were 
used, rhodamine-conjugated anti-mouse antibody (for HA or p i07) or fluoroscein- 
conjugated anti-rabbit antibody (for DP-1). U20S cells were either immuno-stained for 
HAE2F-5 and DP-1 or pl07 and DP-1. The majority of E2F-5 and the mutant 
derivatives were cytoplasmic when over-expressed with DP-1 (Fig 4.4a, panel i, iii, v). 
Similarly DP-1 was predominantly cytoplasmic in these cells (Fig 4.4a, panel ii, iv, vi). 
However, E2F-5 co-localised with DP-1 in the nucleus when they were expressed with 
pl07, suggesting that the heterodimer binds to pl07 and utilises the pl07 NLS to enter 
the nucleus (Fig 4.4c, panel i and ii). Consistent with this, in all cells transfected with 
E2F-5, DP-1 and p i07, a nuclear staining of p i07 was observed, whereas DP-1 was 
only nuclear when expressed in the same cell as pl07 (Fig 4.4b, compare i and ii).
The mutant derivatives of E2F-5 did not differ from E2F-5 in their sub-cellular 
localisation in either the absence (Fig 4.4a, iii to vi) or presence of co-transfected pl07 
(Fig 4.4c, iii to vi). Therefore, phosphorylation of E2F-5 at threonine 251 or serine 307
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Figure 4.4
E2F-5, T251A and S307A are cytoplasmic and their nuclear accumulation is
mediated by pl07.
(a) U20S cells were transfected with either Ijig of HA-tagged E2F-5 (i and ii), Ipg 
of HA-tagged T251A (iii and iv), or l|ug of FlA-tagged S307A (vi and vii), 
together with DP-1 (IjLig). The intracellular distribution of the DP-1 subunit and 
the HA-tagged E2F heterodimeric partner was assessed by immunofluorescence 
with a rabbit polyclonal anti-DP-1 antibody (ii, iv, vii) and an anti-HA 
monoclonal antibody (i, ii, and vi). The majority of exogenous E2F-5 (i), T251A 
(iii), S307A (vi) and DP-1 (ii, iv, vii) is cytoplasmic.
(b) U20S cells were transfected with Ijitg of HA-tagged E2F-5, IjLig of DP-1 and 
Ijig of pl07. The intracellular distribution of DP-1 and p i07 was determined by 
immunofluorescence with a rabbit polyclonal anti-DP-1 antibody (ii) and an anti- 
pi 07 (SD9) monoclonal antibody (i). A nuclear staining pattern was observed for 
pl07 (i). DP-1 was nuclear in cells co-expressing pl07, but cytoplasmic in cells 
where pl07 expression was undetectable (compare i and ii).
(c) U20S cells were transfected with either HA-tagged E2F-5, HA-tagged T251A or 
HA-tagged S307A (Ijig), together with lp,g of DP-1 and Iqg of pl07. The 
intracellulai* distribution of exogenous DP-1 and HA-tagged E2F-5 and the 
mutant derivatives was determined by immunofluorescence with a rabbit 
polyclonal anti-DP-1 antibody (ii, iv, vii) and an anti-HA monoclonal antibody.
A nuclear staining pattern was observed for exogenous E2F-5, T251A and 
S307A (i, iii and vi, respectively) and DP-1 (ii, iv, vii).
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does not effect its ability to bind to p i07 and enter the nucleus via the pl07-directed 
nuclear import mechanism.
4.7 Conclusion
There are several consensus phosphorylation sites in E2F-5. Two of these sites, 
positioned at serine 307 and threonine 251 were mutated to alanine to produce mutant 
derivatives of E2F-5, designated S307A and T251A respectively. It was demonstrated 
that when E2F-5 was over-expressed in COS-7 cells a heterogenous cluster of 
polypeptides was detected on SDS-PAGE (Fig 4.1b). However, the number and 
distribution of these polypeptides was different in cells expressing mutant derivatives 
of E2F-5, incapable of phosphorylation at either serine 307 or threonine 251. 
Specifically, T251A expressing cells lacked one slowly migrating polypeptide relative 
to the cluster produced by wild-type E2F-5. Moreover, two E2F-5 polypeptides were 
absent in extracts of cells expressing S307A. These observations imply that 
phosphorylation at serine 307 and threonine 251 is important for the appearance of 
specific slower mobility E2F-5 polypeptides.
Several properties of E2F-5 were unaffected in the mutant derivatives, namely 
DNA binding activity, interaction with p i07 and sub-cellular localisation. These 
observations establish that mutagenesis of E2F-5 did not alter the integrity of the E2F-5 
protein. Furthermore, they rule out possible mechanisms for the functional consequence 
of phosphorylation of E2F-5 at serine 307 and threonine 251. The E2F-5 mutant 
derivatives are employed in the following chapters to explore the functional 
consequences of phosphorylation at these sites on E2F activity.
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Chapter 5
Regulation of E2F activity by 
phosphorylation
5.1 Introduction
Many of the genes that are believed to play an important role in regulating early cell 
cycle progression contain E2F binding sites in their promoters. Among these are genes 
that encode regulators of the cell cycle (e.g. cdc-2, cyclins A, D and E) and genes 
encoding enzymes required for DNA synthesis (e.g. DHFR, thymidine kinase and DNA 
polymerase d). Physiological E2F consists of an E2F and DP component which 
together bind synergistically to the E2F site and activate transcription through the 
rransactivation domain of the E2F subunit (Dyson, 1998). The fraMj^activation domain 
also contains the interface recognised by pRb, which upon binding E2F is believed to 
hinder the interaction between the activation domain and the transcription apparatus 
(Helin, 1998). However, some E2F binding sites can also mediate transcriptional 
repression (Weintraub et a l, 1992). The cyclin E promoter contains several E2F sites 
which have been shown to be involved in both activation and repression of 
transcription (Butz et a l, 1996; Geng et a l, 1996; Cam et a l, 1999)
Data presented in the previous chapters raised the possibility that phosphorylation 
of E2F-5 may be important for some other aspect of E2F function besides DNA 
binding. In this chapter the S307A mutant derivative of E2F-5 was studied to explore 
the role of serine 307 phosphorylation in E2F-5-dependent transcriptional activation 
and repression.
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5.2 S307A has a compromised transcriptionai activity
In order to investigate the role of E2F-5 phosphorylation in E2F-dependent 
transcription the mutant derivative of E2F-5, S307A, was assessed for its ability to 
activate the cyclin E promoter. Transient transfection of U20S cells with cyclinE- 
luciferase and expression vectors for either E2F-5 or S307A yielded an insignificant 
stimulation of reporter activity (Fig 5.1a). However when E2F-5 or S307A were co­
transfected with DP-1 a significant induction in reporter activity was observed.
Titration of E2F-5 levels in the presence of a constant amount of DP-1 induced reporter 
activity in a dose-dependent manner, to a maximum of 14-fold above that produced by 
DP-1 alone (Fig 5.1a, lanes 4-8, lane 14). The maximal trancriptional activation 
achieved by S307A and DP-1 was 8-fold (Fig5.1a, lanes 9-13). Furthermore, the rise in 
reporter activity in response to increasing amounts of S307A was not as steep as that 
detected when equivalent amounts of wild-type E2F-5 were transfected. These 
observations imply that S307A has a compromised transcriptional activity.
To determine whether the effect of S307A on E2F dependent transcription was 
specific for heterodimers containing DP-1, the reporter assay was repeated replacing 
DP-1 with DP-38. E2F-5 and DP-38 synergistically activated the cyclin E promoter by 
9-fold, whereas the maximum activation caused by S307A and DP-38 was 5-fold (Fig 
5.1b, compare lane 7 and 11). Thus the rran^activation ability of S307A was 
compromised by approximately 45%, irrespective of its heterodimerisation partner.
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Figure 5.1
S307A has a compromised transcriptionai activity.
(a) The S307A/DP-1 heterodimer is less efficient at activating the cyclin E  
promoter than the E2F-5/DP-1 heterodimer. U20S cells were transfected with 
the cyclin E-luciferase reporter (Ipg), together with expression vectors for HA- 
E2F-5 or HA-S307A (0.25, 0.5, 0.75, 1.0, 1.5pg), DP-1 (Ipg), as indicated. 
The’+’ below lane 2 and 3 indicates that 1.5pg of HA-E2F-5 or HA-S307A was 
transfected, respectively.
(b) The S307A/DP-3Ô heterodimer is less efficient at activating the cyclin E  
promoter than the E2F-5/DP-3Ô heterodimer. U20S cells were transfected 
with the cyclin E-luciferase reporter (Ipg), together with expression vectors for 
HA-E2F-5 or HA-S307A (0.25, 0.5, 0.75, 1.0), DP-38 (0.75pg), as indicated. 
The’+’ below lane 2 and 3 indicates that l.Opg of HA-E2F-5 or HA-S307A was 
transfected, respectively.
In both (a) and (b) pCMV-|3Gal (Ipg) was transfected throughout as an internal 
control. Values shown are the means of two separate readings and represent the ratio 
of luciferase to (3-galactosidase activity.
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5.3 Mutation of E2F-5 to S307A does not alter Its ability to bind p107
The pocket protein pl07 can physically associate with the E2F-5/DP-1 
heterodimer resulting in accumulation of the heterodimer in the nucleus (Allen et al. 
1997). In the previous chapter it was shown that this aspect of E2F-5 regulation was not 
altered in S307A. Although these data showed that E2F-5 or S307A and pl07 could co- 
localise in the nucleus, they did not give an indication of the binding efficiency of the 
two proteins for each other. Therefore, an immunoprécipitation assay was performed to 
determine whether E2F-5 and S307A have different affinities for p i07.
Co-expression of E2F-5 with p i07 resulted in an overall increase in E2F-5 
protein levels, with a proportionally greater increase in the levels of E2F-5L (Fig 5.2a, 
compare lane 1 and 4). A possible explanation for this is that binding of E2F-5 to pl07 
stabilises E2F-5. Thus it is conceivable that p i07 binds with greater affinity to E2F-5L 
or 8307A. To test this hypothesis U20S cells were transfected with either HA-tagged 
E2F-5 or S307A, in combination with DP-1 and pl07. The levels of pl07 were equal in 
extracts from these cells as confirmed by western blotting (Fig 5.2b). The extracts were 
immunoprecipitated with an anti-pl07 monoclonal antibody (SD9), followed by 
immunoblotting with anti-HA to assess whether E2F-5 and p i07 formed a complex 
(Fig 5.2c). Both E2F-5 and 8307A were co-immunoprecipitated with pl07 (Fig 5.2c, 
lane 4 and 6). To quantify the relative binding efficiency of E2F-5 and 8307A for pl07, 
the ratio of input E2F-5/8307 in the crude extract to the level of E2F-5 in the pl07 
immunoprecipitate was calculated. The level of E2F-5 and 8307A binding to pl07 was 
11% of that in crude extract, indicating that 8307A had the same affinity for pl07 as 
wild-type E2F-5 in these extracts.
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Figure 5.2
E2F-5 and S307A bind to pl07 with similar efficiencies.
(a) Immunoblot with anti-HA monoclonal antibody of extracts from U20S cells, 
transfected with HA-tagged E2F-5 (4fxg), HA-tagged-S307A (4jag) and pl07 
(4|Lig), as indicated.
(b) Immunoblot with anti-HA monoclonal antibody and anti-p 107 monoclonal 
antibody (SD9) of extracts from U20S cells, transfected with expression vectors 
for pl07 (lOjag) and either lOjig of HA-tagged E2F-5 (lane 1), or lOpg of HA- 
tagged-S307A (lane 2).
(c) Extracts described in (b) and a control extract from U20S cells, transfected with 
the relevant empty vector DNA, were immunoprecipitated (IP) with an anti-pl07 
monoclonal antibody (SD9) or an anti-HA monoclonal antibody, as indicated. 
The immunoprecipitates were resolved by SDS-PAGE and then immunoblotted 
with anti-HA. Lane 7 shows the reactivity of 10% of the input extract from lane 3 
and 4.
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5.4 Transcriptional activation and repression mediated by Gai4-E2F5
To study the effects of E2F-5 phosphorylation on the E2F-5 mediated 
transcriptional activitation domain, a C-terminal region of E2F-5 (amino acids 198- 
335) was fused to a heterologous DNA binding domain (DBD). The resulting construct 
consisted of Gal4 DBD and the ^ran^:activation domain, but not the DNA binding or 
dimérisation domain of E2F-5. Transient transfection of the Gal4E 1B-luciferase 
reporter and increasing amounts of the Gal4-E2F5 expression vector stimulated 
reporter activity between 100 and 700-fold in a dose-dependant manner (Fig 5.4a, lanes 
2-4). However a maximum of 400-fold induction of reporter activity was achieved by 
Gal4-S307A (Fig 5.4a, lanes 5-7). A similar result was observed in C33A cells, where 
the ability of Gal4-S307A to activate transcription was reduced by approximately 50% 
compared to Gal4-E2F5 (Fig 5.4b). Thus the phenotype of full length S307A can be 
transferred to Gal4-S307 (198-335), suggesting that sequences in this C-terminal region 
of E2F-5 were responsible for the compromised ability of full length S307A to activate 
transcription.
The ?ran5activation and pocket protein-binding domain remain intact in Gal4- 
E2F-5 so it was reasoned that proteins that interact with these domains might be 
important in mediating the effects of phosphorylation of serine 307 in E2F-5. 
Previously, by immunoprécipitation, it was shown that the efficiency of binding 
between S307A and pl07 was indistinguishable from that of wild-type E2F-5 (see 
Section 5.3). To further investigate whether phosphorylation of serine 307 has a role in 
modulating the response of E2F-5 to pocket proteins, Gal4-E2F-5 and Gal4-S307A 
were assessed for their ability to be repressed by pocket proteins.
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Figure 5,3
A GaI4-S307A fusion protein has the same effect on transcriptional activation as 
full length S307A.
(a) U20S cells were transfected with the Gal4EIB-luciferase reporter (Ifig), 
together with expression vectors for Gal4-E2F-5 or Gal4-S307A (50, 100,
150ng), as indicated.
(b) C33A cells were transfected with the Gal4EIB-luciferase reporter (Ipg), together 
with expression vectors for Gal4-E2F-5 or Gal4-S307A (50, 75, 100, 125ng), as 
indicated.
In both (a) and (b) pCMV-pGal (Ipg) was transfected throughout as an internal 
control. Values shown are the means of two sepaiate readings and represent the ratio 
of luciferase to p-galactosidase activity.
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SAOS-2 cells were transfected with Gal4EIB-luciferase and either expression 
vectors for Gal4-E2F5 or Gal4-S307, together with increasing amounts of a pl30 
expression vector. The level of traw.sactivation mediated by either Gal4-E2F-5 or Gal4- 
S307A was inhibited in a pl30 concentration-dependent fashion, with maximal 
repression ocurring at 200ng of p i30 (Fig 5.4c). A similar response was observed when 
the transfection was repeated substituting p i30 with p i07, with maximal repression 
requiring 600ng of transfected pl07 (Fig 5.4d). Therefore maximum repression of both 
the wild-type and mutant E2F-5 required the same quantity of p i30 or p i07, suggesting 
that both E2F-5 and S307A bind to either pocket protein with the same efficiency. 
However, the overall percentage of pl07 induced repression was greater with wild-type 
E2F-5 than S307A. This effect is unlikely to reflect a preferential interaction between 
wild-type E2F-5 and p i07, rather wild-type E2F-5 is intrinsically more active than 
S307A and therefore when wild-type E2F-5 interacts with pl07 the consequence is a 
more marked reduction in transactivâtion.
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Figure 5.4
pl07 and pl30 both repress GaI4-E2F-5 and Gal4-S307A to a similar level.
U20S cells were transfected with the Gal4EIB-luciferase reporter (Ipg), together 
with expression vectors for Gal4-E2F-5 or Gal4-S307A (lOOng) and:
(a) the indicated amounts of a pl30 expression vector;
(b) the indicated amounts of a p 107 expression vector.
The red line represents wild-type Gal4-E2F-5 and the blue line represents Gal4- 
S307A. In both (a) and (b) pCMV-gGal (Ipg) was transfected throughout as an 
internal control. Values shown are the means of two separate readings and represent 
the ratio of luciferase to P-galactosidase activity.
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5.5 The transcriptional activity of E2F-5 and S307D are equal
Phosphorylation confers a negative charge to a protein which can be mimicked 
by substituting the phosphorylated residue with aspartate. A mutant E2F-5 derivative 
was created with an aspartate at position 307, refered to as S307D. U20S cells were 
transiently transfected with expression vectors for either E2F-5, S307A or S307D and 
cell extracts were analysed by western blotting (Fig 5.5a). S307D resolved as a single 
polypeptide of a slower mobility than S307A and of approximately the same mobility 
as the major wild-type E2F-5 polypeptide (E2F-5M). Thus, introducing a negative 
charge at serine 307 in E2F-5 resulted in a mobility shift of the faster migrating E2F-5L 
to a more slowly migrating polypeptide, E2F-5M. To explore the reasons for these 
mobility differences cell extracts, transfected with expression vectors for E2F-5 or 
S307D together with DP-1, were treated with lambda-phosphatase. Phosphatase 
treatment induced a mobility shift of E2F-5 from the M to the L form, but did not effect 
the mobility of S307D (Fig 5.5b). This was the expected result if phosphorylation on 
serine 307 is the only reason for the mobility difference between E2F-5L and E2F-5M, 
although the possibility that there are other differences in post translational 
modification of these polypepetides cannot be excluded.
The transcriptional activity of S307D was found to be indistinguishable from 
E2F-5 when they were assessed for their ability to activate cyclinE-luciferase in 
combination with a DP-1 partner (Fig 5.5c). Thus S307D had greater fran.sactivation 
ability than S307A. Taken together these results suggest that when E2F-5 is over­
expressed by transient transfection it is phosphorylated on serine 307 by an endogenous 
kinase. This modification enhances the transcriptional activity of E2F-5 and is 
mimicked in S307D, but is lost in S307A.
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Figure 5.5
Mutation of serine 307 in E2F-5 to aspartate alters E2F-5 electrophoretic
mobility but does not affect E2F-5 dependent transcription.
(a) Immunoblot with anti-HA of extracts from U20S cells transfected with 5pg of 
either HA-tagged E2F-5, HA-tagged S307A or HA-tagged S307D, as indicated.
(b) U20S cells were transfected with 5pg of HA-tagged E2F-5 or HA-tagged S307D 
and extracts were treated with X-phosphatase (lane 2 and 4). Control reactions 
were treated in the same way except X-phosphatase was omitted from the reaction 
mixture (lane 1 and 3). E2F-5 was detected by immunoblotting with anti-HA 
monoclonal antibody.
(c) U20S cells were transfected with the cyclin E-luciferase reporter (Ipg), together 
with expression vectors for HA-E2F-5 or HA-S307D (0.5, 0.75, 1.0), DP-1 
(Ipg), as indicated. The’-f’ below lane 2 and 3 indicates that l.Opg of HA-E2F-5 
or HA-S307D was transfected, respectively. Values were calculated as for figure 
5.1.
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5.7 Effect of S307A on the Cell Cycle
U20S cells were stably transfected with doxycyclin inducible HA-tagged E2F- 
5, HA-tagged S307A or empty expression plasmid (Allen and La Thangue, personal 
communication). These cells were used to investigate the effect of the serine to alanine 
mutation in S307A on cell cycle progression. One cell-line expressing wild-type E2F-5 
(designated W Tl) and another expressing S307A (designated S5) expressed high levels 
of E2F-5 when compared to control cells stably transfected with empty expression 
plasmid (Fig 5.6a). However when these cells were tested for inducibility in the 
absence and presence of doxycyclin the levels of E2F-5 and S307A remained similar 
(Allen and La Thangue, personal communication).
There were only minor differences in the cell cycle profiles of cells expressing 
wild-type E2F-5 and cells expressing S307A (Fig 5.6b). BrdU labelling was employed 
to measure the number of cells in S phase and the BrdU labelled cells were counted by 
FACS. In addition propidium iodide staining was used to assess the DNA content of the 
cells so the number of cells in G1 and G2 phases could also be measured. The number 
of S phase cells in both the WTl and S5 cell lines was 60-62% greater than the number 
in the control cell line (Fig 5.6b). To accommodate this increase in S phase there was a 
fall in the G1 and G2/M population of both WTl and 85 cells, relative to the control. 
However the fall in G1 phase was greater in WTl cells and the fall in G2/M was 
greater in 85 cells.
The stable cell lines were serum starved to investigate whether overexpression 
of E2F-5 or 8307A influenced the ability of the cells to undergo a cell cycle arrest. 
8erum starvation increased the G1 population of control cells and cells expressing 
8307A, but had a much smaller effect on the cells expressing wild-type E2F-5,
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indicating cells that over-expressed S307A could be more readily arrested than cells 
that over-expressed wild-type E2F-5 (Fig 5,6c).
5.8 Conclusion
The data presented in this chapter suggests that E2F-5 transcriptional activity is 
regulated by direct phosphorylation of E2F-5 at serine 307. Evidence supporting this 
conclusion came from the analysis of a mutant derivative of E2F-5 incapable of 
phosphorylation at serine 307 (S307A). S307A has a reduced transcriptional activity, 
both as a heterodimer with DP-1 or DP-3, and as a Gal4-hybrid protein. Data presented 
in this and the previous chapter suggest that phosphorylation of E2F-5 at serine 307 
does not regulate its DNA binding activity or ability to heterodimerise with a DP 
partner. Furthermore there was no difference in the ability of E2F-5 and S307A to 
interact with pocket proteins. Therefore phosphorylation of E2F-5 at serine 307 is 
unlikely to mediate its effect on transcription through any of these mechanisms.
The ability of E2F to promote cell cycle progression is believed to involve the 
activation of key target genes (Dyson, 1998). Both E2F-5 and S307A were capable of 
stimulating cell cycle progression when stably expressed in U20S cells. This was 
demonstrated by an increase in BrdU incorporation, relative to the control cell line. 
Cells stably expressing S307A could be arrested by serum starvation. However cells 
expressing wild-type E2F-5 were incapable of arrest by serum starvation. Therefore 
phosphorylation of E2F-5 on serine 307 may play a role in cell cycle re-entry from 
GO/Gl into S phase.
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Fig 5.6
Differences in the cell cycle profile between cells expressing E2F-5 and S307A.
(a) Immunoblot with anti-HA monoclonal antibody of extracts from cells stably 
transfected with HA-tagged E2F-5 (WTl), HA-tagged S307A (S5), or empty 
expression vector (Control).
(b) The stable cell lines, W Tl, S5 and the control cell line, were analysed by flow 
cytometry after labeling with BrdU and staining with propridium iodide. The data 
are presented as the percentage change of cells in each phase of the cell cycle, 
compared to the control cell line.
(c) W Tl, S5 and control cells were serum starved for 72 hours. The serum starved 
cells and asynchronous populations of W Tl, S5 and control cells were analysed 
by flow cytometry. The data are presented as the percentage change in the 
number of G1 cells in the serum starved populations, relative to the number of 
G1 cells in the asynchronous population.
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Chapter 6
Regulation of E2F-5 by CyclinE- 
CDK2
6.1 Introduction
The G1 cyclin dependent kinases (CDK) control entry into S phase by 
phosphorylating key substrates (Sherr, 1993). Members of the cyclin D family and their 
catalytic partners, CDK4 and CDK6, are most recognised for their role in 
phosphorylating pRb, which plays an important role in the regulation of the Gl/S 
transition. Phosphorylation of pRb releases it from E2F enabling the activation of E2F 
target genes, such as cyclin E. In most cells, the accumulation of cyclin D-dependent 
kinase activity is followed by the activation of cyclinE-CDK2 kinase, which is believed 
to be involved in completing the process of pRb phosphorylation at additional sites 
(Lundberg and Weinberg, 1998). However, in cells anested through the expression of a 
phosphorylation-deficient mutant pRb, the introduction of cyclinE-CDK2 allows cells 
to progress into S phase (Alevizopoulos et a l, 1997; Lukas et a l, 1997), suggesting 
that cyclinE-CDK2 targets at least one other critical effector of cell cycle progression. 
Although it is known that cyclinE-CDK2 activity is necessary for entry into S phase 
few in vivo substrates for cyclinE-CDK2 have been identified (Ohtsubo et a l, 1995). In 
this chapter the phosphorylation of E2F-5 by cyclinE-CDK2 and the functional 
consequence of phosphorylation of the threonine 251 site in E2F-5 are explored.
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6.2 E2F-5 is phosphorylated in vitro by cyclinE-CDK2
In chapter 4 it was shown that in COS7 cells transfected with E2F-5, a number 
of E2F-5 polypeptides with different electrophoretic mobility were detected by western 
blot analysis, with an anti-E2F-5 antibody. One of these polypeptides was absent in 
cells transfected with the T251A mutant derivative of E2F-5 (see Fig 4.1b). The 
polypeptide lost in the T251A mutant form of E2F-5 is of an equivalent mobility to the 
endogenous E2F-5 polypeptide (E2F-5U) in Rati cells which occurs at the Gl-S phase 
transition, suggesting it is the result of phosphorylation of E2F-5 by a G1 cyclin/CDK 
complex (see Fig 3.7b).
To explore the idea that E2F-5 is phosphorylated by cyclinE-CDK2, in vitro 
phosphorylation reactions were performed with recombinant E2F-5. Initially E2F-5 and 
the mutant derivative, T251A, were expressed as GST fusion proteins in bacteria.
When the purified preparations were subjected to SDS-PAGE and Coomassie Blue 
staining a 73kDa band, the estimated size of the GST fusion protein, was detected (Fig 
6.1a). In addition a ladder of smaller bands was detected, probably as a result of protein 
degradation or bacterial contamination in the GST-E2F-5 preparation. The identity of 
full length E2F-5 was confirmed by western blotting with anti-E2F-5 and an abundant 
band at 73kDa and four smaller polypeptides were detected (Fig 6.1a, lane 3). The 
expression and purity of the 73kDa full-length E2F-5 fusion protein was poor. It 
corresponded to approximately 1% of the overall GST-E2F-5 preparation.
In vitro kinase assays were performed using GST-E2F-5 and either cyclinE- 
CDK2 or cyclinA-CDK2 purified from baculovirus infected Sf9 cells. Histone HI was 
used as a positive control to determine the relative activity of the kinases, cyclinA- 
CDK2 being the most efficient at phosphorylating Histone HI in this assay (Fig 6.1b,
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Figure 6.1
GST-E2F-5 but not GST-T251A is phosphorylated by cycIinE-CDK2 in vitro.
(a) Coomassie stained SDS-PAGE of GST-E2F-5 and GST-T251A.
Purified GST-E2F-5 was resolved on SDS-PAGE and transferred to 
nitrocellulose. The nitrocellulose strip was cut in half and one half lane was 
probed with anti-E2F-5 antiserum (see Materials and Methods) and the other half 
was stained with Coomassie.
(c) Purified GST-E2F-5 and GST-T251A (approximately 0.5pg of each full-length 
protein) were used as phosphorylation substrates for cyclinE-CDK2 and cyclinA- 
CDK2 (50ng), purified from baculovirus-infected Sf9 cells. Phosphorylation of 
histone HI served as a positive control (lanes 3, 4 and 5 contain Ipg, lane 6 
contains 0.5pg). The asterisks indicate the position of full-length E2F-5 (73kDa) 
and a smaller specific E2F-5 polypeptide (60kDa). A higher exposure of the 
upper part of the gel is shown so the low intensity bands corresponding to E2F-5 
phosphorylation can be detected. A: cyclin A; E: cyclin E.
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compare lanes 4 and 5). CyclinA-CDK2 and cyclinE-CDK2 both phosphorylated 
polypeptides of 73kDa and 60kDa in the GST-E2F-5 preparation but, relative to 
Histone HI, these two polypeptides were more efficiently phosphorylated by cyclinE- 
CDK2 (Fig 6.1b, lanes 1 and 2). A 73kDa and 60kDa polypeptide were also detected 
by anti-E2F-5 and were therefore deemed to be E2F-5 polypeptides (Fig 6.1a, lane 3). 
However cyclinA-CDK2 or cyclinE-CDK2 phosphorylated neither the 73kDa nor the 
60kDa polypeptides in the GST-T251A preparation (Fig 6.1b, lanes 7 and 8). 
Polypeptides of approximately 30kDa, present in both the GST-E2F-5 and GST-T251A 
preparations, were phosphorylated by cyclinA-CDK2 to the same extent. These are 
likely breakdown products consisting of GST and N-terminal fragments of E2F-5, 
which judging by their size would not contain the C-terminal T251 site and therefore 
served as an internal control for phosphorylation. However the 60kDa polypeptide is 
large enough to be a C-terrrdnally degraded E2F-5 polypeptide which still contains the 
T251 site (Fig 6.1b, lanes 2 and 8). As the only difference between the two preparations 
is a single amino acid at position 251 in T251A then the absence of phosphorylation in 
GST-T251A must be due to the loss of this important threonine residue. This implies 
either that threonine 251 is phosphorylated in E2F-5 or the absence of threonine 
251 in T251A has prevented GST-T251A from becoming phosphorylated on other 
sites.
One drawback of using bacterially expressed GST-E2F-5 was that it was not 
sufficiently pure to prove cyclinE-CDK2 phosphorylation of E2F-5 was direct. In an 
attempt to improve purification, His-tagged bacterial expression vectors of E2F-5 were 
constructed. Purification of His-tagged E2F-5 expressed in bacteria proved the most 
successful system for preparing greater levels of pure E2F-5 (Fig 6.2a, lane 1).
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Figure 6.2
Mutation of threonine 251 in E2F-5 to alanine prevents phosphorylation of
E2F-5 by cyclinE-CDK2 in vitro.
(a) Coomassie stained SDS-PAGE of bacterially expressed purified his-E2F-5 and 
cyclinE-CDK2 purified from baculovims infected Sj9 cells.
(b) Purified His-E2F-5 (Ipg), His-T251A (Ipg) and His-S307A (Ipg) were used as 
substrates for phosphorylation by protein complexes immunoprecipitated from 
Rati cell extracts with control anti-Gal4 (lane 1), anti-CDK2 (lanes 2, 3 and 4) or 
anti-cyclinE (lanes 5, 6 and 7). The aiTow indicates phosphorylated E2F-5.
(c) The cyclinE-CDK2 complex (50ng) purified from baculovirus infected Sj9 cells 
was used to phosphorylate his-E2F-5 (Ipg: lane2), his-T251A (Ipg; lane 3); the 
aiTOw indicates phosphorylated E2F-5. Phosphorylation of histone HI served as 
a positive control (lane 1). The asterisk indicates a non-specific polypeptide, 
which migrates in an equivalent position to purified cyclin E, therefore may be 
autophosphorylation of cyclin E.
(d) His-E2F-5 (Ijag) and histone HI (lp,g) were in vitro phosphorylated by cyclinE- 
CDK2 (50ng) purified from baculovims infected Sf9 cells, in the presence of 
non-radioactive ATP. Reactions were also perfoi*med in the absence of ATP (lane 
1 and 3). Thereafter the reactions were subjected to SDS-PAGE and Coomassie 
staining.
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Initially kinase reactions were performed with His-E2F-5/S307A/T251A using 
kinase complexes immunoprecipitated from Rati cells. Both E2F-5 and S307A were 
phosphorylated by anti-CDK2 and anti-cyclinE immunoprecipitates, but T251A was 
not phosphorylated by either complex (Fig 6.2b). Moreover, E2F-5 was not 
phosphorylated by immunoprecipitates using an irrelevant antibody (Gal4), indicating 
that complexes specifically immunoprecipitated by cyclin E and CDK2 antibodies were 
responsible for phosphorylating E2F-5 (Fig 6.2b, lane 1). To gain evidence that 
cyclinE-CDK2 directly phosphorylated E2F-5, His tagged E2F-5 and T251A were used 
as substrates for purified cyclinE-CDK2 from baculovirus-infected Sf9 cells. CyclinE- 
CDK2 phosphorylated wild-type E2F-5 but did not phosphorylate the T251A mutant 
derivative (Fig 6.2c). Moreover the phosphorylation of E2F-5 led to the appearance of a 
slower migrating band in Coomassie blue stained gels (Fig 6.2d), an expected result if 
E2F-5U represents a form of E2F-5 that has been phosphorylated by cyclinE-CDK2 in 
cells.
6.3 E2F-5 is phosphorylated in vivo by cyclinE-CDK2
It does not always follow that a phosphorylation event that occurs readily in 
vitro will also occur physiologically. Thus to explore further the possibility that a G1 
kinase phosphorylates E2F-5, expression vectors for either cyclinE-CDK2 or cyclinDl- 
CDK4 were co-transfected into U20S cells with either E2F-5 or T251A. The 
appearance of the slower mobility E2F-5U was observed in transfections with cyclinE- 
CDK2 and E2F-5 but not when cyclinE-CDK2 was transfected with T251A, consistent 
with phosphorylation on the threonine 251 being responsible for the observed mobility 
shift (Fig 6.3a).
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Figure 6.3
A threonine residue at position 251 in E2F-5 is phosphorylated by cyclinE-
CDIC2 in vivo.
(a) U20S cells were transfected with either HA-E2F-5 (2p,g; lanes 1,2), HA-T251A 
(2\xg; lanes 3,4), in combination with expression vectors (3pg of each vector) for 
Cyclin E and CDK2, as indicated. Transfected cells were harvested and 
immunoblotted with anti-HA antisera. Note that phosphorylated E2F-5 only 
appears when wild-type E2F-5 is co-transfected with cyclinE-CDK2 (lane 2).
(b) U20S cells were transfected with HA-T251A (2pg; lane 1) or HA-E2F-5 (2)ig; 
lane 2) together with expression vectors for cyclinE-CDK2 (2pg of each) and 
metabolically labelled with [^^P] orthophosphate (see Materials and Methods), 
Cells were harvested and immunoprecipitated with the anti-BLA monoclonal 
antibody. The E2F-5 polypeptides are indicated. Note that the upper polypeptide 
(track 2 indicated by P-E2F-5) is absent from the T251A immunoprecipitate 
(track 1), and represents a non-specific band,
(c) CnBr cleavage of the in vivo labelled HA-T251A (track 2) and HA-E2F-5 
(track 3). For comparison, recombinant His-E2F-5 protein was phosphorylated 
in vitro with ^^P-ATP by cyclinE-CDK2 kinase (track 1) and similarly treated 
with CnBr, The expected size of the E2F-5 cleavage product containing 
phosphorylated T251 and the positions of the size markers (KD) are indicated.
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To investigate whether the threonine residue at position 251 in E2F-5 is 
phosphorylated in vivo, U20S cells were transfected with either HA-tagged E2F-5 or 
T251A together with cyclin E and CDK2 expression vectors and the cells were 
metabolically labeled with [^^P]-orthophosphate. Thereafter the cell extracts were 
immunoprecipitated with an anti-HA monoclonal antibody. The wild-type E2F-5 
immunoprecipitate appeared as two closely migrating polypeptides, which had identical 
mobility to E2F-5U and E2F-5M defined by immunoblotting E2F-5 in cell extracts 
(Figure 6.3b, lane 2). In contrast, the T251A immunoprecipitate appeared as a single 
polypeptide with mobility equivalent to E2F-5M (Figure 6.3b, lane 1). These results 
support the earlier conclusion that phosphorylation in E2F-5U is dependent upon the 
integrity of the CDK site at T251. Furthermore, they argue that in addition to T251, at 
least one other phosphorylation site exists in E2F-5.
To define the position of the phosphorylated residue(s) in E2F-5, peptide 
mapping was performed by cyanogen bromide (CnBr) cleavage of the in vivo ^^Pi- 
phosphorylated E2F-5 immunoprecipitate. CnBr cleavage mapped the major 
phosphorylation site within the C-terminally derived peptide (residue 194 to 256), in 
which the only CDK site is located at T251 (Fig 6.3c). Most importantly, both in vitro 
and in vivo phosphorylated E2F-5 yielded the same size phosphopeptide which, as 
expected, was absent in the T251A mutant derivative (Fig 6.3c). Overall, these results 
support the idea that threonine 251 is phosphorylated in vivo by cyclinE-CDK2.
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6.4 Functional relevance of cycllnE-CDK2 phosphorylation of E2F-5
Having established that E2F-5 can be phosphorylated by cyclinE-CDK2 in vitro 
and in vivo the physiological consequence of this phosphorylation was investigated.
The effect of cyclinE-CDK2 on E2F-5 dependent trancriptional activation of the cyclin 
E promoter was measured. Co-expression of cyclin E and CDK2 expression vectors 
into U20S cells resulted in a dose dependent rise in E2F-5 transcriptional activity (Fig 
6.4a). This stimulation was markedly reduced when E2F-5 was replaced by T251A in 
the transfection. The same effect was observed when the transfection was repeated in 
SAOS2 cells (Fig 6.4b, compare lanes 5,6 with 10,11). In extracts from these cells the 
appearance of the slower mobility form of E2F-5, E2F-5U, correlated with the 
enhanced trancriptional activity (Fig 6.4b, lanes 5 and 6).
CyclinDl-CDK4 also stimulated the transcriptional activity of wild-type E2F-5, 
but consistently to a lesser degree than cyclinE-CDK2 (Fig 6.4b, lanes 3 and 4). 
However cyclinDl-CDK4 and cyclinE-CDK2 had very similar effects on T251A 
dependent transcriptional activation (Fig 6.4b, lanes 8-11). To determine whether there 
was any change in the mobility of E2F-5 upon co-expression of cyclinDl-CDK4, 
extracts from this reporter assay were also immunoblotted with anti-E2F-5. CyclinDl- 
CDK4 did not induce a shift in mobility of E2F-5 when cotransfected with E2F-5 (Fig 
6.4b, lanes 3 and 4), although cyclinDl-CDK4 was able to reverse p i07 induced 
repression, confirming that an active kinase was expressed (see Fig 6.5). This suggests 
that the G1 kinases have a general effect stimulating E2F activity, for example through 
the phosphorylation of endogenous pocket proteins. In addition cyclinE-CDK2 has a 
specific effect which depends on the integrity of the T251 site in E2F-5.
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Figure 6.4
CyclinE-CDK2 stimulates E2F-5-dependent transcription.
(a) U20S cells were transfected with the cyclinE-luciferase reporter (2pg) together 
with expression vectors for HA-E2F-5 or HA-T251A (2pg) in the presence of 
increasing levels of cyclinE-CDK2 (1 or 2pg of each vector) as indicated; an 
expression vector for wild-type DP-1 (2pg) was transfected throughout.
(b) U20S cells were transfected with the cyclinE-luciferase reporter (2pg) together 
with expression vectors for HA-E2F-5 or HA-T251A (2|JLg), as indicated. 
Expression vectors for cyclinDl-CDK4 (1 or 2|ag of each vector) and cyclinE- 
CDK2 (1 or 2jLig of each vector) were also transfected as indicated; an expression 
vector for wild-type DP-1 (2pg) was transfected throughout. Transfected cells 
were harvested and immunoblotted with anti-HA antisera. The levels of E2F-5 
are shown in the lower panel.
In both (a) and (b) pCMV-P gal (Ifig) was transfected as an internal control, and the 
values shown are the means of three separate readings (+ or - s.d.), and represent the 
ratio of luciferase to p-galactosidase activity.
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6.5 CyclinD1-CDK4 but not cyclinE-CDK2 reverses p107 mediated 
repression of Gal4-E2F5
The data presented above suggests that phosphorylation of E2F-5 by cyclinE- 
CDK2 facilitates E2F-5 dependent rran.sactivation. A possible mechanism to explain 
this effect is that phosphorylation of E2F-5 contributes to the release of endogenous 
pocket proteins, analogous to the phosphorylation of pocket proteins leading to their 
dissociation from E2F. To investigate this idea, cyclinE-CDK2 and cyclinDl-CDK4 
were assessed for their ability to overcome pl07-mediated repression of E2F-5. 
Transfection of SAOS2 cells with Gal4E 1B-luciferase and the Gal4-E2F-5 expression 
vector resulted in approximately 200-fold stimulation of reporter activity, which was 
repressed by 90% upon co-expression of pl07 (Fig 6.5a/b, lane 2 and 6). This 
repression was relieved by cyclinDl-CDK4 but not by cyclinE-CDK2, although both 
kinases resulted in activation of Gal4-E2F-5 (Fig 6.5a/b, compare lanes 3-6 with lanes 
7-9). This suggests cyclinDl-CDK4 is regulating E2F-5 indirectly, possibly through 
release of endogenous pocket proteins, whereas cyclinE-CDK2 activates E2F-5 through 
an alternative mechanism. As cyclinE-CDK2 augments transactivation of wild-type 
E2F-5 and not T251A, one mechanism may involve direct phosphorylation of threonine 
251 in E2F-5 by cyclinE-CDK2.
6.6 CyciinE-CDK2 phosphorylation of E2F-5 does not alter Its affinity for 
DNA or pocket proteins
Previously it was shown that endogenous E2F-5 polypeptides, E2F-5U and 
E2F-5M, did not differ in their DNA binding ability. Although exogenous E2F-5 
resulting from overexpression of E2F-5 and cyclinE-CDK2 corresponds in its mobility
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Figure 6.5
CycIinDl-CDK4 but not cyclinE-CDK2 reverses pl07 mediated repression of 
Gal4-E2F-5.
U20S cells were transfected with the Gal4E IB -luciferase reporter (l|4g), together 
with expression vectors for Gal4-E2F-5 (lOOng), pl07 (200ng) and either:
(a) CyclinDl-CDK4 (0.2, 0.4, O.Spg of each expression vector).
(b) CyclinE-CDK2 (0.2, 0.4, O.Spg of each expression vector).
In both (a) and (b) pCMV-^Gal (Ipg) was transfected throughout as an internal 
control. Values shown are the means of two sepai'ate readings and represent the ratio 
of luciferase to P-galactosidase activity.
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to E2F-5U and E2F-5M it may not be post-translationally modified in exactly the same 
way. Thus U20S cell extracts, transfected with expression vectors for E2F-5 and 
cyclinE-CDK2, were subjected to gel retardation analysis to determine whether the 
effect of cyclinE-CDK2 on E2F-5-dependent 7ran.yactivation correlated with the level 
of E2F-5 bound to DNA. There was no change in DNA binding activity of either wild- 
type E2F-5 or T251A upon co-expression of cyclinE-CDK2 (Fig 6.6a, lanes 1,2 and 
5,6). Thus phosphorylation of E2F-5 by cyclinE-CDK2 does not increase the affinity of 
E2F-5forDNA.
Gel retardation assays were carried out to determine whether the hyper- 
phosphorylated E2F-5 present in cells transfected with E2F-5 and cycIinE-CDK2 
interacted with pocket proteins. A discrete p i30 complex was resolved in extracts 
transfected with expression vectors for E2F5, DP-1 and pl30, which disappeared upon 
co-expression of cyclinE-CDK2 (Fig 6.6a, lanes 3 and 4). CyclinE-CDK2 had a similar 
effect when transfected with T251A, DP-1 and pl30 and thus the effect of cyclinE- 
CDK2 on p i30 did not depend on the integrity of the threonine 251 site. Furthermore 
there was an increase in E2F-5/T251A levels when pl30 was co-transfected which 
dropped upon co-transfection of cyclinE-CDK2 (Fig 6.6b, lane 3 and 4). Recent studies 
have suggested that E2F is stabilised by binding to pocket proteins (Flateboer et al., 
1996; Hofmann et a l, 1996). The results presented here are consistent with pl30 
stabilising E2F-5 and cyclinE-CDK2 dissociating the E2F-5/pl30 complex as a 
consequence of pl30 phosphorylation, detected as a reduction in E2F-5 levels and the 
absence of a E2F-5/pl30 complex in the bandshift analysis. The transfection efficiency 
was similar throughout because the levels of a coexpressed B-galactosidase plasmid, 
the internal control, were unchanged (Fig 6.6b).
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Figure 6.6
CyclinE-CDK2 phosphorylation of E2F-5 does not affect the ability of E2F-5 to
bind to DNA or pocket proteins.
(a) U20S cells were transfected with expression vectors for HA-tagged E2F-5 (4pg), 
HA-tagged T251A (4pg), HA-tagged pl30 (4pg) and cyclinE-CDK2 (4pg of 
each vector). Expression vectors for DP-1 (4pg) and P-galactosidase (2pg) were 
transfected throughout. Extracts were prepared and analysed by gel retardation 
using the E2F site from the adenovirus E2a promoter (see Materials and 
Methods). The positions of the E2F-5/DP-1 heterodimer and the E2F/pl30 
complex, resulting from overexpression, aie indicated. The asterisk indicates a 
complex that is present in untransfected U20S cells and therefore may be an 
endogenous E2F complex.
(b) Cell extracts from (a) were immunoblotted with an anti-HA monoclonal antibody 
and anti-pgalactosidase (see Materials and Methods). The position of 
Pgalactosidase, HA-tagged E2F-5 and HA-tagged pl30 are indicated.
(c) U20S cells were transfected with expression vectors for HA-tagged E2F-5 (4pg), 
HA-tagged T251A (4pg), pl07 (4pg) and cyclinE-CDK2 (4|Ltg of each vector). 
Expression vectors for DP-1 (4pg) and p-galactosidase (2pg) were transfected 
throughout. Extracts were prepared and analysed by gel retardation using the E2F 
site from the adenovirus E2a promoter (see Materials and Methods). The 
positions of ‘free’ E2F and E2F complexed to pocket proteins are indicated. Note 
the increase in intensity of the bands corresponding to complexed E2F, upon 
expression of p i07 and the fall in intensity of free E2F (compare lanes 1,2 with 
lanes 3,4). Due to the low stringency of the buffer, several non-specific 
complexes were also detected.
(d) Cell extracts from (c) were immunoblotted with an anti-HA monoclonal antibody 
and anti-pi07 (SD9) (see Materials and Methods). Note that the level of pl07 
(lanes 3,4,6,7) coiresponds to the increase in intensity of complexed E2F in (c) 
(lanes 3,4,6,7).
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When the gel retardation analysis was repeated with p i07 in place of p i30 the 
outcome was different. Previous attempts to detect E2F-5/pl07 complexes by gel 
retardation had not been successful. Therefore the KCl levels in the gel retardation 
buffer were reduced from lOOmM to 75mM to reduce the stringency of the assay. In 
these conditions a higher order complex was detected when pl07 was expressed 
together with E2F-5 and DP-1 and this was retarded further upon co-expression of 
cycE/CDK2 (Fig 6.6c, lanes 3 and 4). Complexes containing E2F-4/pl07 and cyclinE- 
CDK2 have been detected in endogenous cell extracts during S phase in several studies 
(Lees et a l, 1992; Shirodkar et a l, 1992; Cobrinik et al, 1993). Thus it is likely that 
overexpression of these proteins had reconstituted this S phase complex, containing 
E2F-5 in place of E2F-4, as both of these E2F’s are capable of binding pl07. There was 
no difference in the abundance of these complexes in cells transfected with E2F-5 or 
T251A. Furthermore the levels of E2F-5/T251A and pl07 in western blot analysis of 
these extracts correlated with the level of E2F-5/T251A complexed to pl07 (Fig 6.6d). 
To conclude, there appeared to be no apparent difference in the ability of wild-type 
E2F-5 or T251A to bind pocket proteins in the presence of cyclinE-CDK2.
6.7 T251D mimics phosphorylation of E2F-5 by cyciinE-CDK2
To investigate whether introducing a negative charge on threonine 251 could 
mimic phosphorylation at this site, an aspartate derivative of E2F-5, designated T251D, 
was constructed. T251D had a slower mobility than E2F-5 on SDS-PAGE and 
underwent no further mobility shift upon co-transfection of cyclinE-CDK2 (Fig 6.7a). 
T251D was resolved as two polypeptides on SDS-PAGE, which were almost 
equivalent in their mobility to the two forms resolved when E2F-5 and cyclinE-CDK2
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Figure 6.7
T251D mimics phosphorylation of E2F-5 by cycIinE-CDK2.
(a) U20S cells were transfected with 5pg of DP-1 and either HA-tagged E2F-5 
(5pg) or HA-tagged T251D (5pg) and extracts were prepared and treated with X- 
phosphatase (lane 2 and 4). Control reactions were treated in the same way 
except X-phosphatase was omitted from the reaction mixture (lane 1 and 3). E2F- 
5 was detected by immunoblotting with anti-HA monoclonal antibody.
(b) U20S cells were transfected with expression vectors for HA-tagged E2F-5 (2pg) 
or HA-tagged T251D (2pg) together with DP-1 (2pg) and cyclinE-CDK2 (2pg of 
each vector) as indicated. Extracts were prepared from transfected cells and 
subjected to immunoblotting with an anti-HA monoclonal antibody.
(c) U20S cells were transfected with the cyclinE-luciferase reporter (Ipig) together 
with expression vectors for wild-type HA-E2F-5 or HA-T25 ID as indicated, and 
DP-1 (750ng), with pCMV-p-gal (Ipg) transfected as an internal control. The 
values shown ai'e the average of three separate readings, and represent the ratio of 
luciferase to P-galactosidase.
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were over-expressed, suggesting phosphorylation on threonine 251 occurs in both of 
these forms. Furthermore T251D can still undergo a mobility shift upon treatment with 
À-phosphatase, indicating the form corresponding to E2F-5U is phosphorylated on at 
least one additional site, apart from threonine 251. Results presented in the previous 
chapter, using the S307D mutant, suggest one of the other phosphorylation sites is 
likely to be serine 307. The mobility of S307D in a SDS gel was not effected by X- 
phosphatase treatment. Thus, as the S307 phosphoacceptor site remains intact in wild- 
type E2F-5 and T251D, it can be inferred that dephosphorylation of serine 307 may be 
responsible for the response of E2F-5 and T251D to phosphatase.
T251D is more active than E2F-5 in co-operation assays with DP-1, although 
the affect of the aspartate mutation is not as striking as the induction by cyclinE-CDK2 
on wild-type E2F-5 (Fig 6.7c). This suggests that the negative charge on threonine 251 
as a result of phosphorylation is at least partly responsible for the effect of cyclinE- 
CDK2 on E2F-5 transcriptional activity.
6.8 Phosphorylation of E2F-5 promotes cell cycle progression
The incorporation of BrdU into cells was used to assess the ability of E2F-5 
and cyclinE-CDK2 to stimulate entry into S phase. Co-expressing cyclinE-CDK2 with 
E2F-5 in U20S cells caused a 3-fold induction of BrdU incorporation relative to E2F-5 
alone, whereas the increase in S phase cells was far less marked when T251A was co­
expressed with cyclinE-CDK2 (Figure 6.8). This result suggests that the 
phosphorylation of the threonine 251 in E2F-5 by cyclinE-CDK2, promotes cell cycle 
progression.
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Figure 6.8
Phosphorylation of E2F-5 by cycIinE-CDK2 promotes cell cycle progression.
(a) U20S cells were transfected with HA-E2F-5 or IÎA-T251A (2pg) together with 
DP-1 (2|ag) in the presence or absence of cyclinE-CDK2 (2pg of each vector) as 
indicated. BrdU incoiporation was measured as described, and immunostaining 
with the anti DP-1 antibody was performed in parallel to determine the 
proportion of double positive cells. In the absence of cyclinE-CDK2, the level of 
BrdU incorporation was similar for E2F-5 and T251A (about 20% of the 
transfected cell population). The data shown are a representative example of four 
different experiments.
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6.9 Conclusion
In this chapter E2F-5 but not T251A was phosphorylated in vitro by cyclinE- 
CDK2. This suggests that threonine 251 is either the only target site for cyclinE-CDK2 
in E2F5 or that phosphorylation on this site is required prior to phosphorylation of 
other CDK sites within E2F5 by cyclinE-CDK2. E2F-5 can also be phosphorylated in 
vivo, as detected by incorporation of ^^P-orthophosphosphate and an E2F-5 mobility 
shift induced in extracts of cells transfected with cyclinE-CDK2 and E2F-5. 
Furthermore CnBr cleavage mapped the site of phosphorylation in E2F-5 in vivo to a 
peptide where the only CDK site is positioned at threonine 251. Evidence that cyclinE- 
CDK2 phosphorylation of endogenous E2F-5 occurs in a regulated fashion, and is thus 
not dependent on manipulating the levels of E2F-5 and cyclinE-CDK2, was shown by 
cell cycle analysis of Rati cells presented in chapter 3. The appearance of E2F-5U 
during the Rati cell cycle corresponded to the time when cyclinE-CDK2 became active 
and is consistent with the phosphorylation of E2F-5 on threonine 251. Thus E2F-5 is 
likely to be a physiological target for cyclinE-CDK2.
The transcriptional activity of E2F-5 is enhanced by cyclinE-CDK2 when 
assayed on a cyclinE-luciferase reporter, a well-studied E2F-regulated gene. These 
observations enable an attractive model to be proposed, where a positive feedback loop 
exists between E2F-5 and cyclin E. E2F-5 transcriptionally activates the cyclin E 
promoter, causing a surge in cyclin E protein levels which can, on complexing with 
CDK2, further feedback on E2F-5 transcriptional activity and thereby enhance its own 
levels, to promote irreversible entry into S phase (see Chaper 8 for discussion and Fig 
8.1). The mechanism of transcriptional activation by cyclinE-CDK2 phosphorylated 
E2F-5 is explored in the next chapter.
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Chapter 7
Regulation of E2F-5 by p300/CBP 
co-activators
7.1 Introduction
The p300/CBP family of co-activators are transcriptional adapters that interact with 
diverse transcription factors and facilitate îran^activation (Shikama et al, 1997). They 
are part of multi-protein complexes that connect the activation domains of transcription 
factors with the transcription apparartus. Both p300 and GBP possess intrinsic acetyl 
transferase activity, which can acetylate hi stones and a number of non-histone proteins, 
such as p53 and TFIIE (Gu and Roeder, 1997; Imhof et al., 1997). Acétylation of 
histones modifies chromatin increasing the accessibility of DNA for transcription 
factors (Grunstein, 1997), whilst acétylation of p53 is believed to facilitate transcription 
by increasing the DNA binding activity of p53 (Gu and Roeder, 1997).
Given that the p300/CBP family can bind to E2F-1 and that GBP is an important 
co-activator for E2F-1 regulation of the DHFR promoter (Trouche and Kouzarides, 
1996; Lee et a l, 1998; Fry et a l, 1999), it is possible that E2F-5 dependent 
transcription also utilises p300/GBP. Therefore this chapter explores the importance of 
p300/GBP in E2F-5-dependent transcription.
Evidence presented in the previous two chapters implied that phosphorylation of 
E2F-5 on serine 307 and threonine 251 enhanced E2F-5-dependent transcription. To 
elucidate the mechanism responsible for these observations the possibility that 
phosphorylation of E2F-5 may regulate the interaction of the activation domain with 
p300/GBP was considered.
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7.2 E2F-5 interacts with p300
A variety of approaches were taken to assess the role of p300 in E2F-5-dependent 
transcription. A mammalian two-hybrid assay was employed to determine whether 
E2F-5 interacted with p300. E2F-5, T251A and S307A (residues 90-335) were fused to 
VP 16 transdiCiivsAion domain to construct VP16-E2F-5, VP16-T251A and VP16- 
S307A. A construct consisting of full-length p300 fused to the Gal4 DNA-binding 
domain (Gal4-p300) was used as ‘bait’. Expression of Gal4-p300 had an insignificant 
effect on the froM^'activation ability of the Gal4-E 1 b-luciferase reporter in U20S cells 
(Fig 7.1a, compare lane 1 and 2). However, co-expression of VP16-E2F-5 with Gal4- 
p300 caused a 10-fold induction in reporter activity (Fig 7.1a, compare lane 1 with 
lanes 6-8). This induction was not due to an interaction between Gal4-p300 and the 
VP 16 rraw.yactivation domain, as these two proteins did not significantly activate the 
reporter (Fig 7.1a, compare lane 2 and 15). VP16-T251A and VP16-S307A also 
interacted with the Gal4-p300 bait although the induction in reporter activity was 
marginally less than that of wild-type E2F-5 (Fig 7.1a, compare lanes 6-14). These data 
indicate that E2F-5 and the mutant derivatives interact with p300, although it does not 
establish whether the interaction is direct.
To determine whether endogenous E2F-5 and p300 were physically associated 
in cells Rati cell extract, prepared from asynchronous cells, was immunoprecipitated 
with anti-E2F-5. Western blot analysis and subsequent immunoblotting with an anti- 
p300 N15 rabbit polyclonal anti serum (Santa Cruz) revealed the presence of p300 in 
the E2F-5 immunocomplex (Fig 7.1b), Moreover the interaction between E2F-5 and 
p300 was specific as it was prevented by pre-incubation of the anti-E2F-5 antibody 
with the homologous peptide (Fig 7.1b, compare lane 2 and 3).
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Figure 7.1
p300 interacts with E2F-5 in vivo.
(a) Mammalian two-hybrid interaction assay between between p300 fused to Gal4 
DNA binding domain and E2F-5, T251A, or S307A (residues 90-335) fused to 
the fmoj-activation domain of VP 16 (see Materials and Methods). The quantities 
of expression plasmids used were: Gal4-p300 (0.5jig) and VP16-E2F-5/ VP16- 
T251A/ VP16-S307A (0.25, 0.5, 1.0 jig), with 1.0 jig of the indicated VP16 
construct in lanes 3, 4 and 5. The Gal4-p300 bait was co-expressed with 
VP16TAD alone (1.0 jig) in lane 15. The Gal4-EIB-luciferase reporter (Ijig) and 
pCMV-pGal (Ijig) were transfected throughout and the results are presented as a 
ratio of luciferase activity to p-Galactosidase activity and are means of three 
separate readings (+/-s.d.).
(b) Extracts prepared from asynchronously growing Rati cells were 
immunoprecipitated with anti-E2F-5 peptide antiserum in the presence (+) and 
absence (-) of competing E2F-5 peptide. The immunoprecipitate was resolved by 
SDS-PAGE and subsequently immunoblotted with the anti-p300 antibody (see 
Materials and Methods). Track 1 shows the input (5%) reactivity of the anti- 
p300 with the crude Rati extract.
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7.3 Role of p300 In E2F-5 dependent transcriptional activation
To determine whether endogenous p300/CBP proteins are functionally 
important for E2F-5 activity in vitro the effects of a truncated p300 molecule, namely 
were studied. As residues 1572 to 1903 of p300 harbour the E2F 
interaction domain it was anticipated that p300^^^ '^^ ^^  ^would act in a dominant- 
negative fashion by competing with endogenous p300 for E2F-5 activation domain. 
Expressing p300^^^ '^^ ^^  ^caused a marked reduction in the E2F-5-dependent activation 
of the cyclinE promoter without affecting the level of E2F-5 protein (Figure 7,2a). In a 
similar type of experiment, expression of p300^^^ '^^^^  ^also compromised the 
transcriptional activity of the Gal4-E2F-5 hybrid protein (Figure 7.2b). These data 
establish that p300/CBP proteins are important effectors of E2F-5-dependent 
transcription in vitro.
7.4 Phosphorylation of E2F-5 on threonine 251 augments its interaction 
with p300
Data presented in the previous two chapters revealed that phosphorylation of 
E2F-5 on threonine 251 and serine 307 augment E2F-5 transcriptional activity. Given 
that p300/CBP proteins are required for E2F-5-dependent transcription, the 
phosphorylation of threonine 251 or serine 307 may enhance the interaction of p300 
with the E2F-5 activation domain. The mammalian two-hybrid assay showed that the 
mutants, T251A and S307A can still interact with p300 , albeit more weakly. The 
individual phosphorylation status of each of these mutant derivatives is not known 
when expressed as VP 16 fusion proteins in vivo. Therefore a biochemical-binding
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Figure 7.2
p300 is important for E2F-5 dependent transcription.
(a) U20S cells were transfected with the cyclinE-luciferase reporter (2pg) together 
with expression vectors for wild-type HA-E2F-5 (2pg) and DP-1 (2pg) in the 
presence of increasing (2, 4, 6 and 8|xg), as indicated. pCMV-p-gal
(Ipg) was transfected as an internal control, and the values calculated as a ratio 
of luciferase to P-galactosidase activity and presented as the means of three 
separate readings (+/- s.d.). Transfected cells were harvested and immunoblotted 
with anti-HA antiserum (shown underneath) to monitor the levels of E2F-5.
(b) U20S cells were transfected with the pGal4-ElB-luc (2)JLg), together with 
expression vectors for Gal4-E2F-5 (150ng) and an increasing level of p300^^^^‘
(1,2, and 4jLtg) as indicated. pCMV-p gal (IjLig) was transfected as an 
internal control, and the values calculated from triplicate readings as described 
in (a).
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assay, using purified and in vitro phosphorylated recombinant E2F-5, was
employed to explore the effect of E2F-5 phosphorylation on its interaction with p300.
An interaction between purified His-tagged E2F-5 and Flag-tagged 
was detected, as the amount of E2F-5 bound to Flag-tagged was greater
than that bound to the Flag antibody control (Figure 7.3a, compare lane 5 and 6). In the 
previous chapter it was shown that cyclinE-CDK2 phosphorylates threonine 251, but 
the kinase responsible for phosphorylation of serine 307 is unknown. Thus it was 
decided to investigate whether phosphorylation of E2F-5 by cyclinE-CDK2 had an 
effect on the interaction between E2F-5 and p300. A shift in mobility of recombinant 
E2F-5 as a result of in vitro phosphorylation was readily detected by western blot 
analysis with anti-E2F-5 (Fig 7.3a, lane 1 and 2). This mobility shift did not occur 
when ATP was omitted from the in vitro phosphorylation reaction. This observation is 
in agreement with the data from the previous chapter concluding that cyclinE-CDK2 
phosphorylation of E2F-5 causes a shift in its mobility in SDS-PAGE. To determine the 
p300 binding affinity of E2F-5 the ratio of the level of E2F-5 bound to Flag-p300 to 
level of E2F-5 bound to the Flag-antibody was calculated by measuring the intensity of 
the bands with a densitometer, in each of the different treatments (Fig 7.3b). 
Phosphorylation of E2F-5 by cyclinE-CDK2 enhanced the interaction between E2F-5 
and p300 by between three to five-fold (Figure 7.4a, lanes 3 and 4). Furthermore, the 
interaction between E2F-5 and p300 required the integrity of the T251 CDK site, as in 
a similar binding assay, a specific interaction between the T251A mutant and p300 was 
not seen (Figure 7.3a and 7.3b). These data strongly suggest that phosphorylation of 
E2F-5 at threonine 251 by cyclinE-CDK2 augments transcription by enhancing the 
interaction of E2F-5 with p300/CBP co-activator proteins.
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Figure 7.3
Phosphorylation of E2F-5 by cyclinE-CDK2 facilitates its interaction with p300.
(a) The indicated input His-tagged E2F-5 or T251A (IN; tracks 1 and 2, 7 and 8) 
were treated as shown and thereafter immunoblotted with anti-E2F-5. Binding to 
flag-tagged-p300^^^^'^‘^ ‘'^  (Ipg) or flag-control beads was assessed for the 
pretreated input E2F-5 and T251A as indicated (lanes 3-6 and 9-12). The level of 
E2F-5 and T251A bound to flag-tagged-p300^^^^’^ '^ '^^  or flag-control beads was 
determined by immunoblotting with anti-E2F-5. Ipg of E2F-5 or T251A was 
used in the binding assay; lOOng of E2F-5 and T251A were immunoblotted in 
lanes 1,2,7 and 8. Phosphorylated E2F-5, which is absent in the T251A mutant, is 
indicated.
(b) Quantification of the data shown in (a) where the level of pre-and post- 
phosphorylated E2F-5 and T251A bound to p300 is indicated. The relative 
specific binding represents the difference between the amount of E2F-5 or 
T251A bound to flag-tagged p300 compared to the flag-control beads. A value 
of 1.0 would indicate that there was no evidence of specific binding to p300.
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7.5 p300 acetylates E2F-5 in vitro
A  recent study has reported that p/CAF (p300/CBP associated factor) and to a lesser 
extent p300 can acetylate E2F-1 (Martinez-Balbas et al., 2000). Moreover acétylation 
of E2F-1 was shown to be involved in stimulating gene transcription. Thus E2F-5 
acétylation may be important in the ability of E2F-5 to activate transcription. To 
determine whether E2F-5 could be acetylated, in vitro acétylation reactions were 
performed using purified flag-tagged full length p300 and his-p300 HAT domain 
(residues 1195-1673). Full-length p300 efficiently acetylated hi stones and to a lesser 
extent also acetylated E2F-5 (Fig 7.4a, lane 4 and 5). However the p300 HAT domain, 
whilst acetylating both histones and pRb (Fig 7.4a, lane 1 and 6), was unable to 
acetylate E2F-5 (lane 3), suggesting regions outside the HAT domain were necessary 
for p300 to acetylate E2F-5.
177
Figure 7.4
E2F-5 is acetylated by p300 in viti'o.
In vitro acétylation was performed using full-length flag-p300 (lOOng), GST-p300 
(residues 1195-1673, encompassing the HAT domain) (lOOng), GST-Rb (1.5pg), 
His-E2F-5 (1.5pg) and histones, as indicated (see Materials and Methods). The 
samples were resolved on SDS-PAGE and subjected to autoradiography for one 
week. FL: refers to Full-^ngth p300. HAT: refers to the HAT domain. Track 2 is a 
damaged lane and does not contain any relevant sample.
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7.6 Conclusion
Data presented in this chapter has demonstrated that p300 can interact directly 
with E2F-5. Moreover phosphorylation of E2F-5 on threonine 251 by cyclinE-CDK2 
enhanced the interaction between E2F-5 and p300. A region of p300 that interacts with 
E2F-5, namely blocked E2F-5 transcriptional activity implying E2F-5
dependent transcription utilises endogenous p300. Thus p300 is a critical effector 
protein involved in E2F-5 transcriptional regulation. Taken together these results 
suggest that phosphorylation of E2F-5 by cyclinE-CDK2 may augment transcription by 
stabilising the interaction between E2F-5 and p300.
E2F-5 was also shown to be a substrate for p300 acetyl transferase activity in 
vitro. It is possible that the acétylation of E2F-5 by p300 may be important in the 
mechanism of E2F-5 activation. Thus it will be interesting to determine whether the 
ability of E2F-5 to bind to p300 or the phosphorylation status of E2F-5 influences the 
level of E2F-5 acétylation.
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Chapter 8
Discussion
The important role that E2F plays in the control of early cell cycle progression is 
mediated principally through regulating the activity of banks of genes necessary for 
entry into and through S phase. The activity of E2F must be tightly regulated in order 
to ensure the timely activation and repression of E2F target genes during cell cycle 
progression. In this study, the role of phosphorylation of the E2F-5 family member in 
the regulation of E2F activity has been investigated.
8.1 E2F-5 is an abundant component of E2F DNA binding activity
E2F-5 is an abundant component of ‘free’ E2F DNA binding activity in Rati 
fibroblasts, F9EC cells and leukaemic cell lines, for example DAUDI and RAGI cells 
(Chapter 3). Consequently, E2F-5 may make a significant contribution to the control of 
cell cycle progression and DNA synthesis in these cell lines. Previous studies have 
reported the selective induction of E2F-5 in various differentiated cells and the 
association of E2F-5 with pl30 in GO cells (Moberg et a l, 1996; Dagnino et al., 1997). 
E2F-5 is structurally and functionally related to E2F-4. Given that E2F-4 is often 
associated with p i07 in vivo, it is noteworthy that E2F-5 can be detected in p i07 
immunoprecipitates in RAGI cell extract (Fig 3.5b). However, E2F-5 was not a major 
component of DNA bound E2F/pl07 complexes in Rati cell extracts (Fig 3.7c). The 
majority of E2F-5 in Rati extract bound to DNA as a ‘free’ heterodimer with DP-1. 
The distinct E2F/pl07 complex observed in Rati cell extract must therefore be 
composed of another E2F family member, a likely candidate being E2F-4, as E2F-4 is 
the most abundant E2F found in a variety of cells types and is the only E2F that has
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been reported to bind in significant amounts to pl07 (Beijersbergen et al, 1994; 
Ginsberg et al, 1994; Moberg et al., 1996). If this is the case, then there is likely to be 
a major difference in the regulation of E2F-4 and E2F-5 in Rati cells. However, it is 
possible that E2F-5/pl07 complexes are present in Rati cell extracts but not in a form 
that is capable of binding to DNA in the conditions used in this assay.
The presence of a high level of ‘free’ E2F-5 DNA binding activity relative to 
E2F-5 complexed to pocket protein suggests that E2F-5 may make a significant 
contribution to the activation of E2F-target genes in Rati cells. Accordingly, the level 
of E2F-5/DP-1 was high at the Gl-S transition and therefore would be expected to 
coineide with the induction of E2F target genes. However, it has been suggested that 
E2F-5, and the related E2F-4, are primarily involved in the repression of E2F- 
dependent genes in GO and G l, through the recruitment of pocket proteins. Several 
studies support this idea, including the demonstration that E2F-5 is relatively abundant 
in quiescent and differentiated cells (Sardet et al, 1995; Moberg et al, 1996; Dagnino 
et al., 1997). Furthermore, E2F-4 and E2F-5 do not contain a nuclear localisation signal 
(NLS), but can enter the nucleus when associated with pl07 and pl30 (Magae et al., 
1996; Buck et al., 1997; Lindeman et al., 1997). Although E2F-5 mRNA is prevalent in 
GO and G l cells, a notable increase in E2F-5 mRNA occurs towards the end of Gl 
phase in HaCat cells (Sardet et al, 1995). A role for E2F-5 strictly as a repressor of 
genes in GO/Gl does not explain the function of the increase in E2F-5 expression 
towards the end of G l phase. Moreover the oncogenic effect of E2F-5 and the increase 
in E2F-5 RNA in certain breast tumour cell lines (Polanowska et al, 2000) are 
supportive of a role for E2F-5 as an activator of proliferation, presumably be 
rrart^activating E2F target genes required for cell cycle progression.
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The results presented here demonstrate that ‘free’ E2F-5 DNA binding activity 
is present in late Gl and during S phase of the Rati cell cycle and therefore, once 
released from p i30, E2F-5 may contribute to the activation of E2F target genes (Fig 
3.7c). In this respect E2F-5 may differ from the closely related E2F-4, as E2F-4 may be 
largely present in a complex with p i07 and in this form would not be capable of 
activating transcription (Shirodkar et al, 1992; Moberg et a l, 1996). It is noteworthy 
that, although the level of E2F-5/DP-1 DNA binding activity remained relatively 
constant throughout the Rati cell eycle, an overall fall in the level of ‘free’ E2F DNA 
binding activity as cells entered S phase was observed (Fig 3.7c). The prevalence of 
E2F-5/DP-1 DNA binding activity during S phase in Rati cells may reflect a 
requirement of E2F-5/DP-1 for the regulation of a specific subset of E2F target genes 
that are transcribed in S phase, at a stage when other free E2F DNA binding activity 
has been down-regulated. Alternatively, it could be argued that inefficient cell 
synchronisation may account for the detection of E2F-5/DP-1 DNA binding activity in 
the later stages of S phase.
8.2 E2F-5 is a phosphorylated protein
Several lines of evidence indicate that E2F-5 is a phosphorylated protein. Firstly, 
multiple forms of E2F-5 with different electrophoretic mobilities exist in extracts from 
Rati cells and F9EC cells, and phosphatase treatment of these extracts causes a shift in 
these polypeptides to a faster mobility (Chapter 3). Specifically, three E2F-5 
polypeptides, defined according to mobility as U, M and L, were detected. Secondly, 
mutant derivatives of E2F-5 that contain alanine substitutions at potential 
phosphorylation sites, namely S307A and T251A, exhibited different electrophoretic
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mobilities in SDS-PAGE (Chapter 4). Finally, E2F-5 can be phosphorylated in vitro by 
cyclinE-CDK2 and metabolically labelled with ^^P-orthophosphate in vivo (Chapter 5).
The presence of exogenous E2F-5U, M and L in extracts from U20S cells 
transfected with an E2F-5 expression vector was variable, suggesting that the 
expression of individual differentially phosphorylated E2F-5 polypeptides may be 
related to transfection efficiency. For example, good transfection efficiency results in 
high expression of exogenous E2F-5 and therefore it is possible that the availability of 
the endogenous kinase, responsible for the phosphorylation dependent mobility shift of 
E2F-5, becomes limiting. Despite unavoidable variations between transfections, E2F- 
5M was consistently observed as the most abundant exogenous E2F-5 polypeptide 
detected when wild-type E2F-5 and DP-1 were co-transfected (see Fig 4.1b, Fig 4.2b as 
examples). E2F-5U was always absent in cells transfected with T251A, whilst E2F-5L 
was the predominant polypeptide detected in cells transfected with S307A. This is 
consistent with E2F-5U being phosphorylated on threonine 251 and E2F-5M being 
phosphorylated on serine 307.
The identity of the sites phosphorylated in E2F-5U, M and L can be postulated 
by comparison of the mobility of T251D and S307D, both in the absence and presence 
of phosphatase. T25 ID resolved as a mixture of E2F-5U and E2F-5M, and upon 
treatment with phosphatase E2F-5U disappeared and E2F-5M increased. S307D 
resolved as E2F-5M and did not undergo a mobility shift upon treatment with 
phosphatase. Therefore, E2F-5M is most likely a mixture of polypeptides, either 
phosphorylated on threonine 251 or on serine 307, whilst E2F-5U polypeptides may be 
phosphorylated on both serine 307 and threonine 251 (Fig 8.1). Moreover, E2F-5L 
represents a hypophosphorylated E2F-5, as it increases in abundance on treatment of 
wild-type E2F-5 with phosphatase. This conclusion is by no means exhaustive as the
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E2F-5 polypeptides may contain other post-translational modifications which this study 
has not addressed.
The relatively high level of E2F-5M compared to E2F-5L deteeted is cells 
transfected with wild-type E2F-5, suggests that the kinase responsible for the 
appearance of E2F-5M is not limiting. Thus, a kinase that is constitutively active in the 
various cell lines tested, rather than a cell cycle regulated kinase may be responsible for 
phosphorylation of serine 307.
The distribution of endogenous E2F-5L, M and U also varied in different cell 
lines. Rati cells contain predominantly E2F-5U and M, whereas in F9EC cells E2F-5U 
was barely detectable and forms M and L were most abundant. Thus, E2F-5 may be 
regulated by different kinases and phosphorylated on different sites in these two cell 
lines.
E2F-5 Relative mobility 
on SDS-PAGE
Predicted phosphorylation 
status
E2F-5U Slowest Phosphorylated on T251 
and S307
E2F-5M Intermediate Mixture of polypeptides either 
phosphorylated on 
T251 or S307
E2F-5L Fastest Hypophosphorylated 
(neither phosphorylated on 
T251 or S307)
Figure 8.1 Prediction of the phosphorylation status of E2F-5 polypeptides detected on SDS-PAGE. The 
prediction is based on the relative mobilities of mutant derivatives of E2F-5, in which serine 307 or 
threonine 251 were substituted with alanine or aspartate residues.
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The data presented here implies that E2F-5 is subject to cell-cycle dependent 
phosphorylation in Rati cells. The appearance of E2F-5U occurs as Rati cells approach 
and enter S phase, suggesting that E2F-5 may be phosphorylated by a kinase that is 
active at this stage of the cell cycle (Fig 3.7b). This timing correlates well with the 
induction of cyclinE-CDK2 kinase, which has been shown to peak in activity as cells 
progress towards S phase (Sherr et al, 1993, 1996). Consistent with this idea the results 
presented here indicate that E2F-5 phosphorylation is mediated by cyclinE-CDK2, 
rather than the mitogen-responsive cyclinD-dependent kinase. Phosphorylation of His- 
tagged E2F-5 in vitro with purified cyclinE-CDK2 from baculovirus infected cells 
results in a mobility shift of E2F-5 in SDS-PAGE (see Fig 6.2d). An equivalent 
mobility shift was observed in extracts from cells co-transfected with E2F-5 and 
cyclinE-CDK2. Taken together these results infer that the mobility shift seen in 
transfected extracts is the result of direct phosphorylation of E2F-5 by cyclinE-CDK2.
Cyanogen bromide mapping of wild-type E2F-5, which had been in vitro 
phosphorylated by cyclinE-CDK2 identified a phosphopeptide in which the only CDK 
site is positioned at threonine 251. Moreover a peptide of identical size was derived 
from cyanogen bromide cleavage of in vivo phosphorylated wild-type E2F-5, but not 
T251A. These findings suggest that cyclinE-CDK2 phosphorylates E2F-5 on threonine 
251 in vivo. That phosphorylation of this site is likely to occur in a physiological 
context was implied by the appearance of E2F-5U towards the end of G l phase in the 
Rati cell cycle.
A comparison of polypeptide sequences of the E2F family members reveals that 
the threonine at 251 is unique to E2F-5, therefore E2F-5 may be the only E2F family 
member that is phosphorylated by cyclinE-CDK2. Consistent with this idea it has 
previously been shown that E2F-1 was efficiently phosphorylated by cyclinA-CDK2 in
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vitro but was not phosphorylated by an excessive amount of cyclinE-CDK2 (Dynlacht 
et al, 1994). However, to control for differences in the assay conditions, the specificity 
of cyclinE-CDK2 for the different E2F family members should be compared within the 
same assay. Thus the possibility that different sites are phosphorylated by cyclinE- 
CDK2 in the other E2F family members cannot be excluded.
8.3 Phosphorylation of serine 307 may regulate E2F-5 activity
Phosphorylation can affect the activity of a transcription factor by modulating its 
DNA binding activity, subcellular localisation and its interaction with co-activators and 
components of the basal transcription machinery (reviewed in Hill and Triesman, 1995; 
see Section 1.7).
The mutant derivatives of E2F-5, T251A and S307A were competent in their 
ability to bind to the E2F-recognition site as a heterodimer with DP-1 and as a complex 
with pl30 and DP-1. Moreover, the subcellular localisation of T251A and S307A was 
similar to that of wild type E2F-5. These findings imply that E2F-5 DNA binding, 
heterodimerision, subcellular localisation and interaction with p i30, are not dependent 
upon phosphorylation of E2F-5 at either of these two sites. In addition, they 
demonstrate that the integrity of E2F-5 was not altered by mutagenesis.
The analysis of S307A and S307D presented in chapter 5, suggests that 
phosphorylation of serine 307 may regulate E2F-5 activity. S307A has a reduced 
transcriptional activity, both as a heterodimer with DP-1 or DP-35 when assessed for its 
ability to activate the cyclinE-luciferase reporter (Fig 5.1). Furthermore, the rise in 
reporter activity in response to increasing amounts of S307A was not as steep as that 
detected when equivalent amounts of wild-type E2F-5 were transfected. There are a
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number of possible explanations for this observation. One possibility is that as 
increasing levels of S307A are transfected an endogenous protein involved in 
transcriptional activation becomes limiting. This may be because S307A has a lower 
affinity for this protein so cannot efficiently recruit it to the promoter. Many proteins 
have been shown to have a role in E2F-dependent gene regulation, such as the 
p300/CBP co-activator, TBP and Spl (Hagemeier et al, 1993; Lin et a l, 1996; 
Tronche and Kouzarides 1996; Lee et a l, 1998). It is possible that E2F-5 
phosphorylation on serine 307 has a role in recruiting one of these proteins to the 
promoter. Alternatively the DP-1 component of the heterodimer itself may become 
limiting, since the levels of exogenous DP-1 were kept constant in the transfection. 
Another possibility is that as the level of S307A expression plasmid was increased in 
cells, the resulting rise in S307A expression was offset by an accompanying increase in 
the degradation of S307A.
The phenotype of full-length S307A can be transferred to a Gal4 fusion protein, 
consisting of the Gal4 DNA binding domain and the transactivation domain of E2F-5. 
This observation allows a number of important conclusions to be made. In agreement 
with the previous gel retardation results, the compromised transcriptional activity of 
S307A cannot be explained by a change in its ability to bind DNA or heterodimerise 
with a DP subunit. Moreover, the phenotype of S307A in the Gal4- fusion protein 
gives a direct indication of the activity of the S307A fran^activation domain. Whereas 
the results from overexpression of the full-length E2F-5 and S307A proteins, whilst 
useful for mimicking the physiological proteins, may be indirect. For example the full- 
length proteins may modulate the transcription of genes encoding endogenous E2F 
proteins, which in turn regulate the cyclin E reporter. The phenotype of Gal4-S307A
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demonstrates that the /ran^activation domain of S307A is intrinsically less active than 
that of wild-type E2F-5.
Serine 307 is within the pocket protein-binding region of E2F-5. Given the 
importance of pocket protein binding in the regulation of E2F activity, it was therefore 
possible that phosphorylation of E2F-5 itself modified the interaction between E2F-5 
and pocket proteins. Several experiments indicated that this was not the case. S307A 
was demonstrated to interact with p i07 by immunoprécipitation and with p i30 as a 
DNA-binding complex to a similar extent as wild-type E2F-5. Moreover both pocket 
proteins inhibited transaciiwaiion mediated by Gal4-E2F-5 or Gal4-S307A to a similar 
level.
Serine 307 is conserved in E2F-1, E2F-2, E2F-4 and E2F-5. Thus it may be a 
physiologically relevant site of phosphorylation in several E2F proteins. The 
homologous serine in E2F-1 is positioned at 403. Interestingly, a recent study 
demonstrated that mutation of serine 403 in E2F-1 to alanine increased the stability of 
E2F-1 (Vandel and Kouzarides, 1999). In the results presented here, the steady state 
levels of S307A did not differ from wild-type E2F-5 (see Fig 4.2, 4.3; data not shown). 
However the rate of degradation of S307A relative to wild-type E2F-5 was not 
determined. Thus the possibility that the stability of S307A differs from wild-type E2F- 
5 cannot be ruled out. However if, by analogy to E2F-1 (S403A), the stability of 
S307A were greater than wild-type E2F-5 then this would create a paradox whereby an 
increased level of S307A was accompanied by a reduction in the ability of S307A to 
activate transcription. Therefore further investigation is required to determine whether 
phosphorylation of serine 307 in E2F-5 and the homologous serines in the other E2F 
family members have similar functional consequences.
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Expression of E2F-5 or S307A in cells can cause an increase in the number of 
cells in S phase. This was demonstrated by labelling cells expressing either wild-type 
E2F-5 or S307A, with BrdU. BrdU labelling measures DNA synthesis in cells during a 
short time period. However, quantifying the number of cells that incorporate BrdU does 
not establish whether cells are being forced into S phase at an increased rate or whether 
there is an accumulation of cells in S phase. It is possible that cells expressing S307A 
proceed more slowly through S phase due to a reduced capacity to activate the 
appropriate genes, and therefore they accumulate in S phase. To investigate this 
hypothesis cells could be treated with Nocodazole, a drug that causes cells to 
accumulate in G2/M. If cells are accumulating in S phase then they should not proceed 
into M phase, and therefore they will not be responsive to a Nocodazole block.
Studies of the function of individual E2F proteins has revealed that E2F-5 is 
considerably weaker than E2F-1, -2, and -3 in promoting cell cycle progression and a 
significant induction in S phase required the co-expression of E2F-5 and DP-1 (Lukas 
et al, 1996). It has also been shown that E2F-5/DP-3Ô promotes cell cycle progression 
(Allen et al, 1997). Therefore the ability of E2F-5 or S307A to promote cell cycle 
progression may be more marked if co-transfected in cells together with DP-1 or 
DP-3Ô.
The results presented here also showed that cells stably expressing S307A could 
be anested by serum starvation, whilst cells expressing wild-type E2F-5 were incapable 
of arrest by serum starvation. This is compatible with phosphorylation of E2F-5 on 
serine 307 playing a role in cell cycle re-entry from GO/Gl into S phase. However 
some caution should be taken in the interpretation of these results. It is possible that 
differences exist, between the stable cell-lines expressing wild-type E2F-5 and S307A,
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besides the alanine substitution at position 307. Therefore an inducible system of E2F-5 
and S307A expression would provide a more reliable control, as it would enable a 
comparison of cell cycle profile of cells before and after E2F-5 induction in the same 
cell line.
Several important questions remain to be resolved concerning the 
phosphorylation of serine 307 in E2F-5. Firstly in vivo mapping would determine 
whether serine 307 is a physiological site of phosphorylation. Secondly the identity of 
the kinase responsible for phosphorylation of serine 307 may enable a link to be made 
between the signals that trigger the phosphorylation of E2F-5 and the regulation of 
E2F-5 dependent transcription. In this respect, the possibility that MAP kinases, for 
example the ERKs, phosphorylate serine 307 warrants further investigation. ERKs can 
be triggered in response to mitogenic signals and promote proliferation by modulating 
the activity of a variety of transcription factors, for example Elk-1, a transcriptional 
activator of the c-fos promoter (reviewed in Hill and Triesman, 1995). Given that MAP 
kinase activation is often linked with proliferation and that phosphorylation of serine 
307 increases the activity of E2F and may be required for progression of cells into S 
phase, the MAP kinases are potential candidates for the phosphorylation of serine 307.
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8.4 Regulation of E2F-5 activity by cyclinE-CDK2
The results presented here demonstrate that cyclinE-CDK2 stimulates E2F-5 
dependent transcription in a dose-dependent fashion, and this correlates with the 
appearance of the slower migrating phosphorylated E2F-5U polypeptide. Although 
cyclinDl-CDK4 caused a marginal increase in E2F-5 dependent transcription, it did not 
cause a phosphorylation dependent mobility shift of E2F-5. Moreover cyclinDl-CDK4 
but not cyclinE-CDK2 can reverse p i07-mediated repression of Gal4-E2F-5, 
suggesting the effect of cyclinDl-CDK4 on E2F-5 dependent fra/wactivation may be 
caused by disruption of the interaction between E2F-5 and endogenous pocket proteins 
(Fig 6.5).
The evidence that threonine 251 in E2F-5 is phosphorylated by cyclinE-CDK2 
was discussed above (see Section 8.2). The E2F-5 mutant incapable of phosphorylation 
on threonine 251, namely T251A, displayed a markedly reduced response to cyclinE- 
CDK2 in transactiwation, the expected outcome if phosphorylation of this site 
augments E2F-5-dependent rran^activation. In support of this a mutant containing an 
aspartate residue at position 251, T251D, had a greater transcriptional activity than 
wild-type E2F-5. In addition, cyclinDl-CDK4 and cyclinE-CDK2 had similar effects 
on the activity of T251A, but cyclinE-CDK2 had a considerably greater effect on the 
activity of wild-type E2F-5. Therefore the regulation of E2F-5 activity by the 
phosphorylation of threonine 251 appears to be a specific property of cyclinE-CDK2.
It was demonstrated that cells co-transfected with T251A and cyclinE-CDK2 
exhibited less BrdU labelling than cells transfected with wild-type E2F-5 and cyclinE- 
CDK2. This suggests that threonine 251 is important for facilitating the entry of cells
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into S phase. Therefore phosphorylation of E2F-5 by cyclinE-CDK2 may contribute to 
the necessary induction of target genes required for cell cycle progression.
Although cyclinE-CDK2 is essential in allowing cells to move from G l into S 
phase (Ohtsubo et a l, 1995), physiological protein substrates other than pRb that are 
subject to cyclinE-CDK2 phosphorylation, and which are necessary for cell cycle 
progression, have not yet been defined. Of relevance to this point is that cells arrested 
by a constitutively hypophosphorylated mutant pRb protein can enter S phase upon the 
expression of exogenous cyclinE-CDK2 (Lukas et al, 1997), arguing that cyclinE- 
CDK2 has at least one other target in addition to pRb that is necessary for cell cycle 
progression. Considering the role that E2F has in activating genes required for cell 
cycle progression, the ability of cyclinE-CDK2 to directly phosphorylate E2F-5 and to 
increase E2F-5 activity opens up the possibility that E2F may be an important target 
required for cyclinE-CDK2 to exert its effects on cell cycle progression.
The regulation of E2F-5 dependent transcription by cyclinE-CDK2 presented 
here, along with the well-established role of pRb in regulating E2F, allows a model to 
be postulated whereby E2F and cyclinE-CDK2 cooperate in the induction of S phase. 
As cells leave quiescence the mitogen-dependent induction of cyclinD-CDK4 kinase 
plays a primary role in the phosphorylation control of pRb family proteins, which is 
followed by the induction of cyclinE-CDK2 and the completion of pRb 
phosphorylation. The subsequent release of E2F results in the activation of E2F target 
genes including cyclinE, causing a surge in cyclinE-CDK2 activity which can then 
further feedback and increase the activity of E2F-5 through phosphorylation. This 
positive feedback loop may cause the necessary increase in E2F activity to drive the 
expression of E2F target genes to a level that allows progress into S phase (Figure 8.2). 
As DNA replication approaches completion several mechanism are believed to be
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involved in E2F inactivation. These include phosphorylation control of the DP subunit 
by cyclinA-CDK2 kinase (Krek et al., 1995), the regulated ubiquitin-dependent 
degradation of E2F (Marti et ah, 1999) combined with the down-regulation of cyclinE- 
CDK2 (Koff et al., 1992) and the relocation of E2F-4 and E2F-5 to the cytoplasm 
(Buck et al., 1997; Lindeman et al., 1997). Therefore through the sequential action of 
the cyclin-CDKs, E2F activity is increased and decreased in a temporal pattern as cells 
progress from GO/Gl into S phase.
Interestingly, a similar model of positive feedback control has been proposed to 
occur during the yeast cell cycle. In budding yeast, the G l transcription factor 
complexes SWI4/SWI6 and MBP/SWI6 regulate a similar set of genes to E2F in 
mammalian cells (Johnston et al., 1992). Their activity is thought to be in part regulated 
by the G l cyclin-CDK complexes, the genes for which are themselves under the direct 
control of SWI4/SWI6 and MBP/SWI6. As in the proposed model of E2F activation 
by cyclinE-CDK2, it has been suggested that this positive feedback loop facilitates the 
rapid and timely induction of yeast genes necessary for entry into S phase.
The proposed positive feedback model may also incorporate other cyclinE- 
CDK2 substrates, which upon phosphorylation augment cyclinE-CDK2 activity. For 
example the CDK inhibitor, p27 inhibits the kinase activity of cyclinE-CDK2 and is 
also phosphorylated by cyclinE-CDK2, resulting in its elimination from the cell (Sheaff 
et al., 1997). It was suggested that the binding of ATP to CDK2 governs which state 
predominates. Thus it is conceivable that several cyclinE-CDK2 substrates may 
contribute to the ability of cyclinE-CDK2 to promote irreversible entry into S phase, by 
positive feedback.
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w h ich  a c t s  th ro u g h  a n  a u to r e g u la to r y  f e e d b a c k  loop  to  p h o s p h o r y l a t e  E 2 F -5  a n d  
th e r e b y  a u g m e n t  E 2 F - d e p e n d e n t  t r a n sc r ip t io n .  E: cyclin E; K 2 :C D K 2; re d  circ le  
r e p r e s e n t s  E 2 F -5 ,  g r e e n  circ le  r e p r e s e n t s  a  p h o s p h a t e  g ro u p .
8.5 Phosphorylation of E2F facilitates p300 co-activator recruitment
The p300/CBP family of co-activators has been the subject of intense 
investigation over recent years. Of particular interest is how p300/CBP regulate diverse 
cellular processes through their interaction with different transcription factors. 
Previously the interaction between E2F-1 and p300/CBP has been demonstrated to 
regulate E2F-1 dependent transcription (Trouche and Kouzarides, 1996; Lee et al., 
1999).
The results presented here demonstrate that cyclinE-CDK2 phosphorylates a site 
in the activation domain of E2F-5 that stimulates binding of E2F-5 to the p300 co­
activator. The phosphorylation-dependent interaction of p300/CBP co-activators 
occurs with other transcription factors, such as CREB and p53 (Chivria et al., 1993; 
Lambert et al., 1998). However this may be the first example of a CDK-dependent 
phosphorylation event which stimulates the binding of p300/CBP to a transcription 
factor. Several lines of evidence support the importance of this interaction for the 
proper regulation of E2F target genes and orderly progression of the cell cycle. Firstly, 
the isolated E2F-interaction domain in p300 has a dominant negative effect on E2F-5- 
dependent transcription. This implies that p300/CBP is an important co-activator of 
E2F-5. Secondly, the reduced transcriptional activity of the T251A mutant in the 
presence of cyclinE-CDK2 suggests that cyclinE-CDK2 phosphorylation of this site 
increases E2F-5-dependent transcription. Finally, the T251 CDK site was demonstrated 
to facilitate entry into S phase.
It has become clear that p300/CBP proteins exist in cells bound to a variety 
of other proteins in a co-activator complex (reviewed in Shikama et al, 1997). The 
hi stone acetyltransferase (HAT) activity that is associated with the co-activator
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complex is believed to be important in regulating chromatin and thus the accessibility 
of genes to the transcription machinery (Bannister and Kouzarides, 1996; Ogryzko et 
ah, 1996). Recently it has been shown that the HAT activity of p300/CBP and 
p300/CBP-associated factor (p/CAF) can acetylate a number of non-histone proteins, 
for example p53, E2F-1 and TFIIE (Gu and Roeder et al, 1997; Imhof et al, 1997; 
Martinez-B albas et al, 2000). The consequence of E2F-1 acétylation was to potentiate 
E2F-1 activity by increasing its DNA-binding ability, activation potential and protein 
half-life (Martinez-Balbas et al, 2000). As the results presented here demonstrate that 
E2F-5 can also be acetylated in vitro by p300 it would be interesting to determine 
whether the mechanism of transcriptional activation of E2F-5 by p300/CBP involves 
the acétylation of E2F-5.
Both p300 and CBP are believed to be limiting in the cell relative to the 
levels of transcription factors they bind to and regulate. Therefore a role for a cyclin- 
dependent kinase in the recruitment of p300/CBP to E2F, a transcription factor 
important for the control of genes necessary for cell cycle progression, provides a 
mechanism whereby p300/CBP can be directed away from processes such as 
differentiation and engaged in the regulation of proliferation. Perhaps of significance to 
these results is the discovery that p300/CBP can bind to cyclinE-CDK2 (Perkins et al, 
1997). CyclinE-CDK2 may regulate p300/CBP function, since inhibition of p300 
associated cyclinE-CDK2 by p21 increases NF-kB transaciivaiion. Moreover cyclinE- 
CDK2 can increase CBP HAT activity (Ait-Si-Ali et a l, 1998). Therefore, it is possible 
to speculate that the regulation of p300/CBP by cyclinE-CDK2 may enhance the 
activity of transcription factors that require CBP HAT activity and are involved in 
proliferation and compromise the activity of transcription factors involved in other 
cellular outcomes, such as growth arrest. Since p300/CBP interacts with cyclinE-
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CDK2, it is conceivable that it recruits cyclinE-CDK2 to E2F-5, thereby augmenting its 
phosphorylation. Thus a weak interaction occurring between unphosphorylated E2F-5 
and p300/CBP, could be dramatically increased at the Gl-S transition through the 
phosphorylation of E2F-5 by p300/CBP bound cyclinE-CDK2, stimulating E2F-5 
rrawisactivation and thereby contributing to the surge of gene expression necessary for 
entry into S phase. Moreover the increase in HAT activity that occurs at this stage of 
the cell cycle (Ait-Si-Ali et a l, 1998), may be mechanistically important for enhancing 
transcription through acetylating histones, the basal transcription machinery or E2F-5 
itself. Thus it will be important to establish whether E2F-5 acétylation occurs in vivo 
and whether acétylation of E2F-5 regulates E2F-5 activity. This line of inquiry will 
surely create further questions such as whether acétylation and phosphorylation have 
synergistic or antagonistic effects on E2F-5 activity.
The results presented here provide a plausible pathway through which G1 CDK 
complexes can directly act to increase E2F activity and stimulate the transcription of 
E2F target genes by facilitating the recruitment of the p300/CBP co-activator complex. 
As such, this mechanism is likely to be of central importance in regulating and co­
ordinating gene expression during early cell cycle progression.
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8.5 General Discussion
The data presented in these studies focused on the regulation of E2F-5 activity 
by phosphorylation. Prior to this work it was known that E2F DNA binding activity 
was negatively regulated by phosphorylation of the DP-1 subunit by cyclinA-CDK2. 
The results presented here now reveal that E2F activity is also regulated by cyclinE- 
CDK2. Specifically cyclinE-CDK2 stimulates E2F-5 dependent transcription by 
phosphorylation of a single site positioned at threonine 251 in the activation domain of 
E2F-5, which increases its ability to interact with p300/CBP. At least one other site is 
phosphorylated in E2F-5, a likely candidate being serine 307, Evidence that E2F-5 may 
be phosphorylated on other sites besides threonine 251 was provided by the observation 
that T251A mutant was still phosphorylated in cells, as measured by metabolic 
labelling with ^^P-orthophosphate. Moreover, the S307A and S307D mutants have 
different electrophoretic mobilities in SDS-PAGE. S307A, unlike T251A, was 
phosphorylated by cyclinE-CDK2 in vitro to a similar extent as wild-type E2F-5; 
therefore another kinase may be responsible for phosphorylation of serine 307.
Considering that the phosphorylation of either serine 307 or threonine 251 
appears to have similar functional consequences, it would be interesting to determine 
whether phosphorylation of both of these sites has a synergistic effect on E2F activity. 
Alternatively the possibility that each of these sites are involved in different 
mechanisms of transcriptional activation would be interesting to explore. It could be 
speculated that phosphorylation of threonine 251 regulates a subset of E2F target genes 
that have a requirement for the co-activator, p300/CBP, whilst phosphorylation of 
serine 307 activates another set of E2F target genes through the recruitment of a 
different co-activator (Fig 8.3).
199
S307 r
1.
> +  +
► +
cyclinE-CDK2
T 2 5 1
3. D P
>  + +
Figure 8.3 Phosphorylation of E2F-5 activates E2F-5 dependen t 
transcrip tion. (1) Phosphorylation o f E2F-5 on serine 307 may enhance 
transcription by stimulating an interaction between the E2F-5 rra«5activation 
domain and a protein involved in transcriptional activation. (2) Unphosphorylated 
E2F-5 may activate transcription by binding weakly to p300/CBP.
(3) Phosphorylation of E2F-5 on threonine 251 by cyclinE-CDK2 facilitates 
the interaction with p300/CBP. '+ ’ indicates the relative /rawjactivation.
'?' represents an unknown protein
Antibodies that specifically recognise phosphorylated serine 307 or 
phosphorylated threonine 251 in E2F-5 would be useful to confirm whether 
phosphorylation of these sites occurs physiologically. Moreover they could also be 
employed to determine whether specific proteins interact with E2F-5 when it is 
phosphorylated on either of these sites. It is likely that phosphorylation on threonine 
251 and serine 307 occurs to different degrees in different cell lines, as was suggested 
by the different electrophoretic mobilities of E2F-5 in F9EC and Rati cells. As E2F-5 
activity was found to be up-regulated in certain breast tumour cell lines (Polanowska et 
al, 2000), it will be interesting to determine the phosphorylation status of E2F-5 in 
these cell lines to establish whether phosphorylation of a particular site in E2F-5 is 
linked to aberrant growth.
Analysis of the cellular processes that enhance the activity of E2F should 
provide further understanding of the mechanisms controlling the growth of normal and 
cancer cells. Ultimately this should yield important targets for the production of 
specific therapies to treat cancer.
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